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ABSTRACT 
Cysteine proteinase inhibitors of the cystatin superfamily are ubiquitous in 
mammalian system. They serve a protective function to regulate the activities 
of endogenous proteinases, which if not regulated may cause uncontrolled 
proteolysis and damage to cells and tissues. The name cystatin was given to the 
superfamily of natural inhibitors of cysteine proteinases, which are 
evolutionary, structurally and functionally related proteins. 
On the basis of sub cellular localization, disulphide bonds, number of 
amino acid residues and sequence homology, cysteine proteinase inhibitors 
have been classified into three families. Family I called Stefins include 
members containing about 100 amino acid residues (MW 11,000), which lack 
disulphide bridges and carbohydrate content (Abrahamson, M. 1994). This 
family includes cystatin A, B and Stefin C. These inhibitors are present in cells 
and tissues. Family II known as cystatin family includes inhibitors of about 115 
amino acid residues (MW 13000) and two disulphide loops towards the 
carboxyl terminal. This family comprises of cystatins C, D, S, SN and they are 
found both in the cells and body fluids. Kininogens or family III cystatins are 
large precursor molecules of the vasoactive kinins. They are single chain 
glycoproteins, which serve a variety of biological functions such as kinin 
delivery, induction of endogenous blood coagulation cascade and mediation of 
the acute phase response. They are found only in blood plasma. There are three 
distinct types of kininogen designated as high molecular weight kininogen, HK 
(MW 88,000-120,000), low molecular weight kininogen LK (MW 50,000-
70,000) and T-kininogen, designated as TK (MW 68,000) found only in rat 
plasma. 
Cystatins have been purified from several mammalian sources like 
muscle, adder, hoof, brain, kidney, spleen, liver, skin and placenta. In the 
present study two cystatins, a high molecular mass (MW 70,800) and low 
molecular mass cystatin (MW 12,750) have been purified from goat brain and 
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were named as HMGBC (high molecular mass goat brain cystatin) and 
LMGBC (low molecular mass goat brain cystatin) respectively. Both of them 
have been characterized in terms of their biochemical and biophysical 
properties. The purification has been achieved by a simple three step procedure 
involving alkaline treatment, gel filtration chromatography on Sephadex G-100 
and DEAE cellulose ion exchange chromatography. Two protein peaks with 
inhibitory activity were obtained corresponding to HMGBC (Peak I) and 
LMGBC (Peak II). LMGBC was found to be homogenous on the basis of 
molecular weight and charge after gel filtration chromatography and 
polyacrylamide gel electrophoresis respectively, while HMGBC / Peak I 
obtained from gel filtration on Sephadex G-100 was found to be heterogeneous 
on the basis of charge as seen on native PAGE, thus it was purified using an 
additional step of DEAE cellulose ion exchange chromatography at pH 8.0. 
HMGBC was obtained with 13.8% yield and 923 fold purification and 
LMGBC was purified with 14% yield and 1128 fold purification. Both 
HMGBC and LMGBC consist of a single polypeptide chain as determined by 
SDS-PAGE in the presence and absence of p-mercaptoethanol. The stake's 
radii of HMGBC and LMGBC were found to be 36 A and 16 A, respectively 
showing compact globular structure of both the cystatins. HMGBC was found 
to have 2% carbohydrate content and is devoid of disulphide bonds wile 
LMGBC was lacking in both carbohydrate and disulphide bonds. The purified 
cystatins were found to be maximally active in the temperature range of 25°-
65°C and the pH stability was in the range of pH 6 - 10. Both the inhibitors 
were found to be stable upto 45 minutes at 90°C. 
Antibodies raised against HMGBC showed cross reactivity with LMGBC 
indicating that both HMGBC and LMGBC are immunologically identical. 
Purified HMGBC and LMGBC strongly inhibited activities of proteases like 
papain, bromelain and ficin, but they did not inhibit serine proteases namely 
trypsin and chymotrypsin. The inhibition kinetics revealed that both the 
cystatins are tight binding inhibitors. The respective Ki values obtained for 
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papain, ficin and bromelain were 1.875x10 M, 2.05xl0"8M and 4.38xlO"8M 
with HMGBC and 3.125xl0"8M, 3.5xl0"8M and 6xlO"8M with LMGBC. The 
values of association rate constants for the three proteinases papain, ficin and 
bromelain were 4.17xl03M"1S"1, 3.5xl03M"'S"' and 3.5xKENT'S"1 with 
HMGBC and 3.47xlO^'S"1 , 3.44xl03M-' S"1 and 3.33xl03M"'S"' for 
LMGBC, respectively. The dissociation rates with HMGBC were 2.22xlO"3S"', 
3.47xl0"3S"' and 5xl0"3S"' and with LMGBC 3.13xlO"3S"', 3.33xl0'3S"' and 
4.12xlO"3S"' for papain, ficin and bromelain, respectively. The IC50 values for 
HMGBC were 0.076uM, 0.104|LIM and 0.14uM and for LMGBC these values 
were 0.0895uJVI, 0.123uM and 0.172uM for papain, ficin and bromelain, 
respectively. The respective half life values obtained for papain, ficin and 
bromelain were 3.13xl02S, 1.99xl02S and 1.68xl02S with HMGBC and 
2.08xl02S, 2.08xl02S and 1.68xl02S with LMGBC. All the kinetic parameters 
taken together imply that both the cystatins bind more effectively to papain, 
then ficin and least with bromelain. 
Secondary structural composition showed presence of both a-helical content 
and significant amount of (3 structure in both HMGBC and LMGBC. Near UV-
CD spectra of both the cystatins showed peak at 280nm indicating presence of 
sufficient amount of tertiary structure whereas no peak at 250nm depicts that 
disulphide bonds are not present in either of the cystatins. Far UV-CD analysis 
indicated the change in the conformation of both the cystatins upon complex 
formation with papain. 
Ultraviolet spectra of the complex of HMGBC and LMGBC with papain 
indicated that the environments of several aromatic amino acids residues in 
proteins have been perturbed by the interactions. Changes in the fluorescence 
emission intensity by a 2nm red shift only in LMGBC, upon formation of 
inhibitor - papain complex indicate that there is some conformational change or 
local interactions affecting chromophoric groups of the two proteins involved 
in the inhibitor protein complex formation. 
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Thus owing to the absence of carbohydrate content, lack of disulphide 
linkages, low molecular weight and all other results obtained for LMGBC, it 
can be placed in class I, the Stefins class of cystatin superfamily. However, 
HMGBC with its high molecular mass and other properties showed 
resemblance to cystatin purified from goat kidney and low molecular mass 
kininogens. Hence, it may be concluded that HMGBC is a variant of class I and 
class III of cystatin superfamily. Furthermore, it also shows that cystatins of 
different tissues are different in their physicochemical properties owing to the 
specific physiological functions they perform in the mammalian body. 
Riboflavin and hydrogen peroxide are the two common reactive oxidants 
present in the mammalian body under various metabolic conditions. Effect of 
riboflavin and hydrogen peroxide studied with HMGBC showed that both of 
these oxidants inactivated the inhibitor. It was observed that the riboflavin at 
lOOuM concentration for one hour incubation lead to 85% loss of inhibitory 
activity with complete loss of native structure at the same concentration for 
longer time of incubation. Changes upon oxidation by these free radicals were 
observed in the form of degradation of cystatin by PAGE and quenching of 
tryptophan fluorescence. Another oxidant hydrogen peroxide showed 
significant functional and structural damage at 500mM concentration. H202 for 
2 hours of incubation, at 500Mm showed 76.7% loss of inhibitory activity 
along with degradation of the cystatin and oxidation of tryptophan residues as 
shown by PAGE and fluorescence spectra, respectively. The use of scavengers 
and antioxidants showed that both the oxidants involved hydroxyl radicals for 
the damage of the inhibitor. Mannitol and thiourea were found to prevent this 
damage, results revealed that potassium iodide prevents riboflavin induced 
oxidation and catalase prevents hydrogen peroxide induced damage of 
HMGBC. 
The effect of nitric oxide on functional and structural modifications of 
HMGBC was also investigated. It was found that nitric oxide leads to 
degradation of the inhibitor, disruption of its hydrophobic core and quenching 
V 
of the tryptophan residues lead to 89% loss of the inhibitory activity after 3 
hours of incubation. Structural changes were observed by degradation of the 
inhibitor in PAGE, quenching of tryptophan residues were observed in 
fluorescence measurement and disruption of the hydrophobic core was 
indicated by intrinsic and extrinsic fluorescence. Preventive effect of 
Curcumin, a lipid soluble component of turmeric which is widely used as 
scavenger of NO was analyzed. It was found to have very significant 
preventive effect against NO induced functional and structural damage of 
HMGBC. Almost 100% preventive effect for NO induced inactivation of 
HMGBC was observed at lOOuM concentration of curcumin. Structural 
modification was also prevented at the same curcumin concentration. 
The activity and conformational changes of high and low molecular mass 
goat brain cystatin have also been studied in the presence of urea and guanidine 
hydrochloride (GdnHCl). The unfolding of the inhibitors in the presence of 
both the denaturants lead to unfolding and inactivation of cystatins, it was 
followed by activity measurements, intrinsic and extrinsic fluorescence 
spectroscopy and circular dichroism (CD) studies. The denaturation of 
HMGBC by urea was via the formation of an intermediate at 2M concentration 
with a loss of 15% inhibitory activity. HMGBC lost its 50% activity at 3.0M 
urea concentration leading to complete inactivation and unfolding at 8M urea. 
However LMGBC showed urea induced denaturation in a simple two step 
mechanism from native to denatured state, without the formation of 
intermediates. LMGBC lost its 50% activity at 3M urea and only 5% inhibitory 
activity was left at 7M concentration of urea. 
In the presence of GdnHCl, HMGBC lost almost 65% inhibitory activity 
at 3M, and complete inactivation was achieved at 4.5M concentration. No 
intermediate state was observed, it simply followed native —> denatured rule 
whereas LMGBC in the presence of GdnHCl was found to form a compact 
structure at 1.5M leading to its complete unfolding and inactivation at higher 
concentrations. LMGBC lost its 75% inhibitory activity at 3M GdnHCl 
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concentration. Refolding studies showed that both HMGBC and LMGBC in 
the presence of urea and GdnHCl undergo refolding upon dilution. Almost 92% 
of HMGBC and 96% of LMGBC inhibitory activity was retained with 6M 
GdnHCl upon 40fold dilution with the buffer of pH 7.5. In case of urea 50 fold 
dilutions with the buffer resulted in the regain of 89% of HMGBC and 94% of 
LMGBC inhibitory activity. 
The high pH (10.0 - 14.0) induced unfolding of the cystatins and the use 
of salt KC1 and Na2S04 lead to refolding of HMGBC and LMGBC, this was 
monitored by enzyme inhibitory activity, intrinsic and extrinsic fluorescence 
and CD measurements. For both the cystatins as the pH increased to 14.0 under 
low ionic strength there was complete loss of inhibitory activity. The maximum 
activity for HMGBC was obtained at pH 8.0 while pH 7.0 was found to be the 
pH maxima for LMGBC. The results obtained for HMGBC indicate that at low 
ionic strength, increasing the pH value increased the extent of unfolding of the 
inhibitor to the maximum unfolded state at pH 14.0.The unfolding occurs via a 
simple native to unfolded state transition. For LMGBC, also at low ionic 
concentration as the pH increase from 7.0 to 10.0 there is unfolding of the 
cystatin while at pH 12.0, there is formation of a compact intermediate state. 
Thus the alkaline induced LMGBC unfolding occurs via three step transition 
from native —• intermediate —> unfolded state. 
In the absence of salts alkaline denatured HMGBC at pH 12.0 when 
dialyzed against pH 7.5 sodium phosphate buffer showed only 20% recovery 
on refolding while LMGBC showed a maximum recovery of 28% inhibitory 
activity. The results showed that in the presence of salts namely KC1 and 
Na2S04 upon dialysis the recovery of the inhibitory activity for both the 
cystatins was prominently enhanced. For HMGBC, the increase in the 
inhibitory activity was found to be 84% and 75% in the presence of 1M 
Na2S04 and 3M KCl, respectively. For LMGBC the recovery of the inhibitory 
activity was found to be 86% in the presence of 1M Na2S04 and 79% in the 
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presence of 3M KC1. The results indicated that Na2S04 was more efficient in 
refolding the high pH induced unfolded cystatins as compared to the KC1. 
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Cysteine proteinase inhibitors of the cystatin superfamily are ubiquitous in 
mammalian system. They serve a protective function to regulate the activities 
of endogenous proteinases, which if not regulated may cause uncontrolled 
proteolysis and damage to cells and tissues. The name cystatin was given to the 
superfamily of natural inhibitors of cysteine proteinases, which are 
evolutionary, structurally and functionally related proteins. 
On the basis of sub cellular localization, disulphide bonds, number of 
amino acid residues and sequence homology, cysteine proteinase inhibitors 
have been classified into three families. Family I called Stefins include 
members containing about 100 amino acid residues (MW 11,000), which lack 
disulphide bridges and carbohydrate content (Abrahamson, M. 1994). This 
family includes cystatin A, B and Stefin C. These inhibitors are present in cells 
and tissues. Family II known as cystatin family includes inhibitors of about 115 
amino acid residues (MW 13000) and two disulphide loops towards the 
carboxyl terminal. This family comprises of cystatins C, D, S, SN and they are 
found both in the cells and body fluids. Kininogens or family III cystatins are 
large precursor molecules of the vasoactive kinins. They are single chain 
glycoproteins, which serve a variety of biological functions such as kinin 
delivery, induction of endogenous blood coagulation cascade and mediation of 
the acute phase response. They are found only in blood plasma. There are three 
distinct types of kininogen designated as high molecular weight kininogen, HK 
(MW 88,000-120,000), low molecular weight kininogen LK (MW 50,000-
70,000) and T-kininogen, designated as TK (MW 68,000) found only in rat 
plasma. 
Cystatins have been purified from several mammalian sources like 
muscle, adder, hoof, brain, kidney, spleen, liver, skin and placenta. In the 
present study two cystatins, a high molecular mass (MW 70,800) and low 
molecular mass cystatin (MW 12,750) have been purified from goat brain and 
were named as HMGBC (high molecular mass goat brain cystatin) and 
LMGBC (low molecular mass goat brain cystatin) respectively. Both of them 
have been characterized in terms of their biochemical and biophysical 
properties. The purification has been achieved by a simple three step procedure 
involving alkaline treatment, gel filtration chromatography on Sephadex G-100 
and DEAE cellulose ion exchange chromatography. Two protein peaks with 
inhibitory activity were obtained corresponding to HMGBC (Peak I) and 
LMGBC (Peak II). LMGBC was found to be homogenous on the basis of 
molecular weight and charge after gel filtration chromatography and 
polyacrylamide gel electrophoresis respectively, while HMGBC / Peak I 
obtained from gel filtration on Sephadex G-100 was found to be heterogeneous 
on the basis of charge as seen on native PAGE, thus it was purified using an 
additional step of DEAE cellulose ion exchange chromatography at pH 8.0. 
HMGBC was obtained with 13.8% yield and 923 fold purification and 
LMGBC was purified with 14% yield and 1128 fold purification. Both 
HMGBC and LMGBC consist of a single polypeptide chain as determined by 
SDS-PAGE in the presence and absence of p-mercaptoethanol. The stake's 
radii of HMGBC and LMGBC were found to be 36 A and 16 A, respectively 
showing compact globular structure of both the cystatins. HMGBC was found 
to have 2% carbohydrate content and is devoid of disulphide bonds wile 
LMGBC was lacking in both carbohydrate and disulphide bonds. The purified 
cystatins were found to be maximally active in the temperature range of 25°-
65°C and the pH stability was in the range of pH 6 - 10. Both the inhibitors 
were found to be stable upto 45 minutes at 90°C. 
Antibodies raised against HMGBC showed cross reactivity with LMGBC 
indicating that both HMGBC and LMGBC are immunologically identical. 
Purified HMGBC and LMGBC strongly inhibited activities of proteases like 
papain, bromelain and ficin, but they did not inhibit serine proteases namely 
trypsin and chymotrypsin. The inhibition kinetics revealed that both the 
cystatins are tight binding inhibitors. The respective Ki values obtained for 
papain, ficin and bromelain were 1.875><10"8M, 2.05*10"8M and 4.38*10~8M 
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with HMGBC and 3.125xlO"8M, 3.5xlO"8M and 6xlO"8M with LMGBC. The 
values of association rate constants for the three proteinases papain, ficin and 
bromelain were 4.17xl03M"1S"1, S ^ I O ^ ' V and 3.5xl03M~V with 
HMGBC and 3.47xl03M"'S-', 3.44x103M_1 S_l and 3.33xl03M-'S'' for 
LMGBC, respectively. The dissociation rates with HMGBC were 2.22*10"3S"', 
3.47xlO"3S"1 and SxlO'V and with LMGBC 3.13xlO'3S'\ 3.33xl(T3S-1 and 
4.12xlO"3S"' for papain, ficin and bromelain, respectively. The IC5o values for 
HMGBC were 0.076uM, 0.104uM and 0.14uM and for LMGBC these values 
were 0.0895uM, 0.123)aM and 0.172uM for papain, ficin and bromelain, 
respectively. The respective half life values obtained for papain, ficin and 
bromelain were 3.13xl02S, 1.99xl02S and 1.68xl02S with HMGBC and 
2.08xl02S, 2.08xl02S and 1.68xl02S with LMGBC. All the kinetic parameters 
taken together imply that both the cystatins bind more effectively to papain, 
then ficin and least with bromelain. 
Secondary structural composition showed presence of both a-helical content 
and significant amount of [3 structure in both HMGBC and LMGBC. Near UV-
CD spectra of both the cystatins showed peak at 280nm indicating presence of 
sufficient amount of tertiary structure whereas no peak at 250nm depicts that 
disulphide bonds are not present in either of the cystatins. Far UV-CD analysis 
indicated the change in the conformation of both the cystatins upon complex 
formation with papain. 
Ultraviolet spectra of the complex of HMGBC and LMGBC with papain 
indicated that the environments of several aromatic amino acids residues in 
proteins have been perturbed by the interactions. Changes in the fluorescence 
emission intensity by a 2nm red shift only in LMGBC, upon formation of 
inhibitor - papain complex indicate that there is some conformational change or 
local interactions affecting chromophoric groups of the two proteins involved 
in the inhibitor protein complex formation. 
Thus owing to the absence of carbohydrate content, lack of disulphide 
linkages, low molecular weight and all other results obtained for LMGBC, it 
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can be placed in class I, the Stefins class of cystatin superfamily. However, 
HMGBC with its high molecular mass and other properties showed 
resemblance to cystatin purified from goat kidney and low molecular mass 
kininogens. Hence, it may be concluded that HMGBC is a variant of class I and 
class III of cystatin superfamily. Furthermore, it also shows that cystatins of 
different tissues are different in their physicochemical properties owing to the 
specific physiological functions they perform in the mammalian body. 
Riboflavin and hydrogen peroxide are the two common reactive oxidants 
present in the mammalian body under various metabolic conditions. Effect of 
riboflavin and hydrogen peroxide studied with HMGBC showed that both of 
these oxidants inactivated the inhibitor. It was observed that the riboflavin at 
lOOuM concentration for one hour incubation lead to 85% loss of inhibitory 
activity with complete loss of native structure at the same concentration for 
longer time of incubation. Changes upon oxidation by these free radicals were 
observed in the form of degradation of cystatin by PAGE and quenching of 
tryptophan fluorescence. Another oxidant hydrogen peroxide showed 
significant functional and structural damage at 500mM concentration. H202 for 
2 hours of incubation, at 500Mm showed 76.7% loss of inhibitory activity 
along with degradation of the cystatin and oxidation of tryptophan residues as 
shown by PAGE and fluorescence spectra, respectively. The use of scavengers 
and antioxidants showed that both the oxidants involved hydroxyl radicals for 
the damage of the inhibitor. Mannitol and thiourea were found to prevent this 
damage, results revealed that potassium iodide prevents riboflavin induced 
oxidation and catalase prevents hydrogen peroxide induced damage of 
HMGBC. 
The effect of nitric oxide on functional and structural modifications of 
HMGBC was also investigated. It was found that nitric oxide leads to 
degradation of the inhibitor, disruption of its hydrophobic core and quenching 
of the tryptophan residues lead to 89% loss of the inhibitory activity after 3 
hours of incubation. Structural changes were observed by degradation of the 
inhibitor in PAGE, quenching of tryptophan residues were observed in 
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fluorescence measurement and disruption of the hydrophobic core was 
indicated by intrinsic and extrinsic fluorescence. Preventive effect of Curcumin, 
a lipid soluble component of turmeric which is widely used as scavenger of NO 
was analyzed. It was found to have very significant preventive effect against 
NO induced functional and structural damage of HMGBC. Almost 100% 
preventive effect for NO induced inactivation of HMGBC was observed at 
lOOuM concentration of curcumin. Structural modification was also prevented 
at the same curcumin concentration. 
The activity and conformational changes of high and low molecular mass 
goat brain cystatin have also been studied in the presence of urea and guanidine 
hydrochloride (GdnHCl). The unfolding of the inhibitors in the presence of 
both the denaturants lead to unfolding and inactivation of cystatins, it was 
followed by activity measurements, intrinsic and extrinsic fluorescence 
spectroscopy and circular dichroism (CD) studies. The denaturation of 
HMGBC by urea was via the formation of an intermediate at 2M concentration 
with a loss of 15% inhibitory activity. HMGBC lost its 50% activity at 3.0M 
urea concentration leading to complete inactivation and unfolding at 8M urea. 
However LMGBC showed urea induced denaturation in a simple two step 
mechanism from native to denatured state, without the formation of 
intermediates. LMGBC lost its 50% activity at 3M urea and only 5% inhibitory 
activity was left at 7M concentration of urea. 
In the presence of GdnHCl, HMGBC lost almost 65% inhibitory activity 
at 3M, and complete inactivation was achieved at 4.5M concentration. No 
intermediate state was observed, it simply followed native —> denatured rule 
whereas LMGBC in the presence of GdnHCl was found to form a compact 
structure at 1.5M leading to its complete unfolding and inactivation at higher 
concentrations. LMGBC lost its 75% inhibitory activity at 3M GdnHCl 
concentration. Refolding studies showed that both HMGBC and LMGBC in 
the presence of urea and GdnHCl undergo refolding upon dilution. Almost 92% 
of HMGBC and 96% of LMGBC inhibitory activity was retained with 6M 
GdnHCl upon 40fold dilution with the buffer of pH 7.5. In case of urea 50 fold 
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dilutions with the buffer resulted in the regain of 89% of HMGBC and 94% of 
LMGBC inhibitory activity. 
The high pH (10.0 - 14.0) induced unfolding of the cystatins and the use 
of salt KC1 and Na2S04 lead to refolding of HMGBC and LMGBC, this was 
monitored by enzyme inhibitory activity, intrinsic and extrinsic fluorescence 
and CD measurements. For both the cystatins as the pH increased to 14.0 under 
low ionic strength there was complete loss of inhibitory activity. The maximum 
activity for HMGBC was obtained at pH 8.0 while pH 7.0 was found to be the 
pH maxima for LMGBC. The results obtained for HMGBC indicate that at low 
ionic strength, increasing the pH value increased the extent of unfolding of the 
inhibitor to the maximum unfolded state at pH 14.0.The unfolding occurs via a 
simple native to unfolded state transition. For LMGBC, also at low ionic 
concentration as the pH increase from 7.0 to 10.0 there is unfolding of the 
cystatin while at pH 12.0, there is formation of a compact intermediate state. 
Thus the alkaline induced LMGBC unfolding occurs via three step transition 
from native —* intermediate —> unfolded state. 
In the absence of salts alkaline denatured HMGBC at pH 12.0 when 
dialyzed against pH 7.5 sodium phosphate buffer showed only 20% recovery 
on refolding while LMGBC showed a maximum recovery of 28% inhibitory 
activity. The results showed that in the presence of salts namely KC1 and 
Na2S04 upon dialysis the recovery of the inhibitory activity for both the 
cystatins was prominently enhanced. For HMGBC, the increase in the 
inhibitory activity was found to be 84% and 75% in the presence of 1M 
Na2S04 and 3M KCl, respectively. For LMGBC the recovery of the inhibitory 
activity was found to be 86% in the presence of 1M Na2S04and 79% in the 
presence of 3M KCl. The results indicated that Na2S04 was more efficient in 
refolding the high pH induced unfolded cystatins as compared to the KCl. 
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1. INTRODUCTION 
Proteolytic enzymes also termed as proteases catalyze the hydrolysis of 
susceptible peptide bonds in proteins and are of universal occurrence in 
mammalian system. The term protease is a general term applied for both 
exopeptidases and endopeptidases. A protease is classified as a proteinase if it 
exhibits a significant endopeptidases activity regardless of whether it exhibits 
exopeptidases activity. However proteases and proteinases are synonymously 
used in literature. Proteinases are further divided into fours classes - serine 
proteinases, acid proteinases, metalloproteinases and thiol proteinases. Serine 
proteinases require the presence of serine residue at their active sites, acid 
proteinases require low pH conditions for their activity, metalloproteinases 
require metal ions for their for their full activity and thiol proteinases have 
cysteine residue at their active sites. Serine proteinases and their endogenous 
inhibitors are much more explored as compared to thiol proteinases and their 
inhibitors. 
Thiol proteinases synonymous with cysteine proteinases comprise a 
group of proteolytic enzymes which are widely distributed among living 
organisms (Barrett et al., 1986a). They are proteins of MW of about 25-35KDa. 
These proteinases are synthesized in a precursor form and are later subjected to 
co-translation al and post translational modifications that convert them to 
catalytically active mature enzymes (Turk et al., 1995; Cygler and Mort, 
1997;Turk et al., 2000). They contain two principal catalytic amino acid 
residues, cysteine and histidine which are involved in the cleavage of peptide 
bonds of a protein or peptide substrate (Stennicke, 1999). They play an 
important role in the catabolism of proteins and peptides, processing of 
prohormones, maturation and cleavage of a number of precursor proteins 
(Siewinski, 1993) in MHC class II- restricted antigen processing and 
presentation (Turk 2000; Turk et al., 1997; Stoka, 2001). 
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About 40 different families of cysteine proteinases have been so far been 
characterized (Barrett et al., 1998). The first clearly recognized and extensively 
studied cysteine proteinase was papain, isolated from the latex of the plant, 
Carica papaya. Nearly half of the known families of cysteine proteinases are 
represented only in viruses some occur in bacteria, whereas others exist in 
eukaryotic organisms (Rawlings and Barrett, 1994). Current evidence suggests 
that eleven lysosomal cathepsins among the known to date like cathepsins B, 
H, L, S, C, K, O, F, V, X and W) are members of papain family (Kotyza and 
Krepela, 2002). 
Mammalian thiol proteinases have been classified into four different classes 
1. Cathepsins 2.Legumain 3.Calpains 4.Caspases 
Cathepsins are relatively small proteins with the exception of 
cathepsins C which is an oligomeric enzyme of molecular weight of about 200 
KDa. Cathepsins are present in the lysosomes of cells and are involved in 
intracellular protein turnover, proteolytic degradation and cleavage of a number 
of precursor proteins and hormones. These are present in high concentrations in 
spleen (McDonald and ELIS, 1975), kidney, liver (Knight, 1980; Quinn and 
Judah, 1978), lungs (Singh and Kalnitsky, 1978), brain (Suhar and Marks, 
1979) and breast (Mort et al., 1984). 
Legumain is an asparaginyl endopeptidases also present in lysosomes. 
These are involved in MHC class II- restricted antigen presentation (Manoury 
et al., 1998) and local negative regulation of osteoclasts formation and activity 
(Choi etal., 1994). 
Calpains and Caspases are cytoplasmic thiol proteinases. Calpains 
participate in many intracellular processes such as turnover of cytoskeletal 
proteins, cell differentiations and regulation of signal peptides. Mammalian 
calpains have molecular mass of about 110 KDa (Yajima and Kawashima, 
2001). Caspases are the cysteine dependent aspartate specific proteinases, the 
central component of cell apoptosis consists of proteolytic systems involving 
caspases (Nicholson, 1999; Stennicke and Salvensen, 2000). 
Lysosomal cysteine proteinases have been associated with a number of 
pathologies including cancer (Koppel et al., 1994), inflammation, rheumatoid 
arthritis (Trabandt et al., 1991) and osteoarthritis, Alzheimer disease 
(Nakamura et al., 1991), multiple sclerosis (Bever et al., 1995), muscular 
dystrophy (Sohar et al., 1998), pancreatitis, liver disorders, lung disorders, 
lysosomal disorders (Sloane and Honn, 1984), diabetes and myocardial 
disorders (Hopsu-Havu et al., 1983b). In may of these diseased lysosomal 
enzymes have been found in the extracellular and extralysosomal environments 
in their proforms, which are substantially more stable than their mature 
enzymes (Barrett et al., 1998; Turk et al., 2001). 
Regulation of lysosomal thiol proteinase activity 
The process of proteolysis in cells is under biological control acting at 
the level of protein biosynthesis or mediated through protein inhibitors. Several 
processes lead to increase of proteolysis in the cells e.g., starvation of animals 
increases the rate of protein degradation in liver (Dice et al., 1978) and muscle 
(Li and Goldberg, 1976) and causes about two fold increase of Cathepsin D and 
A level in the liver (Katunuma et al., 1982). Similarly, several hormones are 
known to regulate average rates of protein degradation. Various pathological 
conditions have been associated with increased thiol proteinase activities like 
metastasizing cancer (Koppel et al., 1994), muscular dystrophy (Noda et al., 
1981), renal failure (Kabanda et al., 1995) and rheumatoid arthritis (Gabrijeleic 
et al., 1990). Hence the wide implications of the thiol proteinases in various 
biological functions need to be effectively regulated by opposing effects of 
activators and inhibitors. Proteinase inhibitors are ubiquitously present in the 
living system and they constitute a powerful regulatory system for the 
endogenous proteinases. Natural inhibitors of cysteine proteinases include the 
members of cystatin superfamily: stefins, cystatins and kininogens. These 
cystatins play a key role in regulatory process for endogenous cysteine 
proteinases whose activities if not controlled will lead to tissue destruction. 
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Discovery of Cystatin Superfamily 
Protein inhibitors of cysteine proteinases in mammalian tissues were 
first reported by Finkelstadt (1957), who reported a heat stable inhibitor of 
cathepsin B and dipeptidyl peptidase I in Rat liver cytosol. Whitaker and 
coworkers discovered and partially characterized a protein from chicken egg 
white that inhibits papain and ficin (Fossum and Whitaker, 1968; Sen and 
Whitaker, 1973).this protein also inhibits cathepsin B and dipeptidyl peptidase 
I as reported by Keilova and Tomasek (1974; 1975). 
The term cystatin was originally given by Barrett (1981) for these 
inhibitors because of their unique property of arresting the activity of cysteine 
proteinases (CPs). Later, the name was given to a superfamily of evolutionary, 
structurally and functionally related proteins involved in the inhibition of CP 
activities. 
Later on, CPls (cysteine proteinase inhibitors) were isolated and 
characterized from various mammalian tissues. These inhibitors resembled 
chicken cystatin in relative molecular mass and physicochemical properties. 
Subsequently, Machleidt et al (1983) reported that the sequences of stefin also 
called as 'cystatin A' and chicken cystatin are homologous (Green et al., 1984; 
Barrett, 1985). Stefins however, differed in lacking cysteine residues and 
disulphide bonds and hence, were placed in a different family within cystatin 
superfamily. 
All cystatins fall into a single superfamily i.e. a group within which all 
the members can be shown to have a statistically significant relation but they 
do no resemble members of other superfamilies (Dayhoff et al., 1979a). 
Cystatin superfamily comprises of three distinct families, the members of 
which are expected to have atleast half of their amino acid residues in common 
(Dayhoff etal., 1979b). 
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CLASSIFICATION OF CYSTATIN SUPERFAMILY 
The first international symposium on cysteine proteinases and their 
inhibitors in 1985 decided that these inhibitors should be divided into three 
families 1, 2 and 3 (Barrett et al., 1986b). Hence the proteins of cystatin 
superfamily are divided on the basis of sequence homology, molecular 
structure and the number of amino acids in the following three families 
(Rawlings and Barrett, 1990; Turk et al, 1997; Brzin et al., 1984) Fig. 1.0. 
Family 1 (Type I cystatin): Stefins 
The term stefin has been assigned to this family to emphasize the 
structural difference between these proteins and other members of the 
superfamily. The proteins of this family are the smallest among the members of 
the cystatin superfamily lacking in disulphide bonds and carbohydrate moieties 
(Brzin et al., 1983). Stefins are single chain proteins, synthesized without 
signal peptide and consist of about 100 amino acid residues (MW 11000). All 
type I cystatin have blocked N-terminal and contain methionine representing 
the points of initiation of translation (Turk et al., 1995). There are three 
important members of this family cystatin A and B isolated from human (Green 
et al., 1984; Lenney et al., 1979) and stefin C purified from bovine tissues 
(Turk et al., 1986). Cystatins a and (3 are considered to be simply the rat species 
variants of cystatins A and B (Jarvinen, 1986; Lenney, 1979). The amino acid 
sequence of these proteins closely resembles each other (Barrett et. al., 1986). 
Cystatin A 
It is an inhibitor of cathepsin B in human skin discovered by Fraki 
(1976). Later on Jarvinen (1978) studied it as ACPI 'acid cysteine proteinase 
inhibitor'. Brzin et al. (1983) purified an inhibitor from blood leucocytes and 
named it as 'stefin'. The amino acid sequence was determined by Machleidt et 
al (1983). Green et al (1984) characterized same type of CPI from human liver 
and later renamed it as cystatin A. Cystatin A occurs in multiple isoelectric 
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Fig 1.0 Diagrammatic representation of the chain structure of 
proteins in the; cystatin superfamily 
The structure indicated for kininogens is that of L-kininogens; H-kininogens 
have a longer carboxyl terminal extension. J marks potential sites for the 
attachment of the carbohydrate side chains. 
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forms with predominantly acidic pi values in the range 4.5-5.0 (Jarvinen, 1978; 
Hopsu-Havu et al., 1983a). 
Rinnie et al (1978) detected cystatin A in extracts of squamous epithelia 
from oesophagus. It was also found in dendritic reticulum cells of the lymph 
nodes ( Rinnie et al., 1983), seminal plasma (Minakata and Asano, 1985), 
saliva, bovine skin( Turk et al., 1995), human nails (Tsushima, 1993) and in a 
number of epidermoid carcinomas (Rinnie, 1979; 1980; Rinnie et al., 1980; 
1984a). Physiological concentrations of human cystatin A was reported by 
Hopsu-Havu et al (1983b) in serum (10-15ug/g). In tissues the concentrations 
were: epidermis of tongue and mouth, 65-200ug/g; bone marrow, 8ug/g; liver, 
5ug/g, spleen 3ug/g and lung 0.3^g/g. 
The N-terminal sequence of bovine stefin A was identified as a 
truncated form of bovine cystatin C (Hirado et al., 1985; Turk et al., 1995). The 
sequence identity of this stefin A is 86% and 88% respectively with -N and C 
terminal parts of human cystatin A. 
Cystatin a 
Cystatin a is assumed to be a species variant of cystatin A found in rats. 
This protein was characterized by Jarvinen (1976) as specific inhibitor of CP 
from rat skin having MW of 13000. Cystatin a is generally found on the 
epidermal layer (Jarvinen et al., 1978) and various other squamous epithelia 
(Rinnie et al., 1978). Kominami et al (1984a) and Katunuma and Kominami 
(1985) quantified the concentration in skin and small intestine as 2800 ug/mg 
protein and 820 \xg/g protein, respectively. The serum level of cystatin a in rats 
was 2.5ug/ml. 
Cystatin B 
Cystatin B was detected as an inhibitor of cathepsin B and H in human 
tissues by Lenney et al (1979). Jarvinen and Rinnie (1982) purified cystatin B 
from human spleen. Green et al (1984) purified from human spleen and liver 
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with separation of multiple forms. Cystatin B is a relatively basic protein with 
pi values of 6.25 and 6.35 for the two forms of cystatin B (Green et al., 1984). 
Jarvinen and Rinnie (1982) reported pi values of 6.0 and 6.5 and Rinnie et al 
(1984) reported 6.5 and 7.5. Human cystatin B forms dimers but dimeric form 
does not show inhibitory activity (Jarvinen and Rinnie, 1982; Green et al., 
1984; Rinnie et al., 1984). 
Cystatin B is ubiquitously distributed in various cells and tissues like 
epithelial cells, lymphocytes (Davies and Barrett, 1984), monocytes (Hopsu-
Havu et al., 1984; 1985b) and to much lesser extent in seminal plasma (Brzin, 
1982). Jarvinen et al (1983) have shown cystatin B in cells of the upper layers 
of the epithelium of the oral mucosa. Confocal microscopic analysis showed 
the localization of cystatin mainly in the proliferating cells and both in the 
nucleus and cytoplasm of differentiated cells (Riccio, 2001). This cystatin is 
involved in the protection against uncontrolled activity of lysosomal CP 
(Henskens, 1996). Crystal structure of recombinant human cystatin B has been 
elucidated by X-ray crystallographic analysis (Stubbs et al., 1990). Cystatin B 
is more abundant in all cells than cystatin A with the exception of PMNs. 
Stefin B from bovine was reported by Krizaj et al (1992). 
Cystatin fi 
Finkelstadt (1957) and Lenney (1979) reported the existence of a 
thermostable and dialyzable inhibitor of cathepsin B, H and dipeptidyl 
peptidase I in the supernatant of rat liver homogenate. Subsequently, Hirado et 
al (1981) isolated cystatin p from rat liver cytosol. The pi values for cystatin (3 
ranges from 5.04 to 5.6 (Kominami et al., 1981; Hirado et al., 1981). Cystatin p 
has an almost even distribution in the tissues and is more abundant than 
cystatin a in all tissues except skin. This characteristic of cystatin p resembles 
cystatin B of human variant. 
9 
Stefln C 
Several low MW CPIs have been found in bovine thymus, although 
kinetically similar they differ in the primary structure and pi values. Stefin C is 
unique among the inhibitors from stefin family which was found in multiple 
forms resulting from the cleavage of Asn 5-Leu 6 bond of the inhibitor (Turk et 
al., 1986; Brzin et al., 1982; Kopitar et al., 1989). The protein consists of 101 
amino acid residues and its MW is calculated to be 11,546. The inhibitor was 
found to be acidic with pi values from 4.5 and 5.6 (Turk et al., 1993). 
Stefin C exhibits considerable sequence homology with other inhibitors 
from stefin family with maximum homology of 87.4% with bovine stefin B, 
72.4% with human cystatin B and 47.9% with human stefin A. It was identified 
as the first tryptophan (at position 2) containing stefin and it had prolonged N-
terminal (Turk et al., 1993) 
Family 2 (Type II): Cystatins 
Family 2 cystatins like stefins are low MW Cystatins. These inhibitors 
are composed of 115-120 amino acid residues having MW of about 13000. 
Cystatins contain two disulphide bonds and lack carbohydrate contents. They 
are synthesized with the signal peptide and found at a relatively high 
concentration in secretions like chicken egg white, seminal plasma and saliva. 
They originate in cells and may also function intracellularly. The known 
members of this family are chicken cystatin, human cystatin C, D, S, SN, SA, 
E, F and M. Measurements of the concentration of the cystatin in human 
biological fluids reveal that all such fluids contain inhibitors, but the total 
molar ratios of different inhibitors vary markedly. Cystatins are found both in 
cells, tissues and secretions (Lofberg et al., 1983). The general pattern seems 
that secretions contain the highest concentration of family 2 cystatins 
(Abrahamson, 1994). 
Family 2 cystatin genes are clustered in multigene locus on chromosome 
20 together with two pseudogenes (Abrahamson et al., 1990; Schnittger et al., 
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1993; Thiesse et al., 1994). The best known representatives of this class of 
cystatins are human cystatin C and chicken cystatin. The pi values ranges from 
4.4 to 9.3. 
Cystatin C 
Originally cystatin C was termed as y-trace or post y-globulin from CSF 
because of its basic natures and y-electrophoretic mobility (Barrett et al., 
1984a; Brzin, 1984). It was also found in urine from patients with renal failure 
(Butler and Flynn, 1961) and ascetic and pleural fluids (Hochwald and 
Thombecke, 1962). Later, cystatin C was also detected in saliva and normal 
serum (Cejka and Fleischmann, 1973) and in seminal plasma (Colle et al., 
1976). Lofberg and Grubb (1979) determined cystatin C concentration of 
5.8ug/ml in CSF (cerebrospinal fluid), 1.8mg/ml in saliva, 0.095ug/ml in 
normal urine, 21 ug/ml in urine from patients with renal tubular disorders and 
1.1 jag/ml in normal plasma. Seminal plasma contains 50ug/ml i.e. 36 fold 
higher concentration of inhibitor than in normal blood plasma (Grubb et al., 
1983). Abrahamson found cystatin C concentration of 3.4ug/ml in saliva from 
submandibular glands and 0.9|ig/ml from the parotid gland. The high level of 
cystatin C in the CSF compared with blood plasma suggests the production of 
cystatin in the central nervous system (Lofberg and Grubb, 1979). The protein 
is able to cross blood brain barrier to the vascular space and thereby rapidly 
filtered in the glomeruli and catabolised in the renal tubular cells. 
Despite widespread extracellular distribution, cystatin C has also been 
detected intracellularly in brain cortical nerves (Lofberg et al., 1981a), normal 
and neoplastic neuroendocrine cells in the adrenal medulla (Lofberg et al., 
1982), A cells of pancreatic islets ( Lofberg et al., 1981b), thyroid (Lofberg et 
al., 1983) and pituitary ( Lofberg et al., 1983; Moller et al., 1985). Homologues 
of human cystatin C have been found in several mammals including mouse, rat, 
cow and dog (Solan et al., 1990; Esnard et al., 1988; Hirado et al., 1985; Poulik 
et al., 1981). It is also found to be linked with epileptogenesis and epikpsy 
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(Lukasuik, 2002) along with other neurodegenerative diseases (McGreen , 
1995). 
Cejka and Fleischmann (1973) determined the isoelectric point of 
cystatin C to be 9.0 although, values ranging from 8.0 to 9.5 (Brzin et al., 1984; 
Laurenzi and Link, 1978) have been reported. Degradation of N-terminal takes 
place during storage which results in a lower pi value. N-terminal truncation of 
cystatin by cathepsin L has been reported by Popovic et al (1999) leading to 
loss in its activity and lowering of pi to 8.1 and 8.25 due to loss of one or more 
basic residues. It was suggested that cleavage could be of physiological 
significance to control the extent of inhibition by cathepsin B at the site of 
inflammation (Abrahamson et al., 1991). The truncation results in the exposure 
of N-terminal and loss of ordered structure of cystatin in solution (Ekiel et al., 
1997). 
Chicken cystatin was first isolated from chicken egg white by Fossum 
and Whitaker in 1968 and Sen and Whitaker (1973) reported it as low MW 
tight binding CPI of ficin and papain and of cathepsin B and C (Keilova and 
Tomasek, 1974; 1975). Chicken cystatin has also been detected in the serum of 
both male and female chickens at a concentration of 80ug/ml in egg white and 
l^g/ml in the serum (Anastasi et al., 1983). It has also been found in chicken 
muscle cells (Wood et al., 1985) and showed resemblance to cystatin C. 
A MW of about 13,000 has been determined from the amino acid 
composition of chicken cystatin (Lindahl et al., 1988). Nicklin and Barrett 
(1984) resolved this inhibitor as two isoelectric forms I and II having pi values 
of 6.5 and 5.6, respectively. 
Cystatin D 
Frieje et al (1991) cloned a new member of human cystatin multigene 
family from a genomic library using cystatin C cDNA probe. This inhibitor 
consists of 122 amino acid residues having a MW of 13,885. The deduced 
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amino acid composition includes a putative signal peptide and has 51-55% 
homology with either cystatin C or secretory gland cystatins S, SA and SN. 
Cystatin D is a relatively neutral protein with pi in the range 6.8-7.0 
(Frieje et al., 1991). It is expressed in parotid glands, saliva and tears (Balbin et 
al., 1994). This tissue restricted expression is in marked contrast with a wider 
distribution of all other family 2 cystatins. 
Cystatin S 
Human saliva contains several low MW acidic proteins which include 
CPI also (Isemura et al., 1984b; Minakata and Asano, 1985). The first salivary 
inhibitor purified and sequenced was SAP-I (salivary acidic proteinase-I) 
(Isemura et al., 1984a), which was renamed as 'cystatin S'. It was found to 
have 54 and 41% sequence homology with cystatin C and chicken cystatin, 
respectively (Isemura et al., 1984a and b). This inhibitor has also been isolated 
from human submaxillary, submandibular and sublingual glands and found to 
be present in the serous cells of parotid and submaxillary glands (Isemura et al., 
1984b). It is assumed that these cells are responsible for its synthesis. The 
protein has also been found in tears, serum, urine, bile, pancreas and bronchus 
(Isemura et al., 1986). Cystatin S contains no phosphate, in contrast to other 
salivary proteins. 
Variants of cystatin S 
Several molecular variants of cystatin S have been studied by Isemura et 
al (1986). They differ in their N-terminal sequences and pi values (Minakata 
and Asano, 1985; Isemura, 1986). Differences in pi values resulted from 
phosphorylation of residues Ser 3 and Ser 1 in salivary cystatin ((Isemura et al., 
1991). 
Cystatin SN: Originally known as cystatin SV or SA-1 (Abrahamson et al., 
1986). The protein consists of 121 amino acid residues and MW value of 
14,316. The pi value is in the range of 6.6-6.8. 
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Cystatin SA: The protein consists of 1221 amino acid residues and MW value 
is slightly higher than SN, which is 14,351. It has acidic pi value of 4.6 
((Isemura et al., 1991). Cystatin SA isolated from saliva had N-terminal residue 
Glu (Isemura et al., 1986). 
Cystatin E 
Ni et al (1997) found this type of cystatin by expression of amniotic 
fluid and fetal skin epithelial cell cDNA libraries. The mature protein is a 
polypeptide of 121 amino acid residues and has 28 residue signal peptide 
having a MW of 15,000. Cystatin E resembles family 2 cystatins structurally in 
containing two protective disulphide bridges and by being a secreted protein. 
The inhibitor has unusual characteristic of being a glycoprotein carrying an re-
linked oligosaccharide at Asn 108 (Stenmann et al., 1997). 
Cystatin E is a functional tight binding CPI it has amino acid sequence 
similarities with human family 2 cystatins (C, D, S, SN and SA) in the range of 
26 -34%, 18 and 23% homology with family 1 cystatin A and B and less than 
30% with domains 2 and 3 of the family 3 cystatins, that is kininogens (Ni et 
al., 1997). The protein has Pro-Trp pair towards the C-terminal like that of 
family 2 and 3 cystatins. Cystatin E gene is localized on chromosome 11 
(Stenmann et al., 1997). 
Cystatin E has been detected in a variety of specialized tissues and 
organs (Ni et al., 1997). Its high concentration is found in uterus and liver, and 
lower but significant amounts in placenta, pancreas, heart, spleen, small 
intestine and peripheral blood leucocytes, in brain, testis and kidney of 
mammals. The inhibitor serves a protective role during fetal development. 
Cystatin F 
Another described human member of the cystatin superfamily was 
identified as cystatin F by Ni et al in 1998. Its sequence contained a signal 
14 
peptide and the mature protein of 126 amino acid residues has two disulphide 
bonds which resembles family 2 cystatins. Unlike other members, cystatin F 
has two additional Cys residues indicating the presence of an extra disulphide 
linkage which stabilizes N-terminal region of the molecule. The mature protein 
has an extended N-terminal segment, being 6-10 residues longer than the other 
single domain cystatins. Cystatin F has a MW of 14,543 as determined by 
sequence analysis (Ni et al., 1998). 
Cystatin F has two N-linked carbohydrate chains at positions 36 and 88. 
It has 30-34% homologous sequence to human family 2 cystatins, only 29% 
homology to cystatin E, even lower 22-20% identities to cystatin A and B and 
24% with domain 3 of kininogens (Ni et al., 1998). 
The distribution pattern of cystatin F is very different from that of 
cystatin C or E. Blood contains low levels of this inhibitor (0.9 ug/ml). The 
highest concentration is present in the spleen and peripheral blood leucocytes, 
moderate levels in thymus and small intestine. Cystatin F is found mainly in the 
immune cells. However, it could not be detected in B cell lines but appreciable 
amounts were detected from primary dendritic cells, anergic T-cells, bone 
marrow, activated T-cells, multiple sclerosis lesions, osteoarthritic, breast, 
lymph nodes, apoptotic T-cells, osteosarcoma cells, pancreatic islet tumour 
cells, thymus, Jurkat cells, helper T-cells and peripheral blood mononuclear 
cells. The function of cystatin F is important for specialized cells of the 
myeloid or T-cell lineage. Taken together, the expression pattern, inhibitory 
profile and intracellular localization predispose Cys F as possible regulator of 
antigen processesing and presentation (Ni et al., 1998). 
Cystatin M 
Cystatin M was discovered in the primary tumour cell line. It is 
synthesized as a precursor protein and is secreted as a precursor protein (Von 
Heinjie, 1985). The predicted molecular mass is approximately 14.3KDa and pi 
of 7.8 for the mature protein. A single disulphide bond is present (Sotiropoulou 
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et al., 1997). An N-glycosylated form of cystatin M of 20-22KDa was co-
immunoprecipitated and accounted for about 30-40% of total cystatin M 
protein. Both forms of native cystatin M occurred intracellularly. 
Cystatin M resembles other members of the family in having the three 
conserved domains. It has 40% homology to human family 2 cystatins The 
overall homology between cystatin M and other cystatins range from 30-40% 
for conserved amino acid residues and 25 to 33% for identical amino acids. 
Cystatin M shows the closest homology to cystatin C, they share 33% identical 
and 38% conserved amino acid residues (Sotiropoulou et al., 1997). 
Cystatin M is expressed by normal mammary epithelial cells and a 
variety of human tissues but it is not expressed in may metastatic mammary 
tumour cell lines. High levels of cystatin M are present in placenta, lung, 
skeletal muscle, kidney and pancreas and lower level was observed in heart 
tissue (Sotiropoulou et al., 1997; Von Heinjie, 1985).. 
Family 3 (Type HI): Kininogens 
In mammals, three types of kininogens have been found differing in 
size, structure and function. The largest kinin precursor, commonly referred to 
as high molecular weight (HMW) kininogen, has a MW of 88000-114000, 
depending on its species origin (Kato et al., 1981). Among the smaller 
kininogens, a low molecular weight (LMW) kininogen with a MW of 50000-
70000 is found in throughout the mammalian lineage (Muller-Esterl et al., 
1986). The third type, T-kininogen of MW 68000, seems to be unique of rats 
(Okamoto and Greenbaum, 1983). The various types of kininogen have the 
same basic structure, a heavy chain of 50-60KD at the amino-terminus, the 
kinin segment in the core part of the molecules and a light chain of variable 
length at the carboxy-terminus (Kitamure et al., 1985; Lottspeich et al., 1985). 
The primary structure of the heavy chain, kinin portion and a segment of 12 
amino acid residues are identical in HMW and LMW kininogens, but the 
structure of their light chain diverges considerably. HMW kininogen has a 
16 
large light chain of 45-58KDa which harbours unique histidine-rich region 
(Sugo et al., 1980). The HMW kininogen light chain contains the binding site 
for prekallikrein and factor XL The structure of T-kininogen closely resembles 
that of LMW kininogen in its heavy and light chain portions but differs at the 
amino-terminal flanking region of the kinin segment (Cole et al., 1985). 
The primary site of kininogen biosynthesis is the liver with only minor 
expression in other tissues. The kininogens are secretory proteins synthesized 
with a signal peptide and undergoes glycosylation. Important functions of 
kininogens are the release of vasoactive peptide bradykinin, by acting as 
substrate for kallikrein, intrinsic blood coagulation, acute phase reactions and 
inhibition of cysteine proteinases (Muller-Esterl et al., 1986). pi values 
reported for the multiple isoelectric forms of L and H kininogens fall in the 
range 4.0-4.9 (Ryley, 1979; Muller-Esterl et al., 1982; 1983; Kato et al., 1981). 
The proteins are stable to temperature in the range of 50-90°C (Taniguchi et 
al., 1981). 
Plasma concentrations of kininogens have been determined by radio 
immuno assay to be 109-271 ug/ml (L-kininogens) and 69-116 ug/ml (H-
kininogen) (Adam et al., 1985). Plasma concentration of a CPI has been 
reported as 425 ug/ml (Ryley, 1979) and 359 ug/ml (Gounaris et al., 1984). 
Kitamura et al (1985) and Salvesen et al (1985) found that three cystatin like 
segments are present in kininogens, although the first lacks the preserved 
sequence Gln-Val-Val-Ala-Gly. It is known that the LMW- kininogen contain 
no free thiol groups (Salvesen et al., 1985). Kininogens inhibit papain, ficin, 
cathepsin B, H and L (Jarvinen, 1979; Pagano and Engler, 1982; Gounaris et 
al., 1984). Table 1.0 summarises the various mammalian and non mammalian 
sources from where CPIs have been isolated. 
Other cystatins and cystatin-related proteins 
Many other proteins with inhibitory activity against papain-like cysteine 
proteases and with sequences related to well-studied mammalian cystatins have 
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TABLE 1.0: CPI FROM DIFFERENT SOUCES 
Source 
African puff 
Beef 
Bovine 
Carp 
Cat 
Hog 
Dog 
Guinea pig 
Horse shoe Crab 
Human 
Rabbit 
Rat 
Sheep 
Litomosoides 
sigmodontis 
Goat 
Trypanosoma 
cruzi 
Tissue 
Adder 
Spleen 
Brain 
Hoof 
Muscle 
Colostrum 
Ovary 
Skin 
Kidney 
Colostrum 
Parotid gland 
&Kidney 
Skin 
Hemocytes 
Liver 
Placenta 
Spleen 
Liver 
Skin 
Brain 
Plasma 
-
Kidney 
Brain 
-
M r 
13,000 
13,000 
25,000 
11,000 
11,406 
14,000 
14,300 
12,787 
12,000 
-
-
-
_ 
12,600 
12,400 
12,300 
11,400 
5000-
10,000 
12,500 
12,500 
-
280,000 
68,000 
14,000 
67,000 
70,800 
12,720 
11,000 
pi 
6.5 
4.8-7.0 
4.7 
5.23 
-
6.2 
10.0-10.3 
-
acidic 
-
-
" 
acidic 
-
-
-
6.0-6.5 
"* 
6.6 
-
-
-
-
-
-
-
Reference 
Evans and Barrett, 
1987 
Brzinetal., 1982 
Aghajanyan et al., 
1996 
Tsushima et al.. 
1996 
BigeetaL 1985 
ZabarietaL, 1993 
Hiradoetal., 1984 
Tsaietal., 1996 
Jarvinen, 1976 
Lenney et al., 1979 
Pouliketal., 1981 
Sekine and Poulik, 
1982 
Jarvinen, 1976 
Agarwalaet al., 
1996 
Green etal., 1984 
Warwas &Bamicki, 
1985 
Rinnieetal., 1980 
Pontremoli et al, 
1983 
Udaka & Hayashi, 
1965 
Hayashi, 1975; 
Tokaji, 1971 
Kopitaretal., 1983 
Baba et al., 2005 
Plaffetal., 2002 
Zehra et al., 2005 
Sumbul & Bano, 
2006 
Monteiro et al.. 
2001 
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been discovered. Among them, a large group consists of defensive inhibitors 
from plants named as phytocystatins, which have structural features 
intermediate between those of families 1 and 2 cystatins (Rawlings & Barrett, 
1990; Brown & Dziegielewska, 1997; Margis et al., 1998). Phytocystatins also 
possess a specific consensus sequence that is absent in other cystatins. 
Therefore, classification of plant cystatins as an independent family of the 
cystatin superfamily has been suggested. Cystatins from rice (Abe et al., 1988; 
Kondo et al., 1989, 1990, 1991), potato (Waldron et al., 1993), avocado 
(Kimura et al., 1995), papaya (Song et al., 1995), soy (Misaka et al., 1996), 
chelidonium majus (Rogelj et al., 1998), sunflower (Kouzuma et al., 2001) and 
lima bean (Lawrence & Nielsen, 2001) have been described. Related inhibitors 
have also been found in various lower organisms, such as African puff adder 
(Ritonja et al., 1987), carp (Tsai et al., 1996), horseshoe crab (Agarwala et al., 
1996), Sarcophaga peregrina larvae (Suzuki & Natori, 1985; Saito et al., 1989), 
Drosophila (Delbridge & Kelly, 1990) and nematodes (Manoury et al., 2001; 
Hartmann et al., 2002). Cystatins in such lower organisms are more related to 
family 2 cystatins than the phytocystatins (Turk et al., 1997). 
Non specific inhibitors of cysteine proteases of the papain family 
A number of other proteins exhibit inhibitory activity against lysosomal 
papain-like cysteine proteases. a2-Macroglobulins unspecifically trap 
endopeptidases of different types, blocking the access of protein substrates to 
the active site of the trapped proteinases without inactivating them (Sottrup-
Jensen, 1989; Armstrong, 2001). Thyropins, which are homologous to the 
thyroglobulin type-1 domain, are another class of inhibitors (Lenarcic & Bevec, 
1998; Lenarcic & Turk, 1999). Cathepsin L is specifically inhibited by a 
mammalian representative of this class, the major histocompatibility complex 
(MHC) class II-associated p41 invariant chain fragment (Bevec et al., 1996; 
Guncar et al., 1999). The serpin, squamous cell carcinoma antigen 1, has also 
been shown to inhibit proteases of the papain family (Takeda et al., 1995; 
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Schick et al., 1998). Cytotoxic T-lymphocyte antigen-2 beta (CTLA-2 beta), 
which is 36% identical to the proregion of mouse cathepsin L, has been shown 
to inhibit cathepsin L-like proteases (Delaria et al., 1994). CTLA-2 beta has 
been suggested to represent a novel class of cysteine protease inhibitors. In 
addition, peptides constituting the N-terminal proregions that are cleaved off on 
activation of proforms of cysteine proteases may act as potent reversible 
inhibitors of the mature proteases (Cygler & Mort, 1997). 
Chagasin from Trypanasoma cruzi has been shown to inhibit a number 
of papain-like proteases (Monteiro et al., 2001). Chagasin-like proteins were 
found to be encoded by genomes of several eukaryotes, bacteria and archaea, 
and thus appear to be the first protein inhibitors of cysteine proteases identified 
in prokaryotes. Chagasins are the only protease inhibitors known that adopt an 
immunoglobulin-type fold (Rigden et al., 2002). 
EVOLUTIONARY RELATIONSHIP 
Statistical analysis of the similarities between the aligned sequences in 
cystatins is suggestive that they have evolved from a single primitive sequence 
(Barker and Dayhoff, 1972). Difference matrix of the sequences of the 
members of the superfamily revealed that the type I forms one family and type 
II forms a second family whereas kininogens also form a single family. 
However, members of the cystatin superfamily are closely related to each 
other. Fig. 1.1 demonstrates the relationship between all known inhibitory 
active human cystatin domains according to their sequence homology and 
physicochemical properties. 
The structure of the cystatin superfamily indicates that the members of 
the family involved atleast six duplications of genetic material from a single 
primordial sequence to produce the cystatins A, B, C, S and 3 segments of 
kininogens. Gene structure of kininogens (Kitamura et al., 1985) shows that 
each of the three cystatin like segments of kininogens are coded by three exons 
for which, the cystatin gene was the precursor. Some workers reported that 
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Fig 1.1 Schematic illustration of evolutionary relationship of cystatins 
of type I, II and HI 
The evolutionary relationships between all known inhibitory active 
human cystatin families. 
Cystatin A 
Cystatin B 
Cystatin S 
Cystatin SA 
Cystatin SN 
Cystatin C 
Cystatin D 
Cystatin E/M 
Cystatin F 
Kininogen D3 
Kininogen D2 
T y p e I 
Type II 
T y p e III 
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only the first two of the three exons of the primitive family 2 gene was 
represented in family 1 cystatin gene, the third segment is acquired during the 
evolution of family 2 cystatins (Keil-Dlouha, 1986). Analysis of amino acid 
sequence data led to the conclusion that the differences in the length of the 
polypeptides are accounted by the insertion and deletion of the genetic material 
in small blocks (Salvesen et al., 1986). 
Since disulphide bonds are often acquired in the evolution of protein but 
rarely lost, it is assumed that the primitive precursor of the cystatin was not 
unlike a modern type I cystatin (Williams, 1982). 
The evolutionary relationship among the various CPIs remained largely 
obscure until Muller-Esterl et al (1985) suggested a common evolutionary 
origin of stefins, cystatins and kininogens. Their model has been constructed on 
the basis of sequence homology. The diversity of CPI has been evolved from 
two ancestral building blocks A and B. These stefin progenitors represents the 
whole superfamily comprising a single A unit. Cystatins acquired a second 
element B possibly by gene fusion thus forming AB unit. Gene triplication of 
the archetypal inhibitor generated the kininogens heavy chain which contains 
three cystatin like copies (AB)
 3. Hence, the superfamily of mammalian CPI is 
constituted by atleast three distinct families with stefin, cystatin and kininogens 
as their prototype. 
The phylogenetic dendogram depicts that the divergence between 
chicken cystatin and human cystatin C and S may have occurred 300 million 
years ago, the time of appearance of first reptile. The divergence of cystatin A 
and B appears to be about 230 million years ago, before the appearance of true 
mammals (Muller- Esterl, 1985). 
SECONDARY STRUCTURE 
The secondary structure of chicken cystatin and human cystatin C has 
been studied extensively. One line of evidence from analysis of amino acid 
sequence for the distribution of hydrophilic and hydrophobic residues, has 
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predicted that hydrophilic residues are on the surface whereas hydrophobic 
regions are in the interior of the protein inhibitors like other compact globular 
proteins. 
Each sequence possess a large N-terminal hydrophilic region (15-42 
residues) and a prominent central hydrophobic region (55-70 residues) 
followed by another large hydrophilic region at C-terminus. The secondary 
structure of human cystatin C in solution is very similar to that reported for 
chicken cystatin (Dieckmann et al., 1992). The crystalline form of chicken 
cystatin has been reported by Bode et al (1988). 
Both human cystatin C and chicken cystatin as well as the family 1 
cystatins (A and B) consist of five stranded antiparallel {3-pleated sheets 
(Martin et al., 1994; 1995; Stubbs et al., 1990) which is wrapped around a 
straight five turn a-helix (Fig.l.2A, 1.2B and 1.4). X-ray diffraction analysis 
showed an appending segment of partial a - helical geometry in chicken 
cystatin (Saxena and Tayyab, 1997) which is not found in human cystatin C 
(Bode et al., 1988). The confirmation of this region seems to be closer to that 
found in chicken cystatin (Dieckmann et al., 1993). The N-terminal segment 
upto Val 10 seems to be flexible similar to that of other cystatins (Dieckmann 
et al., 1993; Martin et al., 1995). Tip was found only in the second hairpin loop 
of cystatins (Bode et al., 1988). 
Circular dichroism and computer prediction of secondary structure from 
the sequence indicate that the chicken cystatin has about 20% a-helix, 42% P-
structure, 24% p-turn and 12% random coil (Schwabe et al., 1984). 
Ekiel and Abrahamson (1996) and Janowski et al (2001) proposed that 
the human cystatin C undergoes dimerization under mild denaturing conditions. 
NMR studies revealed that the majority of the proteins are not affected by 
dimerization however, the CP binding site is significantly affected which 
accounts for the activity loss (Abrahamson, 2001; Ekiel et al., 1997). Hence, it 
is concluded that hydrophobic CP binding site is involved in the monomer-
monomer contact. The dimerization may be required for regulation of cystatin 
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Fig 1.2 Three dimensional structure of type I and type II cystatins 
Ribbon representation of the three-dimensional structures of (a) cystatin 
A of family 1 and (b) chicken egg-white cystatin of family 2. The side-chains 
of the residues conserved in the respective family are shown in black. 
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C inhibitory activity in vivo (Abrahamson, 2001). Three dimensional swapping 
studies indicate the dimerization of human cystatin C to be a step towards 
protein oligomerization (Janowski et al., 2001). 
INHIBITION OF PROTEASES 
Specificity 
All the enzymes known to be inhibited by the cystatins are proteases 
with cysteine at the active sites. No example of serine, aspartic or metallo-
proteinase or non proteolytic enzymes being inhibited by cystatins is available. 
Tests that have been reported include those on cystatin A and B with tiypsin, 
chymotrypsin, pancreatic elastase, cathepsin G and thermolysin (Fraki, 1976; 
Green et al., 1984). The available data indicates that all cystatins inhibit CP of 
papain superfamily including papain, chymopapain, papaya proteinase III, 
ficin, actinidin and the lysosomal CP and cathepsin B, H and L. 
Of the type II cystatins, chicken cystatin has been shown to inhibit 
papain, ficin, chymopapain, papaya proteinase III, actinidin and cathepsin B, H, 
L and N (Fossum and Whitaker, 1968; Keilova and Tomasek, 1974; 1975; 
Barrett, 1985; Etherington, 1976), cystatin S inhibits papain and ficin (Isemura 
et al., 1984b), beef colostrum cystatin inhibits papain and cathepsin B and H 
(Hirado et al., 1984). Cystatin M inhibits papain (Sotiropoulou et al., 1997). 
Cathepsin B and papain are inhibited by cystatin E (Ni et al., 1997). Cystatin F 
inhibits papain and cathepsin L but not cathepsin B (Ni et al., 1998). Cystatin D 
inhibits cathepsin L, H and S but not cathepsin B (Balbin et al., 1994). 
Ironically, papain homologue bromelain from pineapple stem or fruit is 
not inhibited by cystatin. The low MW cystatin B do not inhibit calpains 
(Kominami et al., 1982b), chicken cystatin (Johnson et al., 1984) and human 
amniotic fluid (Rohrlich et al., 1985). 
Human cystatin A and chicken cystatin partially inhibit clostripain and 
show no inhibition of streptococcal cysteine proteinase (Green et al., 1984). 
Clostripain was also not inhibited by cystatin S (Isemura et al., 1984b). 
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Cystatins also inhibit exopeptidases. Keilova and Tomasek (1975) 
showed that chicken cystatin inhibits dipeptidyl peptidase I, this proteinase is 
also known to be inhibited by human cystatin A, B, C and S (Green et al., 
1984; Barrett et al., 1984a; Isemura et al., 1986), cystatin a (Jarvinen and 
Hopsu-Havu, 1975) and cystatin p (Kominami et al., 1982a). Inhibition of 
lysosomal carboxypeptidase B by cystatin P was reported by Kominami et al 
(1982a). 
Kinetic behaviour 
The cystatins are the first group of protein inhibitors of CP for which the 
mechanism of inhibition has been investigated. Cystatins are a group of potent, 
non covalent and reversible inhibitors of CP of papain superfamily (Barrett, 
1987; Ekiel et al., 1997). Some of the reported values of Ki are presented in 
Table-1.1 a. It can be seen that the inhibition constants extend down to a value 
of 5xl0'12. Inhibition of cathepsin B tends to be weaker than that of papain and 
cathepsin H and L, except with cystatin C which is a strong inhibitor of 
cathepsin B. Some estimates of individual association and dissociation rate 
constants are available in Table-1.1b. 
Reactive site 
The reactive site of the folded, native cystatin molecule could obviously 
involve parts of the molecule well separated in primary sequence. The 
elucidation of the crystallographic structure of cystatin / enzyme complexes 
classified the precise location of the reactive site (Fig. 1.3A and 1.3B). 
The central region of the sequence contains the highly conserved block, 
usually Gln-Val-Ala-Gly at 53-57, Gin 53 and Gly 57 are common to all 
cystatins and inhibitory kininogen segments and neighbouring residues also 
show strong tendency to conserve this type of sequence. In chicken cystatin the 
sequence is QLVSG instead of QVVAG (Barrett et al., 1986; Barrett 1987). 
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Fig 1.3 Three dimensional structure of cystatin and cysteine 
proteinase complex 
Ribbon representation of the crystal structures of the complexes 
(a) Cystatin A and cathepsin H 
(b) Cystatin B and Papain 
Cystatin A 
(a) 
Cathepsin 
H 
(b) 
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TABLE 1.1A Ki VALUES FOR INHIBITION OF CP BY LOW MW CYSTATIN 
Enzyme 
Papain 
Cath. B 
Cath. H 
Cath. L 
Dipeptidyl 
peptidase I 
Cath. S 
Aa 
0.019 
8.2 
0.31 
1.3 
33 
nd 
Ba 
0.12 
73 
0.58 
0.23 
0.23 
nd 
Ca 
0.005 
0.25 
0.28 
0.005 
3.5 
nd 
Db 
0.9 
1000 
8.5 
25 
nd 
0.24 
Fc 
1.1 
-
-
0.31 
nd 
nd 
Ed 
0.39 
32 
nd 
nd 
nd 
0.35 
Chicken 
cystatin 
0.005 
1.7 
0.064 
0.019 
nd 
nd 
Bovine 
stefin 
0.18 
>100 
nd 
0.0065 
nd 
nd 
Puff 
adder 
0.1 
2.7 
nd 
nd 
0.23 
nd 
TABLE LIB RATE CONSTANTS FOR INTERACTION OF CYSTATINS WITH 
THIOL PROTEASES 
Enzyme 
Papain 
Cathepsin B 
Ficin 
Cathepsin H 
Dipeptidyl 
peptidase I 
Inhibitor 
Chicken cystatin 
Bovine cystatin 
B 
Bovine stefin C 
Chicken cystatin 
Chicken cystatin 
Bovine stefin A 
Chicken cystatin 
*^ass 
1.0x10' 
6.3xl06 
1.8xl06 
1.4xl06 
4.3xl06 
l.OxlO7 
K-diss 
<5.0xl0";> 
7.7 xlO"4 
-
2.3 xlO"3 
nd 
2.2 xlO'3 
Reference 
Nicklin & Barrett, 1984 
Nicklin & Barrett, 1984 
Nicklin & Barrett, 1984 
Nicklin & Barrett, 1984 
Sen &Whitaker, 1973 
Nicklin & Barrett, 1984 
Values are given in nanomolar concentration, 
nd- not determined 
a Barrett et al., 1984; Gounaris et al., 1984; Salvesen et al., 1985 and 
Machleidt et al., 1986 
b Balbin et al., 1994 
c Nietal., 1998 and d Nietal., 1997 
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Residues 60-62 are all uncharged generally with large hydrophobic side chains 
in small cystatins. 
The C- terminal part of the sequence tends to be very varied, although 
Cys 71 and Tyr 100 are conserved in the large majority of sequences. There 
also appear to be deletions and insertions in the C-terminal segments that 
suggest variability in structure but the disulphide bonds presumably stabilize 
the folding of these segments in cystatins of type I cystatins and kininogens. 
Chicken cystatin has Trp 104 as the reactive group during the interaction with 
CP. All other type II cystatins also contain the conserved second hairpin loop 
around Trp 104. Estrada et al (1998) emphasized the role of Gly 4 on human 
stefin A (cystatin A) in the binding of target proteinases. Even the smallest 
replacement in this protein by site directed mutagenesis by Ala resulted in 
approximately 1000, 10 and 6000-fold decreased affinities for papain, 
cathepsin L and cathepsin B, respectively. As the side chain of the substituted 
amino acid residue became more bulky, the inhibitory activity of the variant 
decreased markedly (Shibuya et al., 1995), the single cysteine residue, Cys 3 of 
human and bovine cystatin B has appreciable importance for inhibition of CP, 
particular for cathepsin B (Pol and Bjork, 2001). The contact residues in the 
hairpin loop, Leu 73 and His 75 when replaced by Gly it resulted in 
appreciably reduced affinities for papain, cathepsins H and B. These two 
residues contribute 20-30% of the free energy of binding of cystatin B (Pol and 
Bjork, 1999). Replacement of the contact residue in the C-terminal end, Tyr-
97, with Ala resulted in the loss in affinities for papain, cathepsins H and L. All 
affinity decreases were due to increased dissociation rate constants (Pol and 
Bjork, 1999). 
Cystatins form tight equimolar complexes with CP (Anastasi et al., 
1983; Nicklin and Barrett, 1984). Kominami et al (1982b) concluded that the 
binding ratio between cystatin p and rat cathepsin H is found to be 1:1 on the 
basis of titration of the active site of proteinase. Abrahamson et al (1987) also 
reported the rapid formation of 1:1 complex between cystatin C and papain. 
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Fig 1.4 3D Structure of a typical type II cystatin 
The structure contains a large proportion of |3- strands, which form a p-
pleated sheet that is wrapped around a central a-helix; N-terminal is exposed to 
the surface. Letters represent the conserved amino acid residues in the binding 
surface. 
^^^^^^ A ^ 1 ^ ^ f c l 
ft ^%S\ 
/' 
xA 
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Previous studies of chicken cystatin revealed that about two molecules of the 
inhibitor are required for the inhibition of each molecule of papain (Nicklin 
and Barrett, 1984; Bjork et al., 1989). Nicklin and Barrett (1984) found that 
dipeptidyl peptidase I and papain competed for binding site of cystatin. 
contrary to previous report. In a separate experiment cathepsin B was shown to 
compete for binding to the same site too. 
MECHANISM OF INTERACTION OF CYSTATINS WITH 
PROTEASES 
It has been established that no disulphide bond is formed between the 
active site cysteine and the inhibitor because complexes dissociate when 
denatured without reduction (chicken cystatin: Nicklin and Barrett, 1984; 
kininogens; Gounaris et al., 1984) and carboxymethylation of enzyme and 
inhibitor does not prevent complex formation (Anastasi et al., 1983). It became 
clear that complex formation is reversible competitive and non-covalent with 
enzyme. The nature of interaction resembles standard mechanism of inhibition 
described by Laskowski and Kato (1980). The active site of papain in complex 
with chicken cystatin is unreactive with 5,5'-dithio-bis-(2-nitrobenzoic acid) at 
pH 8, 2,2 '-dipyridyl disulphite at pH 4 and [14C] iodo acetate (Nicklin and 
Barrett, 1984). It has also been reported that the complex formation is 
accompanied by pronounced spectroscopic changes, most likely reflecting 
local perturbation of the environment of aromatic residues in both enzyme and 
inhibitor (Lindahl et al., 1988; Bjork et al., 1989). 
The mechanism of inhibition of papain by chicken egg white cystatin 
has been extensively studied. Bode et al (1988) proposed a model for the 
interaction of cystatin with CP based on X-ray crystal structure of chicken 
cystatin and subsequent studies based on docking experiment which indicates 
that Three parts of the inhibitor are in close contact with the active site cleft of 
papain, the amino acid terminus with conserved Gly-9, a first hairpin loop from 
residues 53-57, containing the prototype sequence, QVVAG (Barrett et al., 
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1986; Barrett 1987) and a second hairpin loop ( residues 102-107) containing 
conserved Trp 104. Bode et al (1988) demonstrated that the major contribution 
is from the first hairpin loop containing the QVVAG sequence (Turk, 1985; 
Ohkubo et al., 1984). According to the model of N-terminal segment of 
cystatin which is more flexible bridges over the active site Cys 25 residue of 
papain without completely burying it and additionally the side chain of Leu 8 
binds to the S2 subsite of papain which determines the substrate specificity of 
papain (Drenth et al., 1976; Asboth et al., 1988). The side chain groups of 
QLVSG segment makes the most intimate contact with putative Si subsite of 
papain (Fig. 1.5). This explains the presence of Gly 9 in close vicinity of Cys 
25 of papain but not in direct contact with it. Removal of Leu 7 and Leu 8 
leads to approximately 5000 fold lower affinity of papain. This was supported 
by Brzin et al (1984) who demonstrated that the truncated form of human 
cystatin C starting with Leu-Val before Gly-11 (corresponding to Gly-9 of 
chicken cystatin) has virtually the same affinity for papain as the full length 
form whereas the truncated form starting with Gly 12 has been reported to be 
1000 fold weaker inhibitor (Abrahamson et al., 1987). However, Nycander and 
Bjork (1990) emphasized the role of trp-104 in the inhibition of CP. According 
to his model, Trp 104 of cystatin interacts primarily with two tryptophan side 
chains (Trp 177 and Trp 181) in the active site cleft of papain in such a manner 
that the indole ring of Trp 104 stacks on the side chain of Trp 177 and its edge 
lies on the indole ring of Trp 181 (Fig. 1.5). 
A two step mechanism of inhibition of the lysosomal CP, cathepsin B 
by its endogenous inhibitor, cystatin C was observed by Nycander et al (1998). 
An initial weak interaction in which N-terminal of the inhibitor binds to the 
proteinase is followed by a conformational change. Subsequently, the 
occluding loop of the proteinase that partially obscures the active site is 
displaced by the inhibitor, bringing about another conformational change. The 
presence of occluding loop of cathepsin B renders it much less susceptible to 
inhibition by cystatins as compared to other proteinases. A similar two step 
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Fig 1.5 Scheme of the proposed model for the interaction of chicken 
cystatin with papain 
Interaction of chicken cystatin with papain has been iJJustrated. 
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binding of cystatin A to the CP was suggested by Estrada and Bjork (2000) 
which shows that the flexible N-terminal region of the cystatin binds 
independently to the target proteinases after the hairpin loops. 
PHYSIOLOGICAL FUNCTIONS OF CYSTATINS 
The present knowledge of serine proteinases and their endogenous 
inhibitors at the molecular level is much more detailed than our understanding 
of the structure and functions of thiol proteinases. Since, cystatins constitute a 
powerful regulatory system for endogenous cysteine proteinases, which are 
often secreted or leaking from the lysosomes of dying or diseased cells (Ekiel 
et al., 1997) which otherwise may cause uncontrolled proteolysis and tissue 
damage. It is established that imbalance between these endogenous inhibitors 
and thiol proteinases have been associated with various diseases. The activity 
of thiol proteinases cannot normally be measured in body fluids, but can be 
detected extracellularly in conditions like endotoxin induced sepsis 
(Abrahamson, 1994), metastasizing cancer (Koppel et al., 1994; Lee et al., 
2008) and local inflammatory processes such as rheumatoid arthritis 
(Gabrijeleic et al., 1990; Trabandt et al., 1991), purulent bronchiectasis (Buttle 
et al., 1990) and peridontitis (Cox and Eley, 1989; Lah et al., 1993), renal 
failure (Kabanda et al., 1995; Servais, 2008), Alzheimer's disease (Nakamura 
et al., 1991; Levy, 2008), multiple sclerosis (Bever et al., 1995), muscular 
dystrophy (Sohar et al., 1998) which indicates that a tight enzyme regulation 
by cystatins is a necessity in the normal state. In general, cystatin 
concentrations are elevated in patients suffering from inflammatory diseases 
and autoimmunity (reviewed in Barrett, 1986; Hansen et al., 2000; Mangge et 
al., 2000). 
Cystatin B (p) serves a general protective role. The abundance of 
cystatin A selectively in squamous epithelial cells and in PMN leucocytes 
contrasts strongly with the general distribution of cystatin B and suggests a 
specific function connected with these types of cells (Kotyza and Krepla, 
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2002). These cells are in the front line defence against invading pathogens and 
parasites, many of which use CP for entering in the body (North, 1982). A 
cysteine proteinase produced by Leishmania spp. is inhibited by human 
cystatin A, B and C and kininogens. 
Apart from defensive role, it is possible that cystatin A is involved 
directly in the physiology and pathology of the skin. Jarvinen et al (1978) 
suggested that the inhibitor may contribute to the keratinisation process and 
Hibino et al (1980) demonstrated production of cystatin a in the upper spinous 
or granular cells that became keratinized. Fukuyama et al (1982) have also 
suggested that cystatin a is involved in the differentiation of epidermis on the 
basis of electron microscope immunolocalization work. Hopsu-Havu et al 
(1981) demonstrated antibodies to cystatin A in patients with a wide variety of 
dermatological conditions like dermatitis and psoriasis. Autoantibodies may be 
produced when the inhibitor leaks into the blood stream following damage to 
the epidermis and dermis. Cystatins have also been implicated in other 
inflammatory reactions in the skin (Udaka, 1965; Hayashi et al., 1965). 
Alaviakko et al (1985) reported that one or two cases of AIDS showed 
profound alterations of dendritic reticulum cells revealed by localization of 
cystatin A. A role of type I cystatins has also been considered in connection 
with the control and turnover of myofibrils in the cytoplasm of muscle cells it 
is probably mediated by CP and can be modified by low MW inhibitors. 
Spanier and Bird (1982) indicated that levels of cystatins decrease in the 
guinea pigs with a nutritional muscular dystrophy induced by vitamin E 
deficiency. 
Cystatin A level increases in patients with cardiovascular disease, 
sarcoidosis and hepatic cirrhosis (Hopsu-Havu et al., 1983b). The 
concentration of cystatin B increases in patients suffering from inflammatory 
diseases and kidney failure (Hopsu-Havu et al., 1982; 1985a). 
Some reports tend to implicate the role of lysosomal CP in the 
malignancy suggesting that they may contribute to the nutrition of tumour 
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cells, to the destruction of connective tissue elements, in the invasion and 
sloughing off the metastatic cells into the circulation (Poole, 1973; Strauli et 
al., 1980; Sloane and Honn, 1984). Furthermore the role of cathepsins and their 
inhibitors in various types of cancers has been investigated (Sloane et al., 1994; 
Kos et al., 1996; Mirtii et al., 2003). Nishida et al (1984) have reported that 
cells of one human melanoma cell line released cystatin like inhibitor into their 
culture medium. On the contrary, a deficiency state in which the levels of the 
intracellular cystatin B are lowered due to mutations has been shown to 
segregate with a form of progressive myeclonus epilepsy (Pennacchi et al., 
1996). 
Recent observations indicate that some pathogens produce proteins 
homologous to cystatins that are capable of suppressing the host immune 
response against the pathogens through interference with the MHC class II-
restricted antigen processing in the antigen presenting cells of infected host. 
This type of pathogen induced immunosuppression is exemplified by Bm-CPI-
2 protein, a cystatin homologue secreted by filarial parasite Brugia malayi, 
which inhibits the MHC class II-restricted antigen processing via direct 
inhibition of multiple lysosomal cysteine proteases including cathepsins S, L, 
B and Legumain (Manoury et al., 2001). The concentration of cystatin C may 
be elevated in the serum of patients suffering from autoimmune diseases, lupus 
erythematosus and glomerulonephritis (Brzin et al., 1984). 
Certain genetic disorders are linked to mutation in cystatin gene. In 
Icelandic hereditary cystatin C amyloid angiopathy, a mutation in the cystatin 
C gene (CSTC) causing a single substitution (L68Q) in cystatin C gene is 
coupled to decreased concentration of this major CPI in CSF, and leads to its 
amyloid deposition in almost all tissues including the cerebral arteries 
(Pennacchio et al., 1998; Ghiso et al., 1986; Cohen et al., 1983; Grubb, 1990). 
This deposition results in fatal cerebral haemorrhages in young non-
hypertensive adults. 
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Another pathological condition has been implicated due to a decrease in 
CSF cystatin C level i.e. Guillain-Barr syndrome, chronic inflammatory 
demyelinating poly-neuropathy and muscular sclerosis. In these groups of 
patients, high cathepsin B activity but not cathepsin H was observed in CSF 
(Nagai et al., 2000). Kos et al (1997) pointed out that cystatin C level in the 
sera of advanced melanoma patients increases owing to higher levels of 
cathepsin B and H in these patients. Differently truncated forms of cystatin C 
are found in the urine of patients with nephrological diseases (Popovic et al., 
1990). 
Moreover, cystatins play additional roles in human defence by being the 
members of non-immune defence system of the body against microbial 
invasion (North et al., 1990). Cell culture shows that chicken cystatin C and D 
inhibit the replication of polio (Korant et al., 1985), herpes simplex virus 
(Bjork et al., 1990) and corna virus (Collins and Grubbs, 1991), respectively. 
Antibacterial activity of peptidyl derivative like cyclopeptides structurally 
based upon the inhibitory centre of human cystatin C were reported by 
Kasprzykowski et al (2000) against Streptococcus pyogenes and 
Staphylococcus aureus. Takahashi et al (1994) also reported the inhibition of 
Staphylococcus aureus V8 by phosphorylated cystatin a in the skin cornified 
envelop of Staphylococcus aureus. 
However, the results obtained by Blankenvoorde et al (1998) suggested 
that the growth of Porphyromonas gingivalis is due to the antibacterial 
sequences present in chicken cystatin and cystatin S and that it does not depend 
on the inhibition of P. gingivalis CP. Antifungal role of cystatin from plant 
sources has also been reported (Soares-costa et al., 2002). Cystatin 11 was also 
found to have antimicrobial activity against Escherichia coli. 
Different reports suggest possible clinical application of these proteins 
for prediction of prognosis (Duffy et al., 1996). Serum cystatin C can be used 
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cystatin C can be used as a marker of GFR in patients with various renal 
diseases (Newmann et al., 1995; Servais, 2008). 
SCOPE OF OUR STUDY 
Cystatins are crucial for proper brain functioning. Alzheimer's disease is one of 
the most prevalent diseases of the ageing population which is characterized by 
amyloid plaques. It has been investigated that lysosomal proteinase 
(cathepsins) and their endogenous inhibitors (cystatins) have been closely 
associated with senile plaques, cerebrovascular amyloid deposits and 
neurofibrillary tangles in Alzheimer's disease (Bernstein, 1996; Levy, 2008). 
Cystatin C is also found to be linked with epileptogenesis and epilepsy 
(Lukasuik K., 2002) along with other neurodegenerative diseases (Mc Geer 
P.L., 1995). 
Brain is the most important organ of the mammalian body. It is large soft mass 
of nerve tissue contained within the cranium. The brain consists of five parts: 
the cerebrum, cerebellum, pons varolii, medulla oblongata and the midbrain. It 
is the primary center for regulating and coordinating body activities (Fig 1.6). 
A review of the existing literature showed that cystatins from mammalian 
sources have species as well as organ differences, they differ not only in size 
but in several other properties. Therefore, in view of the reported differences in 
molecular and functional properties of cystatins from various species and 
organs it was thought desirable to isolate and purify cystatin from a hitherto 
uninvestigated source i.e. goat brain and subsequently investigate 
systematically its physicochemical properties. 
In the present study two types of cystatins have been purified from goat brain, a 
high molecular weight cystatin (HMGBC, MW 70,800) and a low molecular 
weight cystatin (LMGBC, MW 12,720). Both the cystatins have been 
characterized for their functional and structural properties. 
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Fig 1.6 Structure of a mammalian brain 
Medial aspect of adult mammalian brain in sagittal section. 
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FREE RADICAL STUDIES WITH HIGH MOLECULAR MASS 
GOAT BRAIN CYSTATIN 
Oxidation and production of free radicals are an integral part of human 
metabolism. Oxygen is the ultimate electron receptor in a closely linked 
electron flow system that produces energy in the form of ATP. Under certain 
conditions, the electron flow become uncoupled, leading to production of free 
radicals, which are molecules with unpaired electrons and thus show high 
reactivity. Examples of free radicals include superoxide (0*2), hydroxyl (OH*), 
peroxyl (RO*2), alcoxyl (R O*), oxides of nitrogen (NO*, NO*2) and thiyl 
(RS*) (Halliwell et.al., 1995, Andreas , 1996). In addition, free radicals may be 
induced by reactive oxygen-containing species (ROS) generated in biological 
systems such as phagocyte activation, lipid oxidation, the arachidonate 
pathway, autoxidation of cathecolamines, reduced flavins, hemoprotein and 
iron mediated reactions. Examples of ROS include singlet oxygen ('02), 
hydrogen peroxide (H2O2) and hypochlorous acid (HOC1) (Halliwell et al., 
1995; Thomas, 1995; Stes, 1991). 
Radicals and non radical oxidants can be generated by a wide range of 
different processes in biological systems. These range from the deliberate, and 
highly controlled, generation of radicals within the active site of enzymes to the 
unintended, essentially random, formation of oxidants in cells and tissues 
exposed to exogenous agents high energy radiation including radiation like X-
rays, gamma rays, UV or visible light in the presence of a sensitizer, metal 
ions, solvents, particulate matter (asbestos, airborne material), nitrogen oxides, 
ozone or smoke of various forms (Davies , 2005; Halliwell et al., 1992; 1999). 
Most highly reactive oxidants, including many radicals, react with 
virtually all biological molecules, including DNA, RNA, cholesterol, lipids, 
carbohydrates, proteins and antioxidants. This oxidative modification of 
macromolecules by ROS plays a role in wide range of common diseases and 
age related degenerative conditions (Borek, 1991; 1993; 1997; Gutteridge et 
al.„ 1993). These include cardiovascular diseases (Witztum, 1993) and 
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neurodegenerative diseases such as Alzheimer's disease (Richardson, 1993), 
and cancer (Borek, 1997). 
Proteins are major targets for ROS as a result of their abundance in 
biological systems. Oxidants react rapidly with protein backbone and side 
chain residues causing various deleterious consequences including protein 
damage and degradation (Davies et al.„ 1987a), modification of amino acids 
(Davies et al.„ 1987b), secondary and tertiary structures of proteins (Davies et 
al.„ 1987c). 
There is now good evidence that proteins are major targets for oxidants 
and also protein oxidation plays a very important role in several pathological 
conditions. Thus in view of this present study was carried out to see the effects 
of oxidative stress produced by photosensitizer riboflavin, hydrogen peroxide 
and nitric oxide radicals, these studies were done only on purified high 
molecular mass goat brain cystatin, HMGBC. LMGBC was not taken under 
consideration because of its poor resolution in the polyacrylamide gel 
electrophoresis in the oxidation experiments. 
Riboflavin and Hydrogen peroxide induced modifications of 
HMGBC 
Riboflavin and H2O2 are two common reactive oxidants present in 
mammalian body under various metabolic conditions. Riboflavin is an 
important constituent of our daily diet .It is present in free and conjugated form 
in almost all biological tissues and fluids (Spector et al.„ 1980; Rose et al.„ 
1986) Flavins are known to photooxidize amino acids and also effect the 
conformation of proteins (Penzer, 1970; Wu and Mc Cormick 1971; McCarrow 
and Chun, 1983). They are known to generate singlet oxygen, hydroxy 1 radicals 
and flavin triplet state on photoillumination ( Joshi, 1985) which can modify 
proteins and other biological molecules. 
H202 is another important oxidant generated as diffusible cofactors in 
inflammation. The steady state concentration of H202 in the cell is 10'9 to 10"8 
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M (Boveris et al.„ 1973). Its concentration may markedly increase when tissues 
are exposed to ionizing radiations during metabolism of carcinogens and at 
inflammatory sites (Simon et al., 1981; Shechter et al., 1975). Generated H202 
may modify amino acids, degrade heme in red blood cells (Nagababu et al., 
2003) and inactivate enzymes (Dean et al., 1997) and antiproteinase (Khan and 
Khan, 2004). 
There are five possible reactive oxygen metabolites (ROMs). These are five 
possible species: 02*", hydroperoxyl radical ( H02*), peroxide ion (H02"), 
hydrogen peroxide and hydroxyl radicals (OH*) 
0 2 e' , 0 2 -
0 2 2e7 2H+ „ H202 
H202 Fe2+/Cu+ „ OH' + OH" 
The 02*" and hydrogen peroxide so formed, in presence of metal catalyst may 
lead to the formation of most reactive *0H. 
EFFECT OF NITRIC OXIDE AND CURCUMIN ON HMGBC 
Nitric oxide is a gas synthesized by a family of enzymes present in the 
cells of the body. NO is a molecule with pleiotropic effects in different tissues. 
It is synthesized by NO synthases (NOS), a family of enzymes with four major 
types: endothelial, neuronal, inducible and mitochondrial. They can be found in 
almost all the tissues and they can even coexist in the same tissue. NO is a 
good vasorelaxant agent (Huang et al.,1999), it works as a neurotransmitter 
when produced by neurons (Bredt and Snyder, 1994) and is also involved in 
defence when produced by immune and glial cells (Guix et al., 2005). NO is 
thermodynamically unstable molecule and tends to react with other proteins 
molecules especially proteins resulting in their oxidation, nitration and 
nitrosylation, with the concomitant effects on many cellular mechanisms. 
However, under pathophysiological conditions NO has damaging effects (F ig. 
1.7a). NO is found to be involved in neural disorders involving oxidative stress 
such as Alzheimer's disease (Tran et ah, 2003; ischemia (Thiyagarajan et al., 
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2004), Parkinson's disease (Torreilles et ah, 1999), Huntington's disease 
(Butterfield et al., 2001), amyotrophic lateral sclerosis (Boll et al., 2003) and 
multiple sclerosis (Kahl et al., 2003). 
Curcumin is a major component of turmeric, extracted from the 
powdered dry rhizome of Curcuma longa Linn. {Zingiberaceae). It has been 
traditionally used in India for food and medicinal purposes. Curcumin has 
shown to possess diversified chemical, biological and pharmacological 
properties, such as antioxidant (Ruby et al., 1995; Sharma, 1976) and anti-
inflammatory activities (Amon and Wahl, 1991; Satoskar et al.„ 1986) (Fig. 
1.7b). Furthermore, the anti carcinogenic activity of Curcumin has been 
reported in a variety of chemically induced tumors including digestive organ 
(Huang et al.„ 1994; Periera et al., 1996), skin (Huang et al.„ 1997) tumors 
and in cell lines (Verma et al., 1997; Kuo et al., 1996; Khan et al., 1999). 
Although the exact mechanism by which Curcumin promotes these effects 
remains to be elucidated, the antioxidant properties of the pigment appear to 
underlie its pleiotropic biological activities (Motterlini et al.„ 2000). 
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Structure of curcumin 
We studied the effect of damage induced by riboflavin and hydrogen 
peroxide on the purified HMGBC. In addition to this the type of ROS involved 
in this damage has also been investigated with the help of the scavengers and 
antioxidants. The damage induced by nitric oxide (NO) and the protective 
effect of curcumin against this damage has also been studied. 
UNFOLDING AND REFOLDING STUDIES OF HMGBC AND 
LMGBC IN THE PRESENCE OF DENATURANTS UREA AND 
GdnHCl 
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Fig 1.7 
(a) The donors and physiological functions of nitric oxide 
(b) Schematic diagram showing multiple biological activities of 
curcumin 
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Biological activity of proteins is strictly related to the three dimensional 
structure which is assumed to depend in principle, only on the primary 
structure of proteins. The transformation of a newly synthesized proteins on 
ribosomes to a functionally active form, involves complex and intricate process 
of folding. The information for the folding of a disordered structure of protein 
lies in its amino acid sequence (Anfinsen, 1973). The identification and 
characterization of intermediates during the folding process is central to 
understand the process of protein folding. These studies provide an insight to 
the mechanism of how and when different forces come into play for directing 
the protein folding (Wuthrich, 1994; Ballery et al., 1993). The mechanism by 
which proteins fold from a denatured structure less stable state to their 
biologically active form is an intricate process (Nolting et al., 1995; Plaxo and 
Dobson, 1996). Recent technological progress especially in the field of 
biophysical studies has helped to show the presence of intermediate states 
during the folding and unfolding pathways (Ptitsyn, 1994; Radford and 
Dobson, 1995). These intermediate states or partially unfolded states have been 
studied for several proteins (Fink et al., 1990; Christensen and Pain, 1991). 
Characterization of these conformational transitions has helped in 
understanding the phenomenon of protein folding (Kim and Baldwin, 1990; 
Redfield et al., 1994). 
It has been shown that the amount of tertiary structure and the 
compactness of intermediate state vary from one protein to another (Kuwajima, 
1989). These intermediate states have structures either close to the native or 
unfolded state depending upon the protein being studied and experimental 
conditions used. Therefore besides presence of molten globule states from 
N<->D folding/ unfolding transition, there exist transition states between native 
and molten globule states or molten globule and unfolded state (Redfield et al., 
1994; Ptitsyn, 1995). Characterization of such states can be of utmost 
importance in further understanding the protein folding phenomenon. There are 
various ways of studying protein stabilization, for example, denaturation by 
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GdnHCl, urea and alkaline denaturation. Much of what is currently known 
about protein folding and protein stability has been observed from theoretical 
and experimental investigations from small monomeric proteins and protein 
domains ranging from 50-150 amino acids in size. Unfolding and refolding 
studies using chaotropic agents have given a wealth of information on the 
structure and biogenesis of proteins (Tanford, 1968). Solvent denaturation 
studies on monomeric proteins have been extremely rewarding in 
understanding protein structure. 
Studies on a number of monomeric proteins have helped in elucidating 
many important factors in protein folding reactions. It has been established that 
electrostatic interactions, hydrophobic effects (Schreiber and Fersht, 1995), 
hydrogen bonding (Koh et al., 1997), folding nuclei (Mirny and Shakhnovich, 
1999) and partially folded intermediates play important role in the process by 
which a single polypeptide chain acquires its secondary and tertiary structure 
(Chamberlain and Marqusee, 2000). 
It s well known that proteins unfold under the action of denaturants like 
GdnHCl and urea. Analysis of solvent denaturation curves using these reagents 
can provide a measure of the conformational stability of a protein (Pace, 1986; 
Yao and Bolen, 1995). Despite the widespread work in this front, description of 
the interaction of GdnHCl and urea with proteins is not complete owing to the 
complex structure of the folded proteins. Our current understanding of the 
protein folding/unfolding mechanism is the result of intense studies on 
denaturation of proteins using both theoretical and biophysical methods 
(Wuthrich, 1994; Ballery et al., 1993). Study of denatured states provides an 
insight to understand the mechanism of unfolding. The development of broad 
range of techniques has led to the characterization of stable intermediates in 
several proteins (Barrick et al., 1994). 
Unfolding of small compact proteins are well defined by a simple two 
state transition, however, it has been pointed out that the simple two state 
model is often too simplified version of a more complex unfolding pathway 
46 
which includes the formation of a metastable intermediates (Kuwajima, 1989). 
It is now accepted that unfolding/refolding of a number of proteins involves 
different steps, that is under different conditions different states have been 
observed that do not appear to be native or completely unfolded (Tanford, 
1968). When transitions were analyzed by different spectroscopic probes, 
intermediate states have been found for several proteins like bovine and human 
carbonic anhydrase P (Wong and Tanford, 1973; Jagannadham and 
Balasubramaniam, 1985), (3-lactamase (Mitchinson and Pain, 1985), bovine 
growth hormone (Brems et al., 1985) and a chemically modified form of 
human growth hormone (Brems et al., 1990). There are various reports 
available which have shown different effects of GdnHCl and urea on protein 
unfolding like Mushroom tyrosinase which shows different behaviour towards 
GdnHCl, urea and SDS in terms of different transition processes for these 
denaturants (Park et al., 2003). Kinetic parameters in these cases have shown 
different unfolding pathways. In case of RNase from Rhizopus stolonifer it has 
been shown that at pH 5.0 urea has a D (1/2) (D- represents concentration at 
amid point of transition) value of 5.7M where as GdnHCl has a D (1/2) value 
of 3.1M (Deshpande et al., 2003). For methanol dehydrogenase, inactivation is 
observed at 1M GdnHCl or 6M urea and fluorescence maximum is observed at 
5M GdnHCl and 8M urea (Wang et al., 2000). 
Though the partially folded forms of various proteins have been 
characterized, it has not yet been possible to generalize the concept of 
'intermediate states as universal equilibrium protein folding intermediates. 
However characterization of protein folding intermediate is helpful in 
identifying and understanding various transition steps and forms located 
between native and denatured states of a protein (Goto et al., 1990, 1993). The 
investigation of the presence of intermediate states in HMGBC and LMGBC in 
the present study has shed some light on the hierarchy of protein folding. 
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HIGH pH INDUCED DENATURATION OF HMGBC AND 
LMGBC 
To be biologically active, all proteins must adopt specific folded three 
dimensional structures. The refolding of denatured proteins in vitro has been of 
great interest and thus extensively studied. It has been demonstrated that 
residual structural preferences, ranging from local clusters of side chains to 
highly ordered sub domains, persist in denatured states of proteins (Kim and 
Baldwin, 1990; Dobson, 1991; Prajapati et al., 1998; Ptitsyn, 1995; Arcus et 
al., 1995). The study of folding intermediates is a key point in protein folding 
investigations. Unfolding transitions induced by various methods such as acid, 
alkali, denaturants or heat are useful for understanding the conformational 
stability of proteins (Shortle, 1996; Fink et al., 1994; Creighton, 1993) 
pH is known to influence the stability of proteins by altering the net 
charge on the protein. Alkaline treatment of proteins result in their denaturation 
and in this state they are often less unfolded than the completely unfolded form 
obtained in high concentrations of urea and GdnHCl. In alkali or acid 
denaturation the major diving force for unfolding is intramolecular charge 
repulsion which may fail to overcome interactions that favour folding such as 
hydrophobic forces, disulphide bonds, salt bridges and metal ion protein 
interactions ( Fink et al., 1996; Creighton, 1993). To investigate this effect 
HMGBC and LMGBC were first denatured under alkaline conditions at high 
pH and then their refolding was studied. 
Effect of salts on the high pH induced refolding of HMGBC 
and LMGBC 
The stability of proteins in the salt solutions is the major concern of 
biologists and pharmacologists. An in depth knowledge of protein denaturation 
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and refolding is central in selection of a particular solvent for protein 
stabilization. 
Salts have been known to affect the physicochemical properties of 
proteins like their solubility (Carbonnnaux et al., 1995) stability (Von Hippie 
and Schleich, 1969) and pKa (Abe et al., 1995; Tan et al., 1995) to a great 
extent. They can induce conformational transitions in alkaline or acidic 
solutions from a largely unfolded state to an intermediate conformational state 
(Hong Bai et al., 1998). Salts mainly affect the electrostatic and hydrophobic 
interactions in the protein molecules. In the presence of salts a conformational 
transition at acidic or alkaline pH from a largely unfolded state to an 
intermediate conformational state has been reported for several globular 
proteins (Fink et al., 1994; Babu and Bhakuni, 1997). The main forces 
unfolding the protein under extreme pH conditions are the repulsive forces 
between charged groups on the protein molecule. Under these conditions the 
presence of higher salt concentration will have two effects on the protein 
conformation. The Debye-Huckel screening effect, i.e. the counter ions 
presence around the charged group will weaken the repulsion thus permitting 
the other forces favouring folding to become relatively strengthened and 
resulting in the folding of the protein. In addition to this, non specific effects of 
salts, specific effects of salts on protein folding will also come into play. The 
stabilizing and destabilizing effects of salts on proteins arise either by effects 
on water surface or due to hydrophobic interactions or by specific interactions 
with charged groups. It is well established that the effect of anions in 
stabilizing protein structure follows the Hoffmeister series (Von Hippie and 
Wong, 1965). The representative series is sulphate > phosphate > fluoride > 
chloride > bromide > iodide > perchlorate > thiocyanle. In this series ion to the 
left of chloride stabilize the native structure of the protein, whereas anions to 
_ v the right of chloride destabilize the proteins native structure of proteins. 
Arakawa and Timasheff (1982) have shown that preferential hydration of 
proteins occurs in the presence of salts such as NaCl, sodium acetate and 
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sodium sulphate and that the resulting unfavourable free energy of the unfolded 
state is related to the stabilization effects of these salts on the proteins. Salt 
dependent conformational transition of proteins at alkaline and acidic pH may 
be a general property, however, the concentration of salt required to bring 
about the transition will depend on the particular protein being studied and the 
conditions employed. Therefore, it was thought worthwhile to study the effects 
of salts on the refolding of alkali denatured HMGBC and LMGBC. 
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2. MATERIALS 
Chemicals used for the present study were obtained from the sources indicated. 
S.no 
1. 
2. 
3. 
4. 
5. 
6. 
Source /Company 
Genei Bangalore, 
India 
Hi -Media, India 
Merck-
Schereherdt, 
Germany 
Pharmacia Fine 
Chemicals 
Sigma Chemicals 
co. USA 
QuaJigens Fine 
Chemicals, India 
Chemicals 
Molecular weight markers -PMW-M, Freund's 
complete and incomplete adjuvant. 
Agarose, sodium azide. 
2-mercaptoethanol, sodium sulphate, potassium 
chloride. 
Blue dextran 
Anti-rabbit alkaline phosphatase (conjugate), 
Bovine serum albumin, Bromelain, 
Chymotrypsin, Curcumin, Cytochrome C, Griess 
reagent, Ficin, hydrogen peroxide, Ovalbumin, 
Papain, p-nitrophenyl phosphate, riboflavin, 
Sephadex G-100, Sodium dithionite, Sodium 
nitrite, Soyabean trypsin inhibitor, Trypsin. 
Ammonium persulphate, ammonium sulphate, 
ascorbic acid, bromophenol blue, disodium 
1 
hydrogen phosphate, ethyl alcohol, 
formaldehyde, glacial acetic acid, glycerol, j 
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7. 
Sisco Research Lab 
(SRL), India 
hydrochloric acid, methanol, isopropanol, 
mannitol, monosodium dihydrogen phosphate, 
potassium iodide, silver nitrite, sodium benzoate, 
sodium carbonate, sodium chloride, sodium 
hydroxide, sodium dodecyl sulphate, sodium 
potassium tartarate, sulphuric acid, thiourea, 
trichloroacetic acid, TEMED, Iris 
(hydroxymethyl amminomethane). 
Acrylamide, N'N' methylene bis-acrylamide, 
casein, L-cysteine, glucose, commassie brilliant 
blue- R250, DEAE cellulose, EDTA, Folin 
Ciocalteau's phenol reagent, GdnHCl, glycine, 
phenol, sucrose and urea. 
t 
52 
3. METHODS 
3.1 PURIFICATION OF HIGH MOLECULAR MASS AND LOW 
MOLECULAR MASS GOAT BRAIN CYSTATINS 
Fresh brain tissue (150 grams) was homogenized in 50 mM sodium phosphate buffer 
of pH 7.5(300ml) containing 0.15 mM NaCl, 3mM EDTA and 2% n-butanol. After 
centrifugation at 3000g for 15 minutes at 4°C in a Beckman J-21 cooling centrifuge 
residue was discarded and the supernatant was further processed. 
Alkaline Treatment 
The supernatant obtained was subjected to alkaline pH 11.0 by 3N NaOH and 
incubated for 15 minutes at 4°C to remove unwanted proteins. After 
incubation, the pH of the supernatant was brought back to pH 7.5 with glacial 
acetic acid. The precipitated proteins were removed by centrifugation at 3500g 
for 30 minutes at 4°C in a Beckman J-21 cooling centrifuge. 
Ammonium Sulphate Fractionation 
The supernatant was fractionated with 30% saturation of ammonium sulphate 
with gentle stirring at 4°C. After 4h the precipitate was removed by 
centrifugation at 3500g for 30 minutes at 4°C and the supernatant thus collected 
was made 80% saturated with ammonium sulphate. The solution was allowed 
to stand for 4h at 4°C, the precipitate thus obtained by centrifugation at 3500g 
for 30 minutes at 4°C was dissolved in 10 ml of 50mM Na-P buffer pH 7.5. 
The dialyzed fraction was extensively dialyzed against several changes with the 
same buffer at 4°C containing 0.15M NaCl to remove ammonium sulphate. 
Gel Filtration Chromatography 
A Sephadex G-100 column was prepared as recommended by Peterson and 
Sober (1962). The gel was allowed to swell in sufficient amount of distilled 
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water for 3h in a boiling water bath. The gel fines were removed by suspending 
the gel in two to four fold excess of 0.05M sodium phosphate buffer, pH 7.5 
and allowing 90-95% of the gel to settle down. A glass column mounted on a 
sturdy vertical support was filled to one third of its length with operating buffer 
in order to check leaks and flush air bubbles from the dead space. The 
dearerated gel slurry was then poured with the help of glass rod into the column 
with care to avoid generating air bubbles. The column was left standing 
overnight. Flow rate was increased gradually and after accomplishing a 
constant flow rate higher than that required for final elution, the column was 
adjusted to the required flow rate. The packed column was thoroughly washed 
with two bed volumes of operating buffer (0.05M sodium phosphate buffer, pH 
7.5). In order to check uniform packing and to determine the void volume of 
the column, 2% (w/v) solution of blue dextran in 0.05M sodium phosphate 
buffer, pH 7.5 was passed through the column. The volume of blue dextran and 
protein solution applied was not more than 2-3% of the total bed volume. Five 
millilitre fractions were collected and assayed for protein and cystatin activity. 
Homogeneity of the preparation was analyzed by 7.5% and 12.5%> PAGE. 
Ion Exchange Chromatography 
Appropriate amount of DEAE-cellulose was suspended with 15 volumes of 
0.5N hydrochloric acid for half an hour with constant stirring and washed in a 
Buchner funnel. The washing was continued till the pH of the filtrate was 
approximately equal to 7.0. The exchanger was then treated with 15 volumes of 
0.5N sodium hydroxide for half an hour and washing continued till the pH of 
the filtrate approached neutrality. The DEAE-cellulose was then resuspended in 
operation buffer (0.05M sodium phosphate buffer, pH 8) to get homogenous 
slurry. This slurry was then poured on a vertically mounted glass column 
plugged with glass wool with the help of a glass rod. The column was left 
standing for one hour. Flow rate was subsequently adjusted with the help of a 
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stop cock until constant flow higher than required for final elution reached. 
Finally the required flow rate was adjusted. The column was then equilibrated 
with excess of the operating buffer till the pH of the effluent was identical to 
that of the eluting buffer. Elution was performed with a linear gradient (0-.5 M) 
of sodium chloride in 0.05M sodium chloride buffer, pH 7.5. Pooled fractions 
after gel filtration having protein and activity were loaded on the column. 
Three milliliter fractions were collected and assayed for inhibitory activity and 
protein concentration. 
3.2 COLORIMETRIC ANALYSIS 
Determination of Protein Concentration 
Protein was estimated by the method of Lowry et al (1951). Aliquots of protein 
solution were taken in a set of test tubes and final volume was made up to 1ml 
with distilled water. Five ml of alkaline copper reagent (containing one part of 
1% (w/v) copper sulphate and 2% (w/v) sodium potassium tartarate in 1 % 
(w/v) sodium hydroxide and sodium carbonate) was added followed after 10 
minutes of incubation at room temperature with 0.5ml of 1.0N Folin-
Ciocalteau's phenol reagent. The tubes were instantly vortexed. The color 
developed was read after 30 minutes at 660nm against a reagent blank. A 
standard curve was prepared using BSA as standard. Protein in the column 
fractions were also monitored at 280nm in Camspec spectrophotometer Model 
M330B. 
Carbohydrate Estimation 
The procedure described by Dubois (1956) was followed. Two milliliter 
aliquots containing 10-70ug of protein was pipetted in to a set of test tubes and 
0.05ml of 80% phenol was added. This was followed by the addition of 
concentrated sulphuric acid. The tubes were allowed to stand for 10 minutes at 
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30°C. The color intensity was measured at 490nm for the quantitation of 
hexose content. Glucose was used as standard, ^ - v ~~' s'^ -4?o> x 
Thiol Group Estimation 
The procedure described by Ellman (1959) was followed for estimating the 
thiol groups of cystatins. SDS and (3-mercaptoethanol induced appearance of 
free thiol group in the cystatin was followed by titration with DTNB reagent. 
Appropriate aliquots of 0.2ml native, SDS and (3-mercaptoethanol treated 
cystatin were mixed with 0.1ml of DTNB reagent (prepared by dissolving 
40mg in 100ml of 0.05M Tris-EDTA buffer, pH 8.0) in a total volume of 
3.1ml. The absorbance was read after 15 minutes at 412nm in Camspec 
Spectrophotometer Model M330 B. free thiol concentration was calculated 
from the absorbance using molar extinction coefficient of 13,600 M" cm" for 
the released thionitrobenzoic acid. A standard plot was prepared using cysteine. 
Assay of Cystatin Inhibitory Activity 
Inhibitory assay of cystatin was performed as described by the Kunitz (1947). 
HMGBC and LMGBC were examined for their ability to prevent thiol 
proteinases from digesting casein. For determination of inhibitory activity, 
papain was activated in presence of 0.14M cysteine and 0.047 M EDTA for 10 
minutes prior to incubation of papain cystatin complex for 30 minutes at 37°C 
in 0.05M sodium phosphate buffer, pH 7.5. The enzyme inhibitor complex was 
further incubated with casein for 30 minutes at 37°C and the reaction was 
stopped by addition of 10% TCA. Acid insoluble material was removed by 
centrifugation at 2500rpm for 15minutes. The supernatant was analyzed for 
acid soluble peptides with Folin phenol reagent as described by Lowry et al 
(1951). Ficin inhibition was also assayed by similar method. 
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Assay of Caseinolytic Activity of Bromelain 
The proteolytic activity of bromelain was measured according to the method of 
Murachi and Neurath (1960). The enzyme was activated at 37°C for 10 minutes 
in the presence of 0.14M cysteine. Then the volume was made upto 1ml by 
sodium phosphate buffer pH 7.5. One ml of 0.5% casein was added and 
incubated for 30 minutes at 37°C. The reaction was stopped by addition of 
1.0ml of 5% TCA. Acid insoluble material was removed by centrifugation at 
2500rpm for 15 minutes. The supernatant was analyzed for acid soluble 
peptides by Folin phenol reagent by the method of Lowry et al (1951). 
3.3 SLAB GEL ELECTROPHORESIS 
Polyacrylamide Gel Electrophoresis (PAGE) 
Electrophoresis was performed by the method of Laemmli (1970) using the 
slab gel apparatus manufactured by Biotech, India. Concentrated stock solution 
of 30% acrylamide containing 0.8% N'N' methylene bis-acrylamide and 1.5M 
Tris, pH 8.8 were mixed in appropriate portion to give the desired 
concentration of gel. It was then poured in to the mould formed by the glass 
plates (8.5x10 cm) separated by 1.5 mm thick spacers. Bubbles and leak were 
avoided. A comb providing template for seven wells was inserted into the 
stacking gel solution before the polymerization began. The polymerization was 
complete in about 30 minutes after which the comb was removed and wells 
overlaid with running buffer. Routinely, 7.5% and 12.5% gel was used. 
Samples containing 40-60ug of protein was mixed with equal volume of 
sample buffer (62.5mM Tris HC1 pH 6.8, 10% (v/v) glycerol and 0.001% 
bromophenol) as tracking dye was applied to the wells. Electrophoresis was 
performed at 100V in the electrophoresis buffer containing 192 mM glycine 
and 25mM Tris-HCl
 PH 6.8 until the tracking dye reached the bottom of the 
gel. 
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SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis was essentially 
performed by the Tris-glycine system of Laemmli (1970) using slab gel 
electrophoresis apparatus. Concentrated stock solution of 30% acrylamide 
containing 0.8% N'N' methylene bis-acrylamide and 1.5M Tris, pH 8.8 were 
mixed in appropriate proportions to give the desired percentage of gel. Protein 
samples were prepared in solution containing 62.5 mM Tris-HCl pH 6.8, 10% 
(v/v) glycerol, 2% (w/v) SDS, 5% (v/v) 2-mercatoethanol and 0.001% (w/v) 
bromophenol blue. The samples were incubated at 100°C for 5 minutes. 
Electrophoresis was performed at 100V till the tracking dye reached the bottom 
of the gel. Running buffer used during electrophoresis contained 1% SDS in 
addition to 192mM glycine and 25mM Tris-HCl, pH 6.8. 
Staining of the Gel 
Commassie Blue Staining 
After electrophoresis the gels were stained with five gel volumes of commassie 
brilliant blue R-250 in 50% methanol and 10% acetic acid for at least 4h. For 
destaining, the gels were incubated with shaking in 5% methanol and 7.5% 
acetic acid at room temperature. 
Silver Staining 
The gel after electrophoresis was silver stained by Blum's silver stain method 
(Nesterenko, 1994). The staining method was initiated by fixation for 10 
minutes in 50% acetone, 1% trichloroacetic acid and 0.015% formaldehyde 
with subsequent washings. After a second fixation in 50% acetone only the gel 
was pretreated with 10% sodium thiosulfate and then impregnated with 20% 
silver nitrate and 37% formaldehyde and 10% sodium thiosulfate for 30 
seconds to 1 minute. The reaction was stopped by 1% glacial acetic acid and 
incubated for 15 minutes in 1% glycerol after rinsing in distilled water. 
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3.4 MOLECULAR WEIGHT DETERMINATION 
The molecular weight of high molecular mass goat brain cystatin and low 
molecular mass cystatin were determined under native and denaturing 
conditions by gel filtration chromatography and SDS PAGE, respectively. 
Molecular weight determination by gel filtration chromatography 
The molecular weight of native HMGBC and LMGBC were computed from its 
elution volume on Sephadex G-100 column (2 x 70cm). the column was 
calibrated by determining the elution volume of the following marker proteins-
phosphorylase b (97 KDa), bovine serum albumin (68KDa), Ovalbumin 
(45KDa), trypsin (23KDa),Cytochrome C (13 KDa) and insulin (5.7 KDa). 
This data was analyzed according to the theoretical treatment of Andrews 
(1964) method. The linear plot between Ve/Vo and logM was used in 
calculating the molecular weight of goat cystatins where Ve is the elution 
volume of the protein and Vo is the void volume of the column determined 
using blue dextran. 
Molecular weight determination by SDS-PAGE 
Molecular weight of cystatins under denaturing conditions was calculated by 
the procedure of Weber and Osborn (1969) using SDS PAGE. The mobilities 
of marker proteins determined under identical conditions were plotted against 
the logarithms of molecular weight. The standard proteins used were 
phosphorylase b (97KDa), bovine serum albumin (68 KDa), ovalbumin 
(45KDa), carbonic anhydrase (29KDa) and soyabean trypsin inhibitor (20 
KDa). The analysis of data indicated a linear relationship between logM and 
relative mobility (Rm) and the plot was used for calculating the molecular 
weight of cystatins. 
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3.5 IMMUNOLOGICAL PROCEDURES 
Immunization of Rabbits 
Antibodies against HMGBC were raised in healthy male albino rabbit. 300|ig 
of electrophoretically pure HMGBC in 0.5ml of normal saline emulsified with 
equal volume of Freund's complete adjuvant was injected simultaneously in 
rabbit. Two weeks later 150 ug of cystatin was injected along with Freund's 
incomplete adjuvant. Similar second and third booster doses were given in the 
third and fourth week respectively and the animal was bled after one week. The 
blood collected was allowed to coagulate at 22°C for 3h. The antisera was 
decomplemented at 57°C for 30minutes and stored at -20°C in small aliquots. 
Immunodiffusion 
Immunodiffusion was performed essentially by the method of Ouchterlony 
(1962). One percent molten agarose in normal saline containing 0.2% sodium 
azide was poured on a glass petriplate and allowed to solidify at room 
temperature. Required numbers of wells were cut and the slides were stored at 
4°C. Fifteen to twenty microlitres of suitably diluted antisera and required 
amount of antigen prepared in normal saline were added in different wells. The 
reaction was allowed to proceed for 12-24h in moist chamber at room 
temperature. The petriplate was immersed in normal saline to remove non-
specific precipitin lines. 
Direct binding ELISA 
The generation of antigen specific antibody was measured in the sera of 
HMGBC immunized rabbit by the technique of direct binding ELISA (enzyme 
linked Immunosorbent assay) as given by Voller et al (1976). 
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Buffers and Substrate: Tris buffer saline (TBS), pH 7.4. 20mM tris, 150mM 
sodium chloride. Tris buffer saline Tween-20 (TBS-T), pH 7.4. 20mM tris, 
14.3mM sodium chloride, 200mg potassium chloride and 5ml Tween 20 was 
dissolved in 1 litre distilled water and pH adjusted to 7.4 with IN hydrochloric 
acid. Bicarbonate buffer, pH 9.5, 50mM containing 0.02% sodium azide as 
preservative. Substrate: 5mg p-nitrophenyl phosphate (in 10ml bicarbonate 
buffer). 
Procedure: ninety six wells polystyrene microtitre plates were taken. The test 
wells were coated with lOOul of the antigen (HMGBC, 0.5ug/aooml of 
bicarbonate buffer). The plate was inoculated for 2h at room temperature and 
then overnight at 4°C. The plate was washed three times with TBS-T buffer. 
The unoccupied sites were saturated by incubation with 150u£/200ul of 1.5% 
milk in TBS for 5-6h at room temperature. Wash it twice with TBS-T. The test 
and control wells were then loaded with lOOul of serially diluted serum. Each 
dilution was done in TBS buffer. Serially diluted blanks corresponding to each 
dilution should be there. Then the plate was incubated for 2h at room 
temperature and overnight at 4°C. Wash the plates twice with TBS-T buffer. 
Bound antibodies were assayed with an appropriate conjugate of anti-rabbit 
alkaline phosphatase (1:3000). lOOul of it is coated in each well and kept at 
room temperature. Wash the plate with TBS-T five times and twice with 
distilled water. Add p-nitrophenyl phosphate (50ug/100jil) in each well and 
incubate at 37°C for 30-45 minutes. The reaction was stopped by the addition 
of lOOul of 3M NaOH in each well. The absorbance of each well was 
monitored at 405nm on a Qualigens ELISA reader. 
3.6 KINETICS OF INHIBITION 
Stoichiometry of Proteinase Inhibition 
Papain was used for the titration of HMGBC and LMGBC. The inhibitory 
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activity of cystatin was assessed by its ability to inhibit caseinolytic activity of 
papain by the method of Kunitz (1947). The concentration of papain was varied 
from 0.01-0.06uM whereas the inhibitor concentration was fixed at 0.06uM. 
papain was activated on incubation with 0.14M cysteine and 0.047 M EDTA 
for 10 minutes at 37°C. The inhibitor was added and the volume was diluted to 
lml by 50mM sodium phosphate buffer, pH 7.5 and further incubated for 30 
minutes for at 37°C. One ml of 2% casein was added and again incubated for 
30minutes at 37°C. The reaction was stopped by adding lml of 10% 
trichloroacetic acid. After centrifugation (2500rpm for 15 minutes) the acid 
soluble peptides were quantitated by the method of Lowry et al (1951) as 
described in section 3.2. Identical experiments were carried out for the 
HMGBC and LMGBC with other proteinases, ficin and bromelain using casein 
as substrate (Kunitz, 1947; Murachi and Neurath, 1960). 
Inhibition constant (Ki) determination 
Ki determination was carried out after lowering the enzyme and inhibitor 
concentration to obtain a non linearity of dose response curves. Thus papain 
was used at a concentration of 0.06uM to react with inhibitor varying from 
0.01-0.24uM and measurement of residual activity was made as described by 
Kunitz (1947) using casein as substrate. Four different substrate concentrations 
were used (0.5 Km, lKm, 2Km and 3Km with Km= 2.4mM) and the results 
were analyzed by the steady state equation of Krupka and Laidler (1959). The 
linear equation is presented as follows (Henderson, 1972). 
1-V7V0 
Ki 1 + -
v Kmj 
~
+n ( i) 
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Where [I]0, [E]0 and [S]0 are the initial concentrations of inhibitor, enzyme and 
substrate respectively. Vo is the velocity without inhibitor. The plot of [I]0/ (1-
Vi/Vo) against Vo/Vi is a straight line, the slope of which gives, 
KkaP P) ~ K i 
V Km 
(2) 
True Ki was obtained from a rep lot of Ki (app) against [S]0. 
Determination of association rate constant (K+l) 
K+i values were determined by monitoring the time dependence of the 
association under second-order condition. Equimolar amounts of enzyme and 
inhibitor (0.06u.M) were mixed in a total volume of 1ml of the same buffer of 
pH 7.4 at 37°C and residual activity was assayed as a function of time after 0, 
5, 10, 15, 29, 25 and 30 minutes as described above using casein as substrate 
for papain, ficin and bromelain. 
Association rate constant K+i was calculated assuming enzyme [E] and 
inhibitor [I] react in according to equation (3) and considering dissociation 
constant (K.|) to be low enough to neglect the reverse reaction during the initial 
part of the process. 
E + I
^ =
± E I
 (3) 
Thus, when initial concentration of enzyme [E]0 and inhibitor [I]0 are identical, 
the integrated form of the equation giving association rate becomes: 
True Ki was obtained from a replot of Ki (app) against [S]0. 
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Determination of dissociation rate constant (K -1) 
Conditions for maximum association between proteinase and the inhibitor were 
achieved before the reaction was shifted towards association by adding excess 
of substrate which binds the entire free enzyme (Beith et al., 1980). Substrate 
induced dissociation was monitored with identical enzyme-inhibitor complex 
incubated for 30 minutes at 37°C. Excess substrate (6%) was added to the 
mixture for different time periods and then it was assayed for inhibitory activity 
as described in section 3.2. 
On the basis of eqn (3) the dissociation rate constant of El complex obeys first 
order kinetics during the initial part of the reaction, ie, when there is almost 
complete association. In this case the integrated form of the dissociation rate 
equation is given by 
( [EI] ) In ±-± =K,t (5) 
1[EI]J -
From which half life of the complex may be calculated by rearranging the 
equation as follows 
tV2=0.693/K., 
Similar experiments for Ki determination, association and dissociation rate 
constants were done for ficin and bromelain with HMGBC and LMGBC using 
their respective substrates. 
3.7 SPECTRAL ANALYSIS 
Absorption Difference Spectra 
Ultraviolet absorption difference spectra were measured for HMGBC and 
LMGBC (70ug/ml) along with activated papain with a molar ratio of 1:1 at 25 
±2°C. Spectra were recorded by measuring the absorption between 200-350nm 
on Cintra -5 spectrophotometer in a cuvette of 1cm path length. Appropriate 
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controls of the solvent buffer were run and corrections were made wherever 
necessary. 
Fluorescence spectroscopy 
Fluorescence measurements for papain, HMGBC and LMGBC along with their 
complexes with papain were performed at 25±1°C in Shimadzu 
spectrofluorimeter model RF-540 equipped with a data recorder DR.-3.The 
excitation wavelength was 280nm (A.ex) and emission wavelength range was 
300-400nm. 2uM HMGBC/LMGBC and 2uM papain in a total volume of 1ml 
was used for the study. Cells with path length were used and samples were 
continuously stirred during measurements. Corrected emission spectra were 
recorded with an excitation and emission band width of 5nm. Appropriate 
controls were run and corrections were made wherever necessary. 
Circular Dichroism (CD) Spectroscopy 
CD measurements were carried out with a Jasco spectropolarimeter, model J-
720, using a SEKONIC XY plotter (model SPL-430 A) with a thermostatically 
controlled cell holder attached to a NESLAB RTE-110 water bath with an 
accuracy of ±0.1°C. The instrument was calibrated with D-10-
camphorsulphonic acid. The spectra were recorded with a scan speed of 
20nm/min and with a response time of 4 seconds. Near UV-CD and far UV-
CD spectra were measured at a protein concentration of lmg/ml and 200ug/ml, 
respectively. The pathlength was 1mm. Each spectrum was recorded as an 
average of four scans. The spectra obtained were normalized by subtracting the 
baseline recorded for the buffer having the same concentration of denaturants 
under similar conditions. Changes in the secondary structure of HMGBC and 
LMGBC on interaction with activated papain were obtained at a molar ratio of 
1:1. 
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3.8 OXIDATIVE STRESS INDUCED HMGBC DAMAGE BY 
RIBOFLAVIN AND HYDROGEN PEROXIDE 
This study was done only with HMGBC because of the poor results obtained with 
LMGBC in the required % of PAGE. 
Antiproteolytic activity of HMGBC 
After oxidative stress the inhibitory activity of HMGBC against papain was 
monitored by the caseinolytic method reported by Kunitz (1947) as described 
in the section of methods 3.2. 
Reaction of photosensitized riboflavin with HMGBC 
HMGBC (500nmoles) was photoilluminated with increasing concentration of 
riboflavin (5-100uM) in a final mixture volume of lOOOul at room temperature 
(25°C-28°C). Stock riboflavin of 2 mM was freshly prepared in 50 mM sodium 
phosphate buffer, pH 7.5. 
To access the time required for damage of HMGBC with riboflavin, it was 
photoilluminated for different time intervals (0-120 minutes) with IOOJIIM of 
riboflavin in the same amount of reaction mixture in a volume of 1 ml. The 
light incubations were done by setting tubes at a distance of 1 cm from 40W 
cool fluorescent lamp. The light intensity was 0.768 mW at a distance of 1cm, 
measured by a model 351-A power meter. 
To see the effect of scavengers on this damage, HMGBC (400-500nmoles) was 
incubated with lOOuM riboflavin for 1 hour along with sodium azide, sodium 
benzoate, potassium iodide, uric acid, mannitol, thiourea and ascorbic acid, it 
was then estimated for residual inhibitory activity. 
To analyze the effect of metal ions on the oxidative damage of HMGBC it was 
incubated with lOOuM riboflavin for 1 hour in the presence of chloride salts of 
Mg+2, Mn+2, Zn+2, Cu+2, Ca+\ Ni+2and Cd+2.After incubation the residual 
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inhibitory activity of HMGBC was measured by the caseinolytic method 
(Kunitz, 1947) as described earlier. 
Reaction of hydrogen peroxide (H202) with HMGBC 
To see the damage caused by hydrogen peroxide on HMGBC (500 nmoles), it 
was incubated with increasing concentration of H202 (0-500mM) in a final 
reaction mixture (volume of 1ml) at room temperature (25°C-28°C) in the dark. 
HMGBC was also tested for varying time intervals (0-120 minutes) with 500 
mM H202. It was also incubated with 500 mM H202 in presence of various 
scavengers and quenchers including catalase for two hours in dark at room 
temperature. Effect of various divalent metal ions was also detected by 
incubating the HMGBC (500nmoles) with 500mM H202 in presence of 2 mM 
metal salts. The residual inhibitory activity of the inhibitor was then estimated 
by the caseinolytic method (Kunitz, 1947) as discussed previously. 
Polyacrylamide gel electrophoresis of riboflavin and hydrogen 
peroxide treated H M G B C 
Structural changes on HMGBC (500nmoles) upon treatment with different 
concentrations of riboflavin and H202, and at lOOuM riboflavin and 500mM 
H202 incubated for varying time intervals, were examined by performing PAGE 
using 12.5% gel as described by Laemmli (27), using tris-glycine buffer, pH 
8.3. To validate the type of radicals involve, different scavengers and 
antioxidants were also used in the incubation mixture of HMGBC and 
riboflavin and H202. Atleast three gels of each experiment were performed. All 
the gels were silver stained by the method previously reported (Nesterenko, 
1994). 
67 
Fluorescence spectroscopy of riboflavin and H202 treated 
HMGBC 
Intrinsic fluorescence measurements were carried out on Shimadzu 
spectrofluorimeter model RF-540 equipped with a data recorder DR-3 at 
25±1°C. The fluorescence was recorded in the wavelength range 300nm-
400nm after exciting the protein solution at 280nm. The slits were set at 5nm 
for excitation and emission. The pathlength of the sample was 1cm. luM of 
HMGBC was incubated with varying concentrations of riboflavin and H2O2 
for 1 and 2 hours respectively and then the fluorescence was measured. 
Appropriate controls were run and corrections were made wherever necessary. 
Each spectrum was the average of four scans. 
3.8 A EFFECT OF CURCUMIN ON THE NITRIC OXIDE 
INDUCED DAMAGE OF HMGBC 
Thiol proteinase inhibitor assay of cystatins 
The inhibitory activity of HMGBC against papain was monitored to see the 
effect of nitric oxide on the inhibitory activity of HMGBC and the protective 
effect of curcumin on its functional modification, HMGBC was incubated with 
NO in the presence and absence of curcumin and was analyzed for cystatin 
inhibitory activity against papain as described by Kunitz (1947). 
Treatment of HMGBC with NO 
To see the effect of nitric oxide on HMGBC, it was incubated with nitric oxide 
generated by the reduction of sodium nitrite with sodium dithionite as 
described earlier (Dixit, 2001). To standardize the time of incubation the 
modification was performed for varying time intervals (Ominutes -3 hours) at 
o 
37 C. The reaction sample contained HMGBC (lOOnmoles), sodium nitrite 
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(lOOmM) and sodium dithionite (lOmM). After incubation the reaction mixture 
was dialyzed against 50mM sodium phosphate buffer, pH7.5 for inhibitory 
activity assay and electrophoresis as described earlier. Native HMGBC 
incubated with 1 OOmM sodium nitrite and 1 OmM sodium dithionite alone were 
taken as controls. 
Measurement of nitrite - the Griess reaction 
This is followed by measurement of the total nitrite in the sample by the 
stoichiometric diazotization reaction using the Griess reagent to form a purple 
azo product (Green et al., 1982). 
For determination of nitrite, the Griess reagent mixture was freshly prepared by 
dissolving 1 gram of Griess reagent powder in 25ml of 50mM sodium 
phosphate buffer. Out of this 500 JLXI of the prepared Griess solution was added 
to the reaction mixture containing HMGBC (lOOnmoles), sodium nitrite 
(lOOmM) and sodium dithionite (lOmM) incubated for two hours. After adding 
Griess reagent it was incubated for 15 minutes and then read at 540nm. 
Effect of Curcumin on NO treated HMGBC 
Stock curcumin solution (ImM) was prepared by dissolving in absolute 
ethanol. To see the protective effect of curcumin against the nitric oxide 
induced modifications of HMGBC, The HMGBC was incubated with NO 
producing chemicals (as described above) in the presence of varying 
concentrations of curcumin (0uM-300uM) for 2 hours at 37°C. For PAGE, 
fluorescence studies and inhibitory activity assay the mixture was dialyzed 
against 50mM, Na-P buffer pH 7.5 to remove excess curcumin which may 
otherwise interfere with the fluorescence measurements. 
To validate the nitric oxide scavenging potency of curcumin, lOOuM curcumin 
was incubated with lOOmM sodium nitrite and lOmM sodium dithionite in 
50mM Na-P buffer for 2 hours. At the end of the incubation, the reaction 
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mixture was collected for measurement of the nitrite converted from NO using 
Griess reagent (Green et al., 1982). 
Polyacrylamide gel electrophoresis of NO treated HMGBC 
To analyze the structural changes of HMGBC upon nitric oxide induced 
modification, HMGBC (500nmoles) treated with NO with varying time 
intervals of incubation was examined by native PAGE using 10% gel 
essentially outlined by Laemmli (Laemmli,1970) using tris-glycine buffer 
,pH8.3. To verify the protective effect of curcumin on NO treated HMGBC 
different concentrations of curcumin with HMGBC and NO were analyzed by 
10% PAGE (native). The gels were stained by the method previously reported 
(Nesterenko, 1994). 
Fluorescence spectroscopy of NO treated HMGBC 
Intrinsic fluorescence measurements were carried out on a Shimadzu 
spectrofluorimeter model RF-450 equipped with data recorder DR-3 at 25CC 
±l°C.The fluorescence was recorded in the wavelength range 300-400nm after 
exciting the protein solution at 280nm for total protein fluorescence. The slits 
were set at 5nm for excitation and emission. The path length of the sample was 
1 cm. luM of HMGBC was incubated with nitric oxide producing chemicals in 
presence and absence of curcumin and then the fluorescence was measured. 
Appropriate controls were run and corrections were made wherever necessary. 
Each spectrum was the average of atleast four scans. 
Fluorescence measurements in the presence of 8-Anilino-
naphthalene sulphonic acid (ANS) 
Fluorescence spectra were recorded with Shimadzu spectrofluorimeter model 
RF-540 equipped with the data recorder DR-3 at 25°C±1°C. HMGBC was 
incubated with NO producing chemicals in presence and in absence of 
curcumin for 2 hours at 37°C. They were then mixed with concentrated stock 
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solution (luM) of ANS dissolved in methanol. The excitation wavelength was 
taken as 365 nm and the emission was recorded in the wavelength range 400-
600nm. The molar ratio of protein and ANS was approximately 1:60 in all 
experiments. Appropriate controls were run and corrections were made 
wherever necessary. Each spectrum was the average of atleast four scans. 
3.9 UNFOLDING AND REFOLDING STUDIES OF HMGBC AND 
LMGBC 
3.9A DENATURANT INDUCED FUNCTIONAL AND STRUCTURAL 
CHANGES 
Assay of inhibitory Activity of HMGBC and LMGBC in the 
presence of GdnHCl and Urea 
The inhibitory activity of both the cystatins was assessed by its ability to 
inhibit caseinolytic activity of papain by the method of Kunitz (1947) and the 
protein concentration was measured by the method of Lowry et.al. (1951). In 
presence of denaturants both HMGBC and LMGBC were incubated with 
increasing concentrations of GdnHCl (1-6M) and urea (1-8M) at 25°C for 2 
hours prior to activity measurement. Untreated HMGBCandLMGBC activity 
was taken as 100%. 
Intrinsic fluorescence study 
Intrinsic fluorescence measurements were carried out on Shimadzu 
spectrofluorimeter model RF-540 equipped with a data recorder DR-3 at 
25±1°C. The fluorescence was recorded in the wavelength range 300nm-
400nm after exciting the protein solution at 280nm for total protein 
fluorescence. The slits were set at 5nm for excitation and emission. The 
pathlength of the sample used in the fluorescent measurements was 1cm. The 
protein concentration was taken as 1 uM for both HMGBC and LMGBC. 
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HMGBC and LMGBC were incubated in 50 mM sodium phosphate buffer pH 
7.5 in the presence of increasing concentrations of GdnHCl (0-6M) and urea 
(0-8M) for 2 hours at room temperature before the spectra were recorded. 
Appropriate controls were run and corrections were made wherever necessary. 
Each spectrum was the average of four scans. 
Extrinsic Fluorescence (ANS binding) 
A stock solution of ANS was prepared in methanol, appropriate stock solution 
of ANS (lOmg/ml) was added to the HMGBC and LMGBC in absence and 
presence of varying concentrations of GdnHCl and urea. For ANS fluorescence 
the excitation wavelength was 380nm and the emission spectra was scanned 
between 400-600nm with slit widths of 5nm. The molar ratio of protein and 
ANS was approximately 1:60 in all experiments. Each spectrum is the average 
of atleast four scans. 
Circular Dichroism measurements 
CD measurements were carried out with a Jasco spectropolarimeter, model J-
720, using a SEKONIC XY plotter (model SPL-430 A) with a thermostatically 
controlled cell holder attached to a NESLAB RTE-110 water bath with an 
accuracy of ±0.1 °C. The instrument was calibrated with D-10-
camphorsulphonic acid. Far UV-CD spectra were measured at a protein 
concentration of 200ug/ml. the pathlength was 1mm. Each spectrum was 
recorded as an average of four scans. The spectra obtained were normalized by 
subtracting the baseline recorded for the buffer having the same concentration 
of denaturants under similar conditions. 
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3.9 B HIGH pH INDUCED FUNCTIONAL AND STRUCTURAL 
CHANGES 
Alkaline denaturation and Assay of Inhibitory Activity of 
HMGBC and LMGBC 
Alkaline unfolding of both the cystatins was carried out using 50mM sodium 
phosphate buffer. For this, 50ul of stock solution (3mg/ml) of HMGBC and 
LMGBC was added to the 950ul of sodium phosphate buffer adjusted to pH of 
desired pH (7-14) using sodium hydroxide solution and after that the samples 
were incubated for 3hours at room temperature. Final pH and protein 
concentration were again measured before spectroscopic measurements. 
The inhibitory activity of both the cystatins were assessed by its ability to 
inhibit caseinolytic activity of papain by the method of Kunitz (1947) and the 
protein concentration was measured by the method of Lowry et al (1951) as 
described earlier in method section 3.2. Both HMGBC and LMGBC were 
incubated with buffers of different pH (7-14) at 25°C for 3 hours before the 
inhibitory activity of cystatins was measured for alkaline unfolding. 
Intrinsic / Tryptophan Fluorescence Measurements of high pH 
treated cystatins 
Intrinsic fluorescence measurements were carried out on Shimadzu 
spectrofluorimeter model RF-540 equipped with a data recorder DR-3 at 
25±1°C. The fluorescence was recorded in the wavelength range 300nm-
400nm after exciting the protein solution at 280nm for total protein 
fluorescence. The slits were set at 5nm for excitation and emission. The 
pathlength of the sample used in the fluorescent measurements was 1cm. The 
protein concentration was taken 1 uM for both HMGBC and LMGBC. 
HMGBC and LMGBC were incubated in 50 mM sodium phosphate buffer of 
various pH (7-14) for 3 hours at room temperature before the spectra were 
recorded. Spectra were also recorded at pH 12 in presence of two 
concentrations of KC1 (2M and 3M) and Na2S04 (0.5M and 1.0 M) for both the 
73 
cystatins. Appropriate controls were run and corrections were made wherever 
necessary. Each spectrum was the average of four scans. 
Extrinsic Fluorescence (ANS binding) of high pH treated 
cystatins 
Extrinsic fluorescence measurements were carried out on Shimadzu 
spectrofluorimeter model RF-540 equipped with a data recorder DR-3 at 
25±1°C. A stock solution of ANS was prepared in methanol, appropriate ANS 
stock solution was added to the HMGBC and LMGBC in sodium phosphate 
buffer of different pH values. Spectra were also recorded at pH 12 in presence 
of two concentrations of KC1 (2M and 3M) and Na2S04 (0.5M and 1.0 M) for 
both the cystatins. For ANS fluorescence the excitation wavelength was 380nm 
and the emission spectra was scanned between 400-600nm with slit widths of 
5nm. The molar ratio of protein and ANS was approximately 1:60 in all 
experiments. Each spectrum is the average of atleast four scans. 
Circular Dichroism Spectroscopic studies of alkaline pH treated 
HMGBC and LMGBC 
CD measurements were carried out with a Jasco spectropolarimeter, model J-
720, equipped with a microcomputer. The instrument was calibrated with D-
10-camphorsulphonic acid. All the CD measurements were carried out at 25°C 
with a thermostatically controlled cell holder attached to a NESLAB RTE-110 
water bath with an accuracy of ±0.1 °C. Far UV-CD spectra were measured at a 
cystatins concentration of 200ug/ml. cystatins were incubated in 50 raM 
sodium phosphate buffer of various pH (7-14) and at pH in presence of salts 
KC1 and Na2S04 for 3 hours at room temperature before the spectra were 
recorded. The pathlength was 1mm. Each spectrum was recorded as an average 
of four scans. The spectra obtained were normalized by subtracting the baseline 
recorded for the buffer having the same concentration of denaturants under 
similar conditions. 
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4. RESULTS 
4.1 PURIFICATION AND CHARACTERIZATION OF HIGH AND 
LOW MOLECULAR MASS GOAT BRAIN CYSTATIN 
4.1.1 PURIFICATION 
In the present study cystatins have been purified from goat brain by the method 
of Sumbul and Bano (2007). As described in the methods section, the 
procedure involved combination of alkaline treatment, ammonium sulphate 
fractionation, gel filtration chromatography and ion exchange chromatography. 
The proteins obtained after alkaline treatment were precipitated between 30-
80% ammonium sulphate saturation. The precipitate thus obtained was 
dissolved in 50mM sodium phosphate buffer, pH 7.5 and dialyzed against the 
same buffer containing 0.15 M NaCl. This resulted in 11.54 fold purification 
and 31% yield (Table 1.2). 
4.1.2 GEL FILTRATION 
The protein after dialysis was chromatographed on a column of Sephadex G-
100 (1.1 x 100cm) equilibrated with 50mM sodium phosphate buffer pH 7.5. 
Two protein peaks with papain inhibitory activity were obtained (Fig. 1.8). 
Peak I corresponding to high molecular mass goat brain cystatin (HMGBC) 
was found to be heterogeneous on native PAGE and was further purified by ion 
exchange chromatography. Papain inhibitory fractions of peak II were pooled, 
concentrated and checked for purity. Peak II corresponding to low molecular 
mass goat brain cystatin (LMGBC) was purified with a fold purification of 
1128 and yield of 14%. 
4.1.3 ION EXCHANGE CHROMATOGRAPHY 
Peak I obtained from Sephadex G-100 column was further fractionated by 
subjecting the pooled fractions to ion exchange chromatography on DEAE-
cellulose column at pH 8.0. The proteins were eluted by running a salt gradient 
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of 0-0.5 M NaCl. Two protein peaks were obtained showing significant papain 
inhibitory activity only in the first major peak (Fig. 1.9). This three step 
procedure resulted in 923 fold enrichment in specific activity and a yield of 
13.8%. The purification of both HMGBC and LMGBC has been summarized 
in Table 1.2. 
4.1.4 HOMOGENEITY 
Homogeneity of the peak II pooled fractions obtained from gel filtration 
column (LMGBC) and the major inhibitory peak obtained from ion exchange 
chromatography the HMGBC were determined by polyacrylamide gel 
electrophoresis (PAGE) in the absence of SDS. HMGBC showed a single band 
on 7.5% gel (Fig. 2.0) however LMGBC also showed a single band on 12.5% 
gel (Fig.2.1). 
4.1.5 REDUCING AND NON REDUCING SDS PAGE 
Purified HMGBC and LMGBC were also analyzed by SDS-PAGE under non 
reducing (in the absence of (3-mercaptoethanol) and reducing conditions (in the 
presence of P-mercaptoethanol) (Fig 4.4A and 4.4B). 
4.1.5 PROPERTIES OF HIGH AND LOW MOLECULAR MASS GOAT 
BRAIN CYSTATINS 
Molecular Weight 
The molecular weight of native HMGBC and LMGBC was determined using 
gel filtration chromatography on Sephadex G-100. The marker proteins, 
phosphorylase b (ph b),bovine serum albumin (BSA), ovalbumin, trypsin, 
cytochrome C and insulin were chromatographed on Sephadex G-100 column 
(1.1x100cm) equilibrated with 50mM sodium phosphate buffer, pH 7.5 and 
their elution volume was determined. Analysis of the data indicated linear 
relationship between logM and Ve/Vo, by the method of Andrews (1964), 
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Fig. 1.9 Ion exchange chromatography on DEAE cellulose 
Inhibitor (obtained in peak I from gel filtration was purified by ion 
exchange chromjatography on DEAE-cellulose column (2.1><7cm) equilibrated 
at pH 8.0 by 5QmM sodium phosphate buffer . the elution was performed in 
3ml fractions using a linear gradient of 0.0M-0.5M sodium chloride at a flow 
rate of 37ml/hrj. each fractions was assayed for thiol proteinase inhibitory 
activity (A) ana| absorbance was taken at 660nm (•). 
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Fig.2.0 Gel electrophoresis of HMGBC during various stages of 
purification 
Electrophoresis was performed on 7.5% at 25°C. Lane a contained 60ug 
brain homogenate, lane b contained 60jug homogenate after alkaline treatment, 
lane c is 60ug clialyzed fraction after ammonium sulphate fractionation, lane d 
is 50|ag fraction after Sephadex G-100 filtration and lane e is 40ug purified 
HMGBC after ion exchange chromatography, respectively 
a b e d e 
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Fig. 2.1 Gel electrophoresis of LMGBC during various stages of 
Purification. 
Electrophoresis was performed on 12.5% non-denaturing 
polyacrylamide gel at 25°C Lane a contained 60ug brain homogenate, lane b 
contained 60ug homogenate after alkaline treatment, lane c contained 60ug 
dialyzed fraction after ammonium sulphate fractionation and lane d has 40fig 
purified LMGBC after Sephadex G-100 gel filtration chromatography. 
a b e d 
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Fig. 2.2 SDS PAGE of the purified inhibitors HMGBC and LMGBC 
under reducing and non reducing conditions 
(A) Electrophoresis was performed on 12.5% acrylamide gel for 40ug 
HMGBC under non reducing (a) and reducing (b) conditions as described 
under methods. 
(B) Electrophoresis was performed on 15.0% acrylamide gel for 40ug 
LMGBC under non reducing (a) and reducing (b) conditions as described 
under methods. 
(A) 
a b 
(B) 
a b 
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where Ve is the elution volume of protein and Vo is the void volume of the 
column. The Ve/Vo of the native HMGBC and LMGBC corresponds to 70,650 
and 12580, respectively (Fig. 2.3). 
The molecular weights of HMGBC and LMGBC under denaturing conditions 
were determined by SDS-PAGE by the method of Weber and Osborn (1969). 
The relative mobility (Rm) of each marker protein was plotted against log 
molecular weight. The least square analysis of the data indicated a linear 
relationship between logM and relative mobility. The molecular mass was 
obtained as 70,800 for HMGBC and 12880 for LMGBC (Fig. 2.4 and 2.5). 
Stoke's Radius 
The stoke's radius of a protein correlates well with its elution behaviour from 
gel filtration column. The stoke's radii of HMGBC and LMGBC were 
determined by their elution volume from a calibrated Sephadex G-100 column 
(l . lx 100cm) using 50mM sodium phosphate buffer, pH 7.5 using marker 
proteins (Fig. 2.6). The column was calibrated by determining the elution 
volume of several proteins with known stoke's radii such as bovine serum 
albumin (35.5 A), ovalbumin (27.3 A), trypsin (20.2 A), cytochrome C (16.4 
A) and insulin (12.3 A). The data was analyzed according to the theoretical 
treatment of Laurent and Killander (1964). The equation is as follows 
Kav = Ve-Vo / Vt-Vo 
Where, Ve=elution volume, Vo= void volume and Vt= toatal volume. The 
linear plot between stoke's radius and [-log Kav '] of the marker proteins was 
used for the calculation of stoke's radii of HMGBC and LMGBC and the 
values were found to be 36A for HMGBC and 16 A for LMGBC (Fig. 2.6). 
Diffusion Coefficient 
The diffusion coefficient (D), of the HMGBC and LMGBC corresponding to 
their respective stoke's radii were computed to be 6.189><10"15 cm2/s and 
1.392xl0"'4 cm2/s with the help of equation 
83 
Fig. 2.3 Molecular weight determination of purified goat brain 
cystatins using Sephadex G-100 gel filtration chromatography 
Purified goat brain cystatins were applied on a column of Sephadex G-
100 (lx 100cm) and eluted with the 50mM sodium phosphate buffer, pH 7.5 at 
a flow rate of 30ml/hr. the molecular weight markers used were 
Phosphorylase b, (ph b ) (97KDa), Bovine serum albumin, (BSA) (68KDa), 
Ovalbumin, (ova ) (45KDa), Trypsin, (Try ) (23 KDa), Cytochrome C, 
(CytC) (13 KDa) and Insulin, (5.7 KDa) 
0.7 0.9 1.1 1.3 1.5 
logM 
BSA^^-HMGBC 
Phb 
1.7 1.9 2.1 
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Fig. 2.4 Molecular mass determination of HMGBC by SDS-PAGE 
(A) Electrophoresis was done on 12.5% polyacrylamide gel at 25 C. 
Lane a contained the molecular mass standards 1: phosphorylase b (97.4KDa), 
2: bovine serum albumin (68 KDa), 3: ovalbumin (43 KDa), 4: carbonic 
anhydrase (29.1kDa), 5: soybean trypsin inhibitor (20.1KDa) 6: lysozyme 
(14KDa). Lane b and c contained 25 ug of HMGBC in presence and in absence 
of p-mercaptoethanol, respectively. 
(B) Log M versus relative mobility (Rm) of molecular mass markers for 
determination of molecular mass of HMGBC. 
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Fig. 2.5 Molecular mass determination of LMGBC by SDS-PAGE 
(A) Electrophoresis was done on 15.0 % polyacrylamide gel at 25 C. 
Lane a contained the molecular mass standards 1: phosphorylase b (97.4KDa), 
2: bovine serum albumin (68 KDa), 3: ovalbumin (43 KDa), 4: carbonic 
anhydrase (29.1kDa), 5: soybean trypsin inhibitor (20.1KDa) 6: lysozyme 
(14KDa). Lane b and c contained 25 ug of HMGBC in presence and in absence 
of (3-mercaptoethanol, respectively. 
(B) Log M versus relative mobility (Rm) of molecular mass markers for 
determination of molecular mass of LMGBC. 
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Fig 2.6 Determination of Stoke's radii of the purified cystatins, 
HMGBC and LMGBC by Laurent and Killander plot. 
The purified cystatins were subjected to gel filtration on Sephadex G-
100. The Kav values were computed from the elution volume of marker 
proteins. Stokes radii of the marker proteins were bovine serum albumin 
(35.5A), ovalbumin (27.3 A), trypsin (20.2 A), Cytochrome C (16.4 A) and 
insulin (12.3 A). 
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D = KT/ 67ir|r 
Where K is the Boltzman's constant (1.386* 10"16 erg/deg), T is the absolute 
temperature (303K) and n is the coefficient of viscosity of the medium 
(0.01 OOP for water and dilute aqueous salt solutions at 20°C) (Friefelder, 
1982). 
Carbohydrate Content 
HMGBC was found to have 2% carbohydrate content. While LMGBC was 
found to be devoid of any carbohydrate content which is a property of class I 
cystatins, that is stefins (Barrett, 1986). 
Sulphydryl Content 
The Sulphydryl groups of HMGBC and LMGBC were titrated against DTNB 
as described in the methods (Ellman, 1959). Colorless solutions were obtained 
indicating that no free sulphydryl groups are present in purified HMGBC and 
LMGBC. 
pH stability of HMGBC and LMGBC 
Both HMGBC and LMGBC are found to be quite stable in the pH range 6-10 
(Fig. 2.7). At pH 3.0 both the inhibitors lost their inhibitory activity. However 
at pH 4 and 5, also HMGBC shows more than 80% inhibitory activity while 
LMGBC retained only 75% of its activity. 
Temperature stability of HMGBC and LMGBC 
Both the inhibitors, HMGBC and LMGBC were found to be maximally active 
to the temperature range of 25°-65°C (Fig. 2.8). At temperatures higher than 
95°C both the inhibitors lose more than 30% of their inhibitory activity. 
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Fig 2.7 Effect i f pH on HMGBC (A) and LMGBC (•) 
50 ng of HMGBC and LMGBC were incubated with 50mM sodium 
acetate buffer pH 3.0-6.0, sodium phosphate buffer pH 7.0-8-0 and tris HC1 
buffer pH 9.0 for 30 min at 37°C. After the incubation, the pH of the inhibitor 
solutions was neutralized and then 50ug of activated papain was added and the 
mixture was fuiither incubated for 60min at 37°C. The following procedure was 
same as described in 'Methods' using casein as substrate. The activity of 
papain in the absence of inhibitor at pH 7.5 was taken as 100%. 
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Fig 2.8 Effect bf temperature on HMGBC (A) and LMGBC (•) 
Fifty micrograms of cystatin in 50mM sodium phosphate buffer, pH 7.5, 
was incubated at various temperatures for 30 minutes. 50 Mg of activated 
papain was added and kept for 30 min at 37°C and then the remaining % 
inhibitory activity was analysed by the caseinolytic method of Kunitz as 
described in the methods section. The inhibitory activity of the HMGBC and 
LMGBC at 37°C was taken as 100%. 
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Thermal Denaturation 
Both the cystatins HMGBC and LMGBC were exposed to 90°C for different 
time intervals, rapidly cooled and inhibitory activity was determined. Both the 
inhibitors were found to be stable upto 45 minutes at 90°C and more than 50% 
inhibitory activity of both the cystatins were retained after 60 minutes of 
incubation (Fig. 2.9). 
4.1.6 IMMUNOGENIC PROPERTIES 
Antibody Titre 
Owing to the high molecular weight, the high immunogenicity of the HMGBC 
led to a high titre of the antibody in the serum of the rabbits. The titre of the 
HMGBC antiserum was determined by direct binding ELISA and was found to 
be 39810 (Fig. 3.0). 
Cross Reactivity 
High molecular mass goat brain cystatin (HMGBC) was highly immunogenic 
and readily induced antibody formation in rabbits. Fig.3.1 shows that the 
antisera raised against purified HMGBC has cross reactivity with the inhibitor 
as indicated by a single precipitin line on immunodiffusion plate exhibiting 
immunogenic purity and homogeneity of the inhibitor preparation (Fig. 3.1). 
HMGBC also exhibited immunogenic identity with low molecular mass goat 
brain cystatin (LMGBC) but showed no immunogenic identity with purified 
goat lung cystatin (Fig. 3.2). 
Inhibition of Proteinases by HMGBC and LMGBC 
The inhibitory activity of HMGBC and LMGBC towards thiol proteinases 
papain, ficin, bromelain and serine proteinases, trypsin and chymotrypsin was 
examined using casein as substrate. Both the cystatins inhibited thiol 
proteinases in the order papain > ficin > bromelain, whereas HMGBC and 
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Fig 2.9 Thermal denaturation of HMGBC and LMGBC 
50 ug of HMGBC and LMGBC were incubated at 90°C in sodium 
phosphate buffer pH 7.5 and rapidly cooled. 50ug of activated papain was 
added and the mixture was further incubated for 60min at 37°C. The following 
procedure was same as described in 'Methods' using casein as substrate. (- -o-
-) indicates LMGBC and (—•—) indicates HMGBC. 
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Fig 3.0 Direct binding ELISA 
Serially diluted antiserum and pre immune serum were incubated with 
0.5ug/100ul antigen (HMGBC). The procedure has been described in 
'methods'. (- -<p- -) denotes preimmunized serum. Immunized serum is 
presented by solid lines (—•—). 
2 3 4 
-log serum dilution 
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Fig 3.1 OuchteHony Immunodiffusion 
Anti HMGBC antiserum was raised in albino rabbits. In the 
immunodiffusion experiment cystatin antisera was allowed to react with 
HMGBC. The central well contained the HMGBC antiserum and well 1, 2 and 
3 contained 20u.g of HMGBC. 
Fig 3.2 Immunodiffusion of HMGBC with LMGBC and goat lung 
cystatin 
Anti HMGBC antiserum was raised in albino rabbits. In the 
immunodiffusion HMGBC antisera was allowed to react with LMGBC and 
goat lung cystatin. The central well contained the HMGBC antiserum and well 
1, 2, 3 and 4 contained 20^g of HMGBC, 20ug of LMGBC, 20ug of goat lung 
cystatin and Saline respectively. 
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LMGBC did not show significant inhibition of serine proteinases trypsin and 
chymotrypsin (Fig.3.3). 
4.1.7 KINETICS OF INHIBITION 
Stoichiometry of Inhibition 
Both the cystatins HMGBC and LMGBC were found to be highly specific for 
thiol proteinases such as papain, ficin and bromelain with no specificity for 
serine proteinases, trypsin and chymotrypsin. The inhibition of proteinases was 
studied by varying the molar concentration of proteinases at a fixed molar 
concentration of cystatin. The remaining activity of proteinase showed that as 
the concentration of proteinase was increased from 0.01-0.06uM it is 
progressively inhibited by the cystatins, HMGBC (0.06 uM) and LMGBC 
(0.06 uM) showing a stoichiometric ratio of 1:1, therefore one molecule of 
HMGBC and LMGBC inhibits one molecule of active proteinase. 
Stoichiometric ratio of 1:1 was also obtained for ficin and bromelain. 
Ki Determination 
Ki values have been determined after lowering the papain and inhibitor 
concentrations, which favour the dissociation of the complexes, Ki values were 
determined using the steady state equation derived by Krupka and Laidler 
(1959), 
,
 u v Kmjv0 L Jo 
Fig. 3.4 shows that the Ki (app) increases as a function of the substrate 
concentration for both HMGBC and LMGBC. The true Ki value may be 
obtained from a replot of Ki (app) against [S]. The Ki (app) values obtained 
from the plot with papain were 1.875* 10"8M for HMGBC (Fig. 3.4A) and 
3.125xl0"8M for LMGBC (Fig. 3.4B). 
Fig. 3.5 depicts the Ki (app) value determination for HMGBC and LMGBC 
using the proteinase ficin. The values thus obtained were 2.05*10"8M for 
l '»J
 = K i 
1-V:/V„ 
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Fig 3.3 Inhibitory activity of HMGBC and LMGBC with different 
proteinases 
40 i^g of thiol proteinases papain, ficin, bromelain and serine proteinases, 
typsin and chymotrypsin were incubated with varying concentrations of 
HMGBC /LMGBC (0-40ng) for 30 min. The inhibitory activity of HMGBC 
(A) and LMGBC (B) towards 
papain (•), ficin (A), bromelain (A), trypsin (O) and cymotrypsin (•) 
was measured by using 2% casein as substrates. 
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Fig 3.4 Determination of inhibition constant (Ki) with papain 
Papain was used at a final concentration of 0.05|j.M with increasing 
amounts of HMGBC and LMGBC (0.01-0.24uM) and mesuremnts of residual 
activity were made using casein as substrate as described in methods. Four 
diffetent substrate concenrtations were used, i.e. 0.5Km, lKm, 2Km and 3Km 
with Km=2.4mM. For the sake of clarity only the resluts obtained for [S]= 
0.5Km for HMGBC (A) and LMGBC (B) are shown. The inset shows the 
replot of expeinnetal Ki (app) values versus [S]. Intercepts on the ordinate give 
the true Ki. 
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Fig 3.5 Determination of inhibition constant (Ki) with Ficin 
Ficin was used at a final concentration of 0.05 uM with increasing 
amounts of HMGBC and LMGBC (0.01-0.24uM) and mesuremnts of residual 
activity were made as described in methods using casein substrate. Four 
diffetent substrate concenrtations were used, i.e. 0.5Km, lKm, 2Km and 3Km 
with Km=2.4mM. For the sake of clarity only the resluts obtained for [S]= 
0.5Km for HMGBC (A) and LMGBC (B) are shown. The inset shows the 
replot of expeirmetal Ki (app) values versus [Sj. Intercepts on the ordinate give 
the true Ki. 
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HMGBC and 3.5*10"8M for LMGBC (Fig. 3.5A and 3.5B). However, the Ki 
values obtained with bromelain were 4.38xlO"8M and 6xlO"8M for HMGBC 
and LMGBC respectively (Fig. 3.6A and 3.6B). The Ki value was found to be 
lowest for papain hence it has highest affinity for the goat brain cystatins. 
IC50 Value 
IC50 is the concentration of inhibitor at which 50% of the enzyme is inhibited. 
The IC50 values obtained with various thiol proteinases have been summarized 
in Table 1.3. The values obtained for the thiol proteinases papain, ficin and 
bromelain showed ^hat papain has maximum affinity for both HMGBC (0.076 
uM) and LMGBC (0.0895 uM). Ficin has IC50 value of 0.104 uM and 0.123 
uM for HMGBC and LMGBC, respectively. Bromelain has IC50 value of 0.14 
uM and 0.172 uM for HMGBC and LMGBC, respectively. 
Association Rate Constant (K+i) 
Association rate constant (K+i) were calculated for the three thiol proteinases 
assuming that the enzyme and the either inhibitor react in such a way that 
dissociation rate is low enough to neglect the reverse reaction during the initial 
part of the reaction. The equation obtained was 
T^-i = r ^ + K^ (4) 
[E] [E0] 
Data in Fig. 3.7A and 3.7B show the plots of 1/ [E] versus time with papain. 
The slope of the straight lines obtained gives K+, which is 4.17xl03sec"lM"1 
and 3.47x 103 s e c ' W for HMGBC and LMGBC respectively. 
The association rate constants obtained for ficin are 3.50xl03sec"'M~'for 
HMGBC and 3.44xl03sec''M"' for LMGBC (Fig. 3.8A and 3.8B). For 
bromelain the association rate constant was calculated to be 3.5x 103sec''M"' for 
HMGBC and 3.33x I O W M ^ for LMGBC (Fig. 3.9A and 3.9B). 
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Fig 3.6 Determination of inhibition constant (Ki) with Bromelain 
Bromelain was used at a final concentration of 0.05|iM with increasing 
amounts of HMGBC and LMGBC (0.01-0.24nM) and mesuremnts of residual 
activity were made as described in methods using casein substrate. Four 
diffetent substrate concenrtations were used, i.e. 0.5Km, lKm, 2Km and 3Km 
with Km=2.4mVI. For the sake of clarity only the resluts obtained for [S]= 
0.5Km for HMGBC (A) and LMGBC (B) are shown. The inset shows the 
replot of expeirmetal Ki (app) values versus [S]. Intercepts on the ordinate give 
the true Ki. 
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Fig 3.7 Determination of association rate constants (Kass) for papain 
Equimolar concentrations of papain and cystatins HMGBC and LMGBC 
(0.05u.M) were incubated and residual activity (Vi) was measured as a funciton 
of time for HMGBC (A) and LMGBC (B). The fractional acvitity Vi/V0 is 
plotted against 
equation (4). 
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Fig 3.8 Determination of association rate constants (Kass) for ficin 
Equimolar concentrations of ficin and cystatins HMGBC and LMGBC 
(0.05(iM) were incubated and residual activity (Vi) was measured as a funciton 
of time for HMGBC (A) and LMGBC (B). The fractional acvitity Vi/V0 is 
plotted against time. Insets represent a plot of the data in accordance with 
equation (4). 
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Fig 3.9 Determination of association rate constants (Kass) for 
bromelain 
Equimolar concentrations of bromelain and cystatins HMGBC and 
LMGBC (0.05(iM) were incubated and residual activity (Vi) was measured as a 
funciton of time for HMGBC (A) and LMGBC (B). The fractional acvitity 
Vi/V0 is plotted against time. Insets represent a plot of the data in accordance 
with equation (4). 
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Table 1.3 Kinetic constants for the interaction of HMGBC and 
LMGBC with different proteinases. 
PAPAIN 
HMGBC 
LMGBC 
FICIN 
HMGBC 
LMGBC 
BROMELAIN 
HMGBC 
LMGBC 
Ki(M) 
1.875 *10"8 
3.125xl0"8 
2.05xl0'8 
3.5xl0"8 
4.38xl0"8 
6xl0"8 
K+1 
(M-'S"1) 
4.17xl03 
3.47xl03 
3.5xl03 
3.44xl03 
3.5xl03 
3.33xl03 
K., 
(S-1) 
2.22xl0'3 
3.13xl0"3 
3.47xl0'3 
3.33xl0"3 
5xlO"3 
4.12xl0"3 
Half life of 
the 
complex 
(S) 
3.13xl02 
2.08xl02 
1.99xl02 
2.08xl02 
1.39xl02 
1.68xl02 
IC50 
OiM) 
0.076 
0.0895 
0.104 
0.123 
0.14 
0.172 
104 
Dissociation Rate Constants (K_j) 
The conditions for the dissociation were taken as the enzyme-inhibitor 
complex obeys first order kinetics during the initial part of the reaction. 
In this case the integrated form of the dissociation rate equation is given by 
Thus, log ([EI]/[EI]0) = -K_,t/2.303. 
K., obtained with papain was 2.22* 1 0 " W f o r HMGBC and S . ^ x K r W for 
LMGBC (Fig. 4.0A and 4.0B). For ficin, the dissociation rate constants were 
3.47xl0"3sec"' and 5xlO'3sec"' for HMGBC and LMGBC, respectively (Fig. 
4.1A and 4.IB). The dissociation rate constant for bromelain was 5xl0"Jsec'' 
for HMGBC and 4.12* 10"3sec"' for LMGBC (Fig. 4.2A and 4.2B). 
Half Life of the Complex 
Half life of the complexes may be calculated by rearranging the equation 
t./2=0.693/ K., 
The~halflife values ofTTMG^ 
1.39xl02sec for papain, ficin and bromelain, respectively. The half life values 
of LMGBC were 2.08xl02sec for papain, 2.08xl02sec for ficin and 
1.68xl02sec for bromelain. Among all three proteinases bromelain cystatin 
complex has shortest half life. 
4.1.8 SPECTRAL ANALYSIS 
Changes in the secondary and tertiary structure of high and low molecular 
mass goat brain cystatins, HMGBC and LMGBC respectively on binding with 
papain were studied by UV absorption difference spectra, fluorescence 
emission spectra and far UV-CD spectra. 
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Fig 4.0 Determination of Dissociation rate constants (Kdiss) for papain 
Papain-HMGBC and papain-LMGBC complexes (1|LIM) were 
preincubated for 30min at 40°C before excess substrate was added to the 
mixture. Appearance of papain activity was recorded as a funciton of time. 
Insets show plots of the data, HMGBC (A) and LMGBC (B). 
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Fig 4.1 Determination of Dissociation rate constants (Kdiss) for ficin 
Ficin-HMGBC and ficin-LMGBC complexes (IJJM) were preincubated 
for 30min at 40°C before excess substrate was added to the mixture. 
Appearance of ficin activity was recorded as a funciton of time. Insets show 
plots of the data, HMGBC (A) and LMGBC (B). 
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Fig 4.2 Determination of Dissociation rate constants (K^s) for 
bromelain 
Bromelain-HMGBC and bromelain-LMGBC complexes (luM) were 
preincubated for 30min at 40°C before excess substrate was added to the 
mixture. Appearance of bromelain activity was recorded as a funciton of time. 
Insets show plots of the data, HMGBC (A) and LMGBC (B). 
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Ultraviolet absorption difference spectra of HMGBC and LMGBC 
with papain 
The ultraviolet difference spectrum (Fig.4.3) of both HMGBC and LMGBC 
with papain showed maxima at around 255-260 nm and another peak at 295-
300nm while minima at around 280nm. The peak around 255nm is partly due 
to phenylalanine or cysteine residues and may also be due to contribution from 
some aromatic amino acids. Peak at around 295 nm suggests involvement of 
aromatic amino acid residues in papain - cystatin complex formation. Minima 
at around 280nm indicates changes around tyrosine residues. 
Fluorescence emission spectra of HMGBC and LMGBC in complex 
with papain 
Fluorescence emission spectra showed maxima at 335nm for HMGBC (Fig. 
4.4) and 336nm for LMGBC (Fig. 4.5). Upon papain inhibitor complex 
formation intensity decreased for both the inhibitors while there is also 2nm red 
shift observed for LMGBC. These changes are indicative for alterations in 
conformation of either one or both the proteins involved in complex formation. 
Circular dichroism spectra of native HMGBC and LMGBC in 
complex with papain 
Secondary structural composition showed presence of cc-helical content and 
significant amount of p structure in HMGBC and LMGBC (Fig.4.6 and 4.7). 
Near UV-CD spectra of both the cystatins showed peak at 280nm indicating 
presence of sufficient amount of tertiary structure whereas no peak at 250nm 
depicts that disulphide bond are not present in both HMGBC and LMGBC 
(Fig.4.8). Far UV-CD analysis indicated the change in the conformation of both 
the cystatins upon complex formation with papain 
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Fig 4.3 UV-absorption difference Spectra measured for HMGBC and 
LMGBC 
HMGBC and LMGBC were incubated with activated papain for 30 min 
and an absorbance difference spectrum was calculated between 240nm-340nm. 
HMGBC ( ) and LMGBC ( ) and papain were in a molar ratio of 
1:1. Bandwidth was on the 0.05 absorbance scale on Camspec 
spectrophotometer model M330B. 
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Fig 4.4 Fluorescence Spectra of HMGBC in complex with papain 
Fluorescence spectra of the HMGBC (dashed lines, ), papain 
(smooth line, ) and papain -HMGBC complex (dotted lines, 
) was measured in excitation wavelength (Xex) of 280nm and emission 
wavelength (km) of 300-400nm. The concentration of HMGBC was 1 uM. the 
fluorescence complex of HMGBC with papain was measured at a molar ratio 
of 1:1. The slit width was 5nm for both excitation and emission beams. 
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Fig 4.5 Fluorescence Spectra of LMGBC in complex with papain 
Fluorescence spectra of the inhibitor ( ), papain ( ) and 
papain -LMGBC complex ( ) was measured in excitation wavelength 
(lex) of 280nm and emission wavelength (Xem) of 300-400nm. The 
concentration of LMGBC was luJVL the fluorescence complex of LMGBC 
with papain was measured at a molar ratio of 1:1. The slit width was 5nm for 
both excitation and emission beams. 
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Fig 4.6 Far UV 
Far UV-
The concentration 
ratio was 1:1. 
50mM sodium 
CD Spectra of HMGBC in complex with papain 
CD spectra of HMGBC, papain and papain-HMGBC complex, 
of HMGBC was 200|iig/ml and HMGBC and papain molar 
complex was obtained after incubation at 37°C for 30 min in 
phosphate buffer, pH 7.5. Cells of 1mm pathlength were used. 
The 
200 210 220 230 
Wavelength (nm) 
240 250 
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Fig 4.7 Far uy-CD Spectra of LMGBC in complex with papain 
Far UV-CD spectra of LMGBC, papain and papain-LMGBC 
complex. The concentration of LMGBC was 200|a.g/ml and LMGBC and 
papain molar ratio was 1:1. The complex was obtained after incubation at 37°C 
for 30 min in 50mM sodium phosphate buffer, pH 7.5. Cells of 1mm 
pathlength were used. 
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Fig 4.8 Near 
with papain 
tJV-CD spectra of HMGBC and LMGBC in complex 
Near IJV-CD spectra of HMGBC/ LMGBC, papain and papain-
HMGBC/ papain-LMGBC complex. The concentration of HMGBC/LMGBC 
was lmg/ml and cystatin and papain molar ratio was 1:1. The complex was 
obtained after incubation at 37°C for 30 min in 50mM sodium phosphate 
buffer, pH 7.5. Cells of 1mm pathlength were used. The unit on the ordinate is 
millidegree 
Wavelength (nm) 
300 310 
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5.1 DISCUSSION 
Endogenous thiol proteinase inhibitors constitute the ultimate level of 
regulation of the overall cellular activity of cysteine proteinases (Sotiropoulou 
et al., 1997). Because of the variety of various important physiological roles of 
cysteine proteinase inhibitors they demand significant attention. A proteinase 
inhibitor is of physiological importance because inhibition is achieved at 
physiological concentration of the inhibitor in a sufficiently short time with 
negligible dissociation of the complex (Beith, 1980) .they perform several 
important functions in the body and are associated with several pathological 
conditions including rheumatoid arthritis (Trabandt et al., 1991), osteoporosis 
(Delaisse et al., 1991), renal failure (Kabanda et al., 1995; Servais, 2008), 
septic shock (Assfalg-Machleidt et al., 1998), cardiovascular diseases (Lutgens, 
2007), metastasizing cancer (Koppel et al., 1994; Lee et al., 2008) and 
Alzheimer's disease (Levy, 2008) resulting due to imbalance of endogenous 
cysteine proteinases and their inhibitors. Extensive work has been carried out 
for the purification and characterization of these inhibitors using various 
isolation procedures. Cystatins have been purified and characterized from 
various sources including bovine muscle (Bige et al.„ 1985), goat kidney 
(Zehra et al., 2005), human spleen (Jarvinen M., 1982) human liver (Green et 
al., 1984), amyloid fibrils (Cohen et al., 1983), human placenta (Rashid et al., 
2006), sheep plasma (Baba et al., 2005), skin of Atlantic Salmon (Synnes et 
al.„ 1998) and bovine brain (Aghajanyan et al., 1988). The CPIs have been 
isolated in multiple forms from several organs. However, brain being the key 
organ of the mammalian system was chosen for the present study as lacuna 
exists in the purification and physico-chemical characterization of cystatin 
from goat brain. Thus, it was envisaged that a thorough and systematic study of 
CPI from this new source will be helpful in understanding in-depth about the 
cystatins of mammalian system and to compare its properties with other known 
mammalian cystatins. 
In the present work purification of brain cystatin was achieved usina a three-
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step procedure including ammonium sulphate fractionation, gel filtration 
chromatography and ion exchange chromatography (only for HMGBC). The 
procedure is efficient and simple with a percent yield and fold purification of 
923 and 13.8% for HMGBC and 1128 and 14% for LMGBC respectively. 
Purification of CPIs from other sources has been reported using a combination 
of several techniques like affinity chromatography, chromatofocussing, gel 
filtration and ion exchange chromatography (Anastasi et al., 1983; Evans and 
Barrett, 1987; Zehra et al., 2005, Rashid et al., 2006; Baba et al., 2005). Our 
simple procedure has given better yield and fold purification as compared to 
the values reported in literature for some other species (Bige et al., 1985; 
Aghajanyan et al., 1988). 
The molecular weight of the purified cystatins by SDS-PAGE under reducing 
and non reducing conditions was found to be 70,800 for HMGBC and 12,880 
for LMGBC. This result suggests that both high and low molecular mass goat 
brain cystatins are single chain polypeptides (Fig. 2.4 and 2.5). The molecular 
weight values obtained from gel filtration under native conditions were 70,650 
for HMGBC and 12,580 for LMGBC (Fig.2.3). 
Cystatin type I (stefins) and type II cystatins have been classified on the basis 
of molecular weight and presence of disulphide bonds. As a result cystatins 
from tissues are usually small inhibitors having Mr in the range of 11 to 25 
KDa (Rashid et al., 2006; Green at al., 1984; Zabari et al., 1993; Turk et al.. 
1995). Hence, the molecular weight of LMGBC obtained in the present study 
suggest it to be a type I cystatin but the anomalous molecular weight of 
HMGBC obtained indicates that it can not be placed in either type I or type II 
cystatins. It resembles cystatin purified from goat kidney (Zehra S., 2005) and 
low molecular weight kininogens (Barrett et al., 1986). 
Generally type I and type II cystatins isolated from from tissues lack 
carbohydrate. However, presence of carbohydrate content has been reported in 
some type II cystatins like rat cystatin C isolated from urine is slightly 
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glycosylated (Esnard et al., 1988) and cystatin isolated from goat kidney had 
also found to be slightly glycosylated (Zehra et al., 2005). Ni et al (1997) found 
carbohydrate attachments in cystatin E. Glycosylation has also been 
demonstrated in cystatin F from the immune cells and cystatin M isolated from 
primary tumour cell lines (Ni et al., 1998; Sotiropoulou et al., 1997). Presence 
of carbohydrate chains is a distinguishing feature of type III cystatins, the 
kininogens (Salvesen et al., 1985; Gounaris et al., 1984; Baba et al; 2005). 
LMGBC was found to be devoid of any carbohydrate content and is also 
devoid of disulphide bonds which are the characteristics similar to type I 
cystatins. However HMGBC containing 2% carbohydrate content is a result in 
agreement with the findings of Bige et al (1985) and Zehra et al (2005) for 
bovine muscle and goat kidney, respectively. Taken this result into 
consideration it was concluded that HMGBC may be a variant of class I and 
class III of cystatin superfamily. 
Hydrodynamic properties for the inhibitors as determined from gel filtration 
behaviour suggested a stoke's radius of 36A and diffusion coefficient of 
6.189xl0"b cm2/s for HMGBC suggesting the shape of the cystatin to be 
closely related to the bovine serum albumin. In case of LMGBC, stoke's radius 
of 16A and diffusion coefficient of 1.392><10"14 cm2/s was similar to that of 
cytochrome C, indicating that the shape of LMGBC is compact globular similar 
to that of cytochrome C ( Fig.2.6). 
Both the cystatins were found to be very stable in the pH range 6-10 (Fig.2.7). 
HMGBC and LMGBC also showed stability towards temperature range of 
25°C -65°C (Fig.2.8). Both the inhibitors were found to be stable at 90°C upto 
45 minutes (Fig.2.9). These properties are in accordance with the reported 
results for other thiol proteinase inhibitors like cystatin isolated from bovine 
muscle (Bige et al., 1985) and chicken cystatin (Saxena and Tayyab, 1997). 
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High molecular mass goat brain cystatin showed high immune response and 
gave a high titre of antibodies in rabbits owing to its high molecular weight. 
The titre of antibodies determined by direct binding ELISA in rabbit serum was 
39810 (Fig.3.0). The antibodies raised against purified HMGBC gave a single 
precipitin line on Immunodiffusion indicating that the HMGBC has 
immunogenic purity and homogeneity (Fig.3.1). The antisera exhibited 
immunogenic identity with LMGBC but did not show any immunogenic 
identity with goat lung cystatin (Fig.3.2). 
Stoichiometry of the binding of HMGBC and LMGBC with papain, ficin and 
bromelain was determined by the titration of the proteases with the inhibitor. A 
stoichiometric ratio of 1:1 was obtained for both HMGBC and LMGBC with 
papain, ficin and bromelain. This suggests that both the goat brain cystatins are 
tight binding inhibitors of these thiol proteinases. Anastasi et al (1983) and 
Nicklin and Barrett (1984) reported equimolar complexes of cystatin with 
cysteine proteinases. The result is also consistent with the findings of 
Abrahamson et al (1987). However, the binding ratio of 1:2 has also been 
reported by Bjork et al (1989). 
Both HMGBC and LMGBC are potent inhibitors of thiol proteinases as is 
evident by their Ki values which were determined by Henderson's (1972) 
method. It was readily apparent that the degree of inhibition varied with 
absolute concentration of the inhibitor as expected for tight binding reversible 
inhibition. The goat brain cystatins exhibited a Ki of 1.875><10"8 M and 
3.125xl0"8 M for HMGBC and LMGBC respectively for papain (Fig.3.4A and 
3.4B), 2.05xlCT8 M for HMGBC (Fig. 3.5A) and 3.5* 10"8 M for LMGBC for 
ficin (Fig. 3.5B) and Ki values of 4.38*10"8M and 6xl0"8M with bromelain 
(Fig. 3.6A and 3.6B), respectively, as shown in the Table 1.3. A comparison of 
Ki (app) values indicates that this cystatin has highest affinity for papain, then 
ficin and least with bromelain. It has been reported that cystatin isolated from 
other sources generally do not inhibit bromelain but in our present study 
bromelain is found to be inhibited by both the cystatins as reported earlier by 
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goat kidney (Zehra et al., 2005), human placental cystatin ( Warwas and 
Sawicki, 1985; Rashid et al., 2006) and human spleen CPI (Jarvinen and 
Rinnie, 1982). 
The values are in good comparison with other thiol proteinase inhibitors. The 
inhibition constant (Ki) for chicken cystatin and cystatin C is 5><10"12M for both 
with papain. Ki values of nanomolar range have been predicted for cathepsin B, 
H and L (cystatin A, Barrett et al., 1984; cystatin C, Machleidt et al., 1986; 
chicken cystatin, Salvesen et al., 1985; cystatin D, Balbin et al., 1994). The Ki 
values of various cystatins have been summarized in Table 1.1 A. 
The increasing value of Ki with an increase in the substrate concentration 
suggests the inhibition to be competitive (Fig, 5.6, 5.7 and 5.8). This finding is 
supported by the apparent results of Nicklin and Barrett (1984) for the 
inhibition of human cathepsin B by chicken cystatin. They obtained Ki (app) 
values of 1.85 and 3.68nM for chicken cystatin with cathepsin B of 0.05 and 
0.39mM, respectively. 
The IC5o values have been summarized in Table 1.3. HMGBC and LMGBC 
have IC50 of 0.076 \xM and 0.0895 uM with papain and highest value of 0.14 
uM and 0.172 uM with bromelain. Low IC50 value suggests a greater affinity 
for the inhibitor towards the enzyme. Hence, the lowest value for papain further 
justifies the higher affinity of the purified cystatins for papain. Katunuma and 
Kominami (1985) have found the IC50 value of 0.16 |ug of the inhibitor isolated 
from rat liver for papain and 0.046 ug for ficin and IC50 value of 4.2 ug for 
cathepsin B and 0.14 ug for cathepsin H. 
Tight binding inhibitors have high association rate constants. Among the three 
thiol proteinases, as expected papain has highest K+! (association rate constant) 
of 4.17xl03sec"'M-' and 3.47xl03sec"'M"'for HMGBC and LMGBC. 
respectively (Fig. 3.7A and 3.7B) (Table 1.3). The K+l values of 3.50><103sec" 
V and 3.44X10WM'1 for ficin (Fig. 3.8A and 3.8B) and 3.5xl03sec"'M"' 
and 3.33x103sec"'M"' for bromelain (3.9A and 3.9B) were obtained for 
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HMGBC and LMGBC, respectively. Again the affinity was in the order of 
papain > ficin > bromelain. 
The dissociation rate constant (K.,) for the enzyme-inhibitor complex was 
determined by displacement procedure, in which the inhibitor released from the 
complex, was trapped by excess substrate (casein) with the increase in time. 
The amount of enzyme released from the complex was monitored by 
continuous measurement of enzyme activity. The respective K-l values of 
HMGBC obtained for papain, ficin and bromelain were 2.22xlO"Jsec"\ 
3.47* 1 0 ' W 1 and 5><10"3sec"\ respectively (Fig. 4.0A, 4.1 A and 4.2A). The 
dissociation rate constants of LMGBC for papain were 3.13xl0'3sec"' (Fig. 
4.0B), for ficin 3.33xlO'3sec"'(Fig.4.1B) and 4.12xlO"3sec'l(Fig.4.2B) for 
bromelain were obtained. The calculated half life values of enzyme inhibitors 
complexes using these K-l values for papain , ficin and bromelain were 
3.13xl02sec, 1.99xl02sec and 1.39xl02sec with HMGBC and 
2.08xl02sec,2.08xl02secand 1.68xl02sec with LMGBC were obtained 
respectively. 
The results of the chapter give comprehensive information about the purity, 
moleculat weight, shape, specificity and kinetics of inhibition of HMGBC and 
LMGBC with papain, ficin and bromelain. The overall comparison showed that 
HMGBC and LMGBC have compact shape and inhibit papain more effectively 
as compared to other two proteinases. 
Ultraviolet spectra also show changes for HMGBC and LMGBC after binding 
with papain indicating that the environments of several aromatic amino acids 
residues in proteins have been perturbed by the interactions (Donovan, 1973a: 
1973b)(Fig.4.3). 
Changes in the fluorescence emission intensity in both the inhibitors and a 2nm 
red shift (only in LMGBC) upon formation of inhibitor - papain complex 
indicates that there is some conformational change or local interactions 
affecting chromophoric groups of the two proteins in the complex (Fig. 4.4 and 
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4.5). 
Owing to the absence of carbohydrate content, disulphide linkages and all other 
results obtained for LMGBC, it can be placed in class I, the Stefins class of 
cystatin superfamily. HMGBC however does not resemble the low molecular 
mass tissue cystatins but they resemble cystatin purified from goat kidney 
(Zehra S., 2005) and low molecular mass kininogens. Hence, it is appropriate 
to conclude that HMGBC is a variant of class I and class III of cystatin 
superfamily. Furthermore, it can also be concluded that all tissue cystatin are 
not same because of the specific physiological functions they perform in the 
mammalian body. 
Owing to the importance and myriad of crucial functions cystatins perform in 
the mammalian body, the study is of great significance as it sheds light on the 
physicochemical properties of cystatins in one of the most important 
mammalian organ, the brain. 
Chapter -2 
pi) Oxidative Stress Induced 
Functionaland'Structured 
Modifications offfldg<BC 
(<B) Nitric oxide induced damage 
and preventive effect ofcurcumin on jmrnc 
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4.2 RESULTS 
(A) Riboflavin and H 2 0 2 Induced Functional and Structural 
Modifications of HMGBC 
Functional inactivation of HMGBC 
To directly quantitate the effects of exposure of oxidants (riboflavin and 
H202) on HMGBC, the antiproteolytic activity of HMGBC was measured in the 
presence of these components by the method of Kunitz (1947) using casein as 
substrate as described in the methods section. 
It was found that photoactivated riboflavin at a concentration from 5-
lOOuM causes significant loss of (maximum of 87%) antiproteolytic activity of 
HMGBC (Table 1.4). Similarly, increase in time duration after exposure (0-
120minutes) of HMGBC with lOOuM of riboflavin resulted in the major loss of its 
inhibitory activity (Fig. 4.9). Riboflavin on photoillumination generates singlet 
oxygen, hydroxyl radicals and flavin triplet state; (Dahl and Richardson, 1980) so, 
free radical scavengers were used for detection of the type of ROS involved. Table 
1.5 shows the scavenging effect of sodium azide, uric acid, potassium iodide, 
mannitol, thiourea and ascorbic acid. Sodium azide is a scavenger of singlet 
oxygen, potassium iodide scavenges triplet state and thiourea and mannitol 
scavenge hydroxyl radicals (Martinez and Caycula, 1995). Biological antioxidants 
uric acid (Kittridge and Wilson, 1984) and ascorbic acid were also tested for their 
scavenging effects. From the data obtained (Table 1.5) it was concluded that 
hydroxyl radicals play major role in photodynamic inactivation of HMGBC, since 
mannitol and thiourea were able to prevent the inactivation of HMGBC by 
riboflavin. It was also found that to certain extent potassium iodide also inhibits 
HMGBC inactivation indicating slight involvement of flavin triplet state also. 
Among biological antioxidants only ascorbic acid was found to have significant 
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Fig 4.9 Effec} of incubation of photoactivated riboflavin and H202for 
varying time intervals on HMGBC antiproteolytic activity. 
Native HMGBC (500nmoles) was incubated with riboflavin (lOOuM) 
and H202 (500Mm) at desired concentration in a final reaction mixture volume 
of 1ml at room temperature. HMGBC was assayed for loss in antiproteolytic 
activity as determined by caseinolytic assay. Values are mean of atleast three 
independent determinations. 
(•—•) Is Untreated HMGBC is shown for comparison purposes, 
(A—A) is H202treated HMGBC and 
(•—••) is for photoactivated riboflavin treated HMGBC. 
100 
10 
T 1 1 1 1 1 r 
15 20 30 40 50 60 75 90 105 120 
Time of incubation (min) 
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Table 1.4: Effect of varying concentrations of photoactivated riboflavin 
and H 2 0 2 on antiproteolytic activity of HMGBC 
S.No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
1 
Concentration of 
photoilluminated 
riboflavin 
(uM)* 
0 
5 
10 
20 
40 
50 
80 
100 
120 
140 
150 
200 
--
%Remaining 
inhibitory 
activity of 
HMGBC* 
90±1.5 
86.7±1 
80±1 
70±2 
55±1.8 
50±3 
35±2.2 
13.3±1.3 
10±4.4 
No activity 
No activity 
No activity 
Concentration 
of H202 
(mM)* 
0 
25 
50 
100 
150 
200 
250 
300 
350 
400 
450 
500 
%Remaining 
inhibitory 
activity of 
HMGBC* 
90±2 
88±3.4 
85±4.2 
80±1.8 
70±1.5 
64±2.2 
53±3.3 i 
45±2.7 i 
40±1.9 
36±1.2 
28±1.4 
21±1.4 
Concentration of photoactivated riboflavin and H202 is as shown in the final 
reaction mixture. All incubations were carried out in fluorescent white light for 1 
hour at room temperature in 50mM sodium phosphate buffer, pH 7.5. 
*HMGBC activity was measured by using caseinolytic method. Results represent 
them mean ± S.E. calculated from three different experiments. % inhibitory 
activity is the inhibitor)' activity of HMGBC against papain. 
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scavenging effect preventing the inactivation of cystatin against photodynamic 
modification. These results collectively suggest that photoilluminated riboflavin 
induced inactivation of HMGBC proceeds mainly via pathway involving hydroxyl 
radicals. Table 1.6 gives the HMGBC inactivation by photoactivated riboflavin in 
the presence of divalent metal ion salts .It was found that the damage is enhanced 
in the presence of metal ions .The destructive effect of Mn+2, Zn+2, Cu+2, Nf2and 
Cd+2 are more pronounced as compared to the effects of Ca+ ' while Mg+ was 
found to have no effect (Table 1.6). 
H202 was also found to induce functional damage to HMGBC leading to 
loss of its antiproteolytic activity. H202 was found to cause no functional or 
structural damage in micromolar quantities however in millimoles it leads to the 
loss of 69% of antiproteolytic activity of HMGBC at 500 mM of H202 (Table 1.4). 
The damage was found to be maximum at this concentration of H202 for 2 hours of 
incubation in the dark (Table 1.5). With mannitol and thiourea, respectively 100 % 
and 98% retention of antiproteolytic activity of HMGBC was observed 
respectively. lOOug/ml of catalase was found to retain only 83% of the 
antiproteolytic activity of HMGBC. Among antioxidants only ascorbic acid was 
found to have protective effect against H202 mediated functional modification of 
HMGBC. As expected with 50 jiM of metal salts especially ZnCl2, Cucl2. FeCl2 
and NiCl2, there is considerable increase in the damage (Table 1.6). This may be 
due to the enhancement of hydroxyl radical generation by Haber - Weiss reaction 
(Tsaietal., 1985). 
Structural modification of HMGBC by photoactivated riboflavin and 
H202 
Polyacrylamide gel electrophoresis was used to analyze the deleterious 
effects of riboflavin and H202 on the structure of HMGBC. The samples incubated 
with different concentrations of riboflavin (5-100uM) (Fig. 5.0) and (25- 500 mM) 
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Fig 5.0N Polyacrylamide gel electrophoresis showing effect of varying 
concentrations of riboflavin on HMGBC 
PAGE of HMGBC (500nmoles) incubated with varying concentration 
of riboflavin (Oj-lOOuM) in light for 1 h. Lane a contains untreated HMGBC, 
lanes b, c, d, e,|f, g contain HMGBC incubated with 5,10, 25, 50, 75,100 uM 
riboflavin in light for 1 hour. 
a b c d e f 
T
ab
le
 1
.5
: E
ff
ec
t o
f v
a
rio
us
 s
c
a
v
e
n
ge
rs
 a
n
d 
a
n
tio
xi
da
nt
s 
o
n
 t
he
 in
hi
bi
to
ry
 a
c
tiv
ity
 o
f 
ph
ot
oa
ct
iv
at
ed
 r
ib
of
la
vi
n 
tr
ea
te
d 
a
n
d 
H
20
2 
tr
ea
te
d 
H
M
G
B
C
. 
C
at
al
as
e 
A
nt
io
xi
da
nt
s 
Sc
av
en
ge
rs
 
C
on
tr
ol
 
Tr
ea
te
d 
So
di
um
 
Po
ta
ss
iu
m
 
A
sc
or
bi
c 
(2
5m
M
) 
w
ith
ou
t 
a
z
id
e 
T
hi
ou
re
a 
M
an
ni
to
l 
io
di
de
 
SO
~t
g/
ml
 
lO
O~
tg
/m
l 
a
c
id
 
U
ri
c 
sc
av
en
ge
r 
a
c
id
 
-
-
-
-
-
-
~
-
-
(Yo
 In
hi
bi
to
ry
 
-
-
-
a
c
tiv
ity
 (
10
0~
tM
 
R
ib
of
la
vi
n 
10
0±
 1.
3 
I 5
± 
1.3
 
17
.9
± 1
.5 
99
.8
±2
.9
 
10
0±
0.
9 
91
.2
±3
.3
 
-
-
88
.6
±4
.1
 
15
.7
±2
.2
 
tr
ea
te
d 
H
M
G
B
C
) ~
 
%
 I
nh
ib
it
or
y 
a
c
tiv
ity
 (S
OO
mM
 
H
20
2 
tr
ea
te
d 
10
0±
2.
1 
23
.3
±1
 .4
 
22
.2
±2
.2
 
97
.8
±2
.1
 
10
0±
1.
3 
28
.9
±2
.3
 
66
.9
±2
.9
 
83
.7
±3
.1
 
47
.8
±3
.9
 
21
.7
±1
.9
 
HM
GB
C)
~ 
~
 H
M
G
B
C
 (5
00
nm
ol
es
) w
a
s 
in
cu
ba
te
d 
w
ith
 lO
O
J1
M
Ri
bo
fla
vi
n 
in
 li
gh
t f
or
 1
 h
ou
r a
n
d 
50
0m
M
 H
20
2 
in
 th
e 
da
rk
 fo
r 2
 h
ou
rs
, i
n 
pr
es
en
ce
 a
n
d 
in
 a
bs
en
ce
 o
f s
c
a
v
e
n
ge
rs
, w
ith
 a
n
tio
xi
da
nt
s 
(2
5m
M
) a
n
d 
c
a
ta
la
se
 (5
0a
nd
 1
 OO
~g
/m
l)
. R
es
ul
ts
 r
e
pr
es
en
t t
he
 m
e
a
n
 
±
 S
.E
. c
a
lc
ul
at
ed
 fr
om
 th
re
e 
in
de
pe
nd
en
t e
x
pe
ri
m
en
ts
 a
n
d 
ar
e 
e
x
pr
es
se
d 
as
 a
 p
er
ce
nt
ag
e 
o
f t
he
 H
M
G
B
C
 in
hi
bi
to
ry
 a
c
tiv
ity
. 
C
on
tr
ol
 is
 %
 in
hi
bi
to
ry
 a
c
tiv
ity
 o
f H
M
G
B
C
 w
ith
ou
t a
n
y 
tr
ea
tm
en
t.
 %
 in
hi
bi
to
ry
 a
c
tiv
ity
 is
 th
e 
in
hi
bi
to
ry
 a
c
tiv
ity
 o
f H
M
G
B
C
 
a
ga
in
st
 p
ap
ai
n.
 
- N
 
-
-
.
.
.
} 
1 
w t C 
v
in
 
c 
o 
f 
R
ib
 
o 
c
tiv
ity
 
ib
ito
ry
 
a
 
in
hi
 
o
n
 
th
e 
/—^ <Z5 
io
n
 
_ 
« 
m
et
 
"B 
4> 
iv
al
 
*o 
en 
io
us
 
m
et
al
 
sa
 
4. 
« 
> 
«•-
: 
E
ff
ec
t 
o
 
Ie
 
1.6
 
53 
H 
-
te
d 
H
M
G
 
es 
cv 
^i 
o 
a 
B 
05 
G
BC
 
s 
M 
<N 
0 
"O 
u 
fN 
u 
z 
<N 
u 
fcu 
f N 
u 
C8 u 
0 
3 
u 
f N 
u 
B 
fN 
B 
s 
fN 
u 013 
s 
CO 
T3 *- * ! 
aj 3 £3 
re
a
t 
ith
o
 
ta
ls
 
H * | 
C
on
tr
ol
 
, - ^ v 
3-© 
in 
M
et
al
: 
_ 
1 
>> 
• W 
ito
ry
 
a
ct
iv
 
In
hi
b 
£ 
0J 
O 
5 
© © 
— 
CN 
+1 i — ( 
Os 
4.
4±
3 
56
±3
 
^r 
+1 
en 
en 
±
1.
9 
3.
3 
i n 
m 
03
±
 
oo' 
fN 
-H 
TT 
en 
+1 
10
0±
1.
4 
+ 
H
M
G
BC
) 
ea
te
d 
>-> 
_•+* 
ito
ry
 
a
ct
iv
i 
In
hi
bi
 
0 N 
-s 
4> 
-
4-> 
0 
Om
M
 
© 
en 
+1 
i n 
ON 
+1 
CO 
© 
±1 
^f' 
8±
3.
3 
i 
r--' 
±
1.
5 
4.
5 
8.
8±
3 
C^ J 
22
.2
±
 
1±
3 
CN 
r^ 
en 
en 
fN 
fN 
+! O 
o 
G
BC
) *
 
« 
c 
c/T u 
3 
O 
fN 
u 
£ 
V 
in
 
da
rl 
C-l 
O 
f N 
X 
an
d 
50
0m
 
ht
 
fo
r 
1 
ho
ur
 
op 
c 
fla
vi
n
 
o 
'C 
s 
3 . © 
© 
1 w
it]
 
in
cu
ba
te
d 
on 
o3 
• — s 
50
0n
m
ol
es
 
u 
a 
S 
K 
i 
id
en
t 
in
d 
u 
fro
m
 
th
: 
-o 
al
cu
la
te
 
n
±
S.
E
.
 
c 
re
se
n
t t
he
 
m
ea
 
O. 
u 
1/5 
.
 
R
es
ul
t 
• s 
ta
l s
al
ts
 
<u £ 
3 . 
© 
i n 
m
et
al
 
io
ns
 
( 
<+-! 
o 
<L> 
d 
in
 
ab
se
nc
 
n
ee
 
an
 
00 
u 
an
y 
+-» 
o 
J3 
w
it 
U 
H
M
G
B
 
m 
tr
ol
 
w
a 
v
ity
.
 
Co
n
 
in
hi
bi
to
ry
 
ac
ti 
U 
ffl 
a S 
£ 
<y 
e 
o
f 
th
 
O0 
en
ta
 
pe
rc
 
3s
se
d 
as
 
a 
u 
ni 
; 
an
d 
ar
e 
< 
im
en
ts 
ex
pe
r 
128 
ure 
ai
ns
t 
pa
p 
00 
03 
U 
CQ O 
fH
M
 
o 
& 
ic
tiv
 
TO 
o 
n
hi
bi
 
ity
 
is
 
th
e 
ii 
_> 
03 
o 
in
hi
bi
to
ry
 
6^ 
-t—* 
3 
<U 
3 
-3 
03 
CD 
u 
129 
H202 (Fig. 5.1) were subjected to PAGE (Fig.5.2). The decrease in the band 
intensity was observed with increasing concentration of oxidants. 
Fig. 5.2 and 5.3 showed the protective effect of scavengers and antioxidants 
on the structural modification of HMGBC by lOOum riboflavin and 500mM H2C>2 
respectively .The maximum protection against the riboflavin induced damage was 
observed with mannitol, thiourea and potassium iodide .In case of H202 significant 
protection against structural damage was observed with thiourea, mannitol and 
catalase (lOOug/ml). Ascorbic acid was also found to protect the cystatin against 
this structural change with both the oxidants. Thus, from these results also it was 
further confirmed that this damage is mainly because of hydroxyl radical 
generation and they are the major radicals causing damage to both antiproteolytic 
activity and structure of HMGBC. Flavin triplet state also cause damage in 
riboflavin induced damage as this is protected by potassium iodide. 
Intrinsic fluorescence of HMGBC in the presence of Riboflavin and 
H202 
Treatment of HMGBC with increasing concentrations of riboflavin 
drastically changed its intrinsic fluorescence properties. The native HMGBC gave 
an emission maximum at 335nm when excited at 280nm (Fig. 5.4). Riboflavin 
treatment (up to 40uM) resulted in a decrease in fluorescence intensity and a blue 
shift of 2nm. While at 50uM and lOOuM of riboflavin no exact peak was 
observed. 
At even 900 micromolar H202concentration no change in fluorescence 
intensity was observed. However from 25-500 mM concentration of H202 there 
was a marked decrease in fluorescence intensity along with prominent blue shift of 
4nm. 
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Fig 5.1 PAGE showing effect of varying concentrations of H202 on 
HMGBC 
PAGE of HMGBC (500nmoles) incubated with varying concentration of 
H202 (0-500mM) in dark for 2 h. Lane a contains untreated HMGBC, lanes b, 
c, d, e, f, g contain HMGBC incubated with 25, 50, 100, 300, 400 and 500 raM 
of H202 in dark for 2 hours. 
t^A 
4* m 
^^yyj 
a b c d e f g 
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Fig 5.2 Effect of various scavengers and antioxidants on 
photoactivated riboflavin treated HMGBC 
HMGBC (500nmoles) was incubated with lOOuM photoactivated 
riboflavin along with antioxidants and scavengers (25mM) in a final reaction 
volume of 1ml for 1 hr. lane a contains native untreated HMGBC, lane b 
contains riboflavin treated HMGBC, lanes c, d, e, f, g contain HMGBC treated 
with riboflavin along with 25mM of sodium benzoate, potassium iodide, 
thiourea, mannitol and ascorbic acid. Sodium azide and uric acid shows no 
protection against the damage. 
a 
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Fig 5.3 Effect of various scavengers and antioxidants on H202 treated 
HMGBC 
HMGBC (500nmoles) was incubated with 500mM of H202 along with 
antioxidants and scavengers (25mM) in a final reaction volume of 1ml for 1 hr 
in the dark. Lane a contains native untreated HMGBC, lane b contains 500mM 
H202 treated HMGBC, lanes c, d, e, f, g contain HMGBC treated with 500mM 
H202 along with 50ug/ml catalase, 100|ig/ml catalase, thiourea, mannitol and 
ascorbic acid. Sodium azide, potassium iodide, sodium benzoate and uric acid 
showed no protection against the damage. 
a b c d e f g 
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Fig 5.4 Fluorescence spectra of HMGBC treated with 
photoilluminated riboflavin at varying concentrations 
The fluorescence emission spectra of untreated (1) and riboflavin 
treated HMGBC at 10, 20, 40, 50, 100 uM (2, 3, 4, 5 and 6) riboflavin treated 
HMGBC for 1 hr incubation. The inhibitor was excited at 280 nm and the 
emission spectra was measured in the wavelength range of 300-400nmwith a 
slit width of 5nm.fluorescence measurements were performed in 50mM sodium 
phosphate buffer, pH 7.5. 
0 I i 1 1 i 1 1 1 1 1 1 
300 310 320 330 340 350 360 370 380 390 400 
Wavelength (nm) 
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Fig 5.5 Fluorescence spectra of HMGBC treated with H202 at 
varying concentrations 
The fluorescence emission spectra of untreated (1) and H202 treated 
HMGBC 50,100,200,300,400 and 500mM (2, 3, 4, 5, 6 and 7) H202 treated 
HMGBC for 2 hours of incubation in the dark. The inhibitor was excited at 280 
nm and the emission spectra was measured in the wavelength range of 300-
400nm with a slit width of 5nm. Fluorescence measurements were performed 
in 50mM sodium phosphate buffer, pH 7.5. 
300 310 320 330 340 350 360 370 380 390 400 
Wavelength(nm) 
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(B) Nitric oxide induced damage and preventive effect of curcumin 
on HMGBC 
Functional inactivation of HMGBC by nitric oxide 
Nitric oxide generated by the reaction of sodium nitrite(lOOmM) and 
sodium dithionite (lOmM) resulted in the loss of inhibitory activity of HMGBC 
(Table 1.7) . It was observed that when HMGBC was incubated with NO 
generating compounds for an hour it caused more than 50% loss of inhibitory 
activity while at 2 hours of incubation almost 90% of the inhibitory activity of 
HMGBC was lost which was further increased upto 100% with further increase 
in the time of incubation with NO (Table 1.7). 
Structural modification of HMGBC by NO 
Structural changes of HMGBC by NO were investigated using 
Polyacrylamide gel electrophoresis, intrinsic and extrinsic (bis-ANS) 
fluorescence. 
Results of PAGE (Fig. 5.6a, 5.6b) showed that from 0-2 hours of 
incubation of HMGBC with NO, there is degradation of the inhibitor (Fig. 
5.8a) .As the time of incubation was increased from 2 hours to 4 hours there is 
formation of aggregates as indicated by the shift of the protein band to the 
upper position in the gel (Fig. 5.8b) 
The results of intrinsic fluorescence indicated that in the initial hours of 
incubation (0-2 hours) there is exposure of tryptophan residues which resulted 
in the increase of intrinsic fluorescence intensity at 335nm (Table 1.8). But as 
the time of incubation was increased from 2 hours to 3 hours there is decrease 
of intrinsic fluorescence this may be because of the burial of tryptophan 
residues during aggregate formation (Fig. 5.8). 
Extrinsic fluorescence with bis-ANS also showed that NO cause 
disruption of hydrophobic core of HMGBC (Table 1.9). Incubation of HMGBC 
with NO upto 2 hours leads to the exposure of hydrophobic patches as 
indicated by the increase in fluorescence at 480nm. But when the time of 
136 
Table 1.7 Effect of varying time intervals of incubation with NO on 
HMGBC antiproteolytic activity 
S.no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
| i o 
Treatment and time of 
incubation* 
Native HMGBC 
HMGBC+SN+SDT(Omin) 
HMGBC+SN+SDT(15min) 
HMGBC+SN+SDT(30min) 
HMGBC+SN+SDT(45min) 
HMGBC+SN+SDT(60min) 
HMGBC+SN+SDT(90min) 
HMGBC+SN+SDT(120min) 
HMGBC+SN+SDT(150min) 
% remaining 
activity 
90±1.5 
89±2 
7 
6.8±1.5 
67.9±2.1 
42.3±2.2 
34.5±2.2 
22.1±1.3 
10.3±2.1 
2.1±1.1 
% loss of 
inhibitory 
activity 
0 
1.11 
14.7 
24.56 
52.97 
61.67 
75.44 
88.56 
97.67 
HMGBC+SN+SDT(180min) | 0 | 100 
SD=Sodium dithionite, SN=sodium nitrite, HMGBC=high molecular mass goat 
brain cystatin. 
*In all the above reactions HMGBC was incubated with lOOmM sodium nitrite 
and lOmM sodium dithionite for varying time of incubation. Inhibitory activity 
was measured by the caseinolytic method. 
Results represent are man ±S.E. calculated from four different experiments. . 
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Fig 5.6 Polyacrylamide gel electrophoresis of HMGBC in the 
presence of nitric oxide generating chemicals for varying time of 
intervals 
HMGBC (500nmoles) incubated with lOOmM sodium nitrite and lOmM 
sodium dithionite for varying time intervals. 
(a) Lane a is native HMGBC, lanes b,c,d e and f contain HMGBC 
incubated with sodium nitrite and sodium dithionite for 15 , 30, 45, 60, 90 and 
120 minutes. 
(b) Lane a is native HMGBC, lanes b,c,d e and f contain HMGBC 
incubated with sodium nitrite and sodium dithionite for 150,180, 195, 210 and 
240 minutes. 
(a) 
a b c d e f 
(b) 
a b c d e f 
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Fig 5.7 Polyacrylamide gel electrophoresis of HMGBC in the 
presence of varying concentrations of curcumin 
HMGBC (500nmoles) incubated with lOOmM sodium nitrite and lOmM 
sodium dithionite in the presence and in absence of curcumin. Lane a is native 
HMGBC Jane b is NO treated HMGBC, lanes c, d, e, f and g are NO treated 
HMGBC along with 20, 40, 60 ,80 and 100 uM curcumin concentrations, 
respectively. 
a b c d e f g 
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Fig 5.8 Intrinsic fluorescence spectra of HMGBC with NO in the 
presence and absence of curcumin 
HMGBC at l|aM concentration was incubated with lOOmM sodium 
nitrite and lOmM sodium dithionite in the presence and in absence of 
curcumin. The intrinsic fluorescence spectra of native HMGBC (A),with NO 
treated for 2 hours(B), with NO treated for 3hours (C) and NO treated HMGBC 
for 2 hours in the presence of 100 uM curcumin (D). 
100 i 
300 310 320 330 340 350 360 370 380 390 400 
Wavelength(nm) 
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Table 1.8 Effect of varying time intervals of incubation with NO on 
intrinsic and extrinsic fluorescence intensities of HMGBC. 
S.no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Treatment and time of 
incubation* 
Native HMGBC 
HMGBC+SN+SDT(15min) 
HMGBC+SN+SDT(30min) 
HMGBC+SN+SDT(45min) 
HMGBC+SN+SDT(60min) 
HMGBC+SN+SDT(90min) 
HMGBC+SN+SDT(120min) 
HMGBC+SN+SDT(150min) 
HMGBC+SN+SDT(180min) 
Intrinsic 
Fluorescence 
intensity 
(*• max:=335nm) 
35.2 
48.2 
53.2 
67.3 
79.4 
84.3 
93.8 
72.3 
60.2 
Extrinsic 
fluorescence 
intensity 
(k
 max=480nm) 
15.3 
17.2 
18.3 
24.5 
26.3 
29.2 
34.3 
22.2 
11.5 
SD=Sodium dithionite, SN=sodium nitrite, HMGBC=high molecular mass goat 
brain cystatin. 
*In all the above reactions HMGBC was incubated with lOOmM sodium nitrite 
and lOmM sodium dithionite for varying time of incubation. 
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incubation is further increased till 3 hours there is disruption of hydrophobic 
patches and thus the fluorescence at 480nm also decreased as the number of 
organized hydrophobic patches was reduced to bind to bis-ANS and gave 
fluorescence at 480nm (Fig.5.9) 
Prevention of functional inactivation of HMGBC by curcumin 
Curcumin (0-100uM) was used to validate its scavenging capacity for 
NO and protection of HMGBC against the NO damage. 
It was found that at 60 uM concentration curcumin helps to prevent 
almost 50% loss of functional inactivation of HMGBC. At lOOuM curcumin 
was able to prevent almost 100% inactivation of HMGBC (Table 1.9). 
In order to rule out the possibility of involvement of nitrite radicals in 
this HMGBC damage, nitrite concentration was measured in the samples using 
Griess reagent. It was also observed that curcumin prevents the conversion of 
NO to nitrite radicals as the amount of nitrite converted from NO was barely 
detectable by the Griess reagent. Curcumin at the range used in the experiments 
did not effect the determination of nitrite concentration with the Griess reagent 
mixture. 
Preventive effect of curcumin on structural modification of HMGBC 
With varying concentration of curcumin (0-100 uM) there is prevention 
of degradation of HMGBC by NO (Fig. 5.8, 5.9). When HMGBC is incubated 
with NO at 100 uM curcumin concentration no structural change of HMGBC 
was observed in PAGE (Fig.5.7). 
Intrinsic fluorescence results also showed that lOOuM curcumin prevents any 
major structural modification of HMGBC (Table 1.9). 
Results of extrinsic fluorescence indicated that curcumin prevents the 
disruption of hydrophobic core of HMGBC by scavenging NO (Table 1.8). It 
was further observed that there is almost 100% retention of extrinsic 
fluorescence of native HMGBC in presence of 100 uM curcumin (Fig. 5.9). 
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Fig 5.9 Extrinsic fluorescence spectra of HMGBC with NO in 
presence and absence of curcumin 
One micromolar concentration of HMGBC was incubated with lOOmM 
sodium nitrite and lOmM sodium dithionite in the presence and in absence of 
curcumin. Fluorescence was measured at an excitation wavelength of 380 nm 
in the emission range of 400-600nm with a slit width of 5nm and the intensity 
at 480nm was measured. The protein ANS concentration was taken as 1:60. 
The ANS (extrinsic) fluorescence spectra of 
(A) Native HMGBC, 
(B) With NO treated for 2 hours, 
(C) With NO treated for 3hours 
(D) NO treated HMGBC for 2 hours in presence of 100 uM curcumin. 
-i 1 1 1 1 1 1 1 1 1 1 r 
400 410 420 430 440 450 460 470 480 490 500 510 520 530 540 550 
Wavelength (nm) 
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Table 1.9 Effect of varying concentrations of curcumin on 
antiproteolytic activity of NO treated HMGBC. 
S.no 
1 
2 
3 
4 
5 
6 
7 
Treatment and time of incubation* 
Native HMGBC 
HMGBC+SN+SDT(2 hours) 
HMGBC+SN+SDT+ 
20uM curcumin (2 hours) 
HMGBC+SN+SDT+ 
40uM curcumin (2 hours) 
HMGBOSN+SDT+ 
60uM curcumin (2 hours) 
HMGBC+SN+SDT+ 
80 uM curcumin (2 hours) 
HMGBC+SN+SDT+ 
lOOuM curcumin (2 hours) 
% remaining activity 
90±1.5 
10.3±2.1 
25.2±1.1 
48.4±2.3 
68.3±2.3 
77.4±2.2 
88.4±1.1 
SD=Sodium dithionite, SN=sodium nitrite, HMGBC=high molecular mass 
goat brain cystatin. 
*In all the above reactions HMGBC was incubated with lOOmM sodium nitrite 
and lOmM sodium dithionite for two hours in the presence and absence of 
curcumin. Inhibitory activity was measured by the caseinolytic method. Results 
represented are mean ±S.E. calculated from four different experiments. 
5.2 DISCUSSION 
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Proteins are major targets for damage by free radicals because of their 
abundance in biological system. They are modified at the backbone or at the 
side chain groups. As many proteins are catalytic in nature, modifications by 
free radicals can have an amplified effect on their activity i.e., susceptibility to 
proteolysis, inactivation and aggregation. Davies (2005) reported that proteins, 
which have been exposed to certain radicals, exhibit altered primary, secondary 
and tertiary structure, and can undergo spontaneous fragmentation or increased 
proteolytic susceptibility. 
Photodynamic effects of various sensitizers have long been applied to 
delineate structural and functional properties of large number of enzymes and 
other biologically active proteins (Hopkins and Spikes, 1969). In the present 
study, it has been shown that HMGBC is susceptible to reactive oxygen species 
generated by oxidants like photosensitized riboflavin, which mimics biological 
exposure to oxygen radicals and H202 (Spikes, 1977) HMGBC susceptibility 
was measured by its ability to inhibit papain after oxidative modification. 
It was observed that photoactivated riboflavin and H202 lead to 
inactivation of HMGBC towards papain (Table 1.4) owing to destruction of 
active site tryptophan residues. Major loss of tryptophan fluorescence intensity 
was observed in HMGBC on incubation with lOOuM riboflavin. Loss of 
fluorescence intensity was also observed with H202 but at considerably higher 
millimolar concentrations compared to riboflavin. Quenching of intrinsic 
fluorescence of HMGBC with increasing riboflavin / H202 concentration 
occurs probably due to oxidation of tryptophan residues leading to 
conformational change as reported earlier (Khan and Khan, 2004) 
The utilization of scavengers, quenchers and enhancers is the method 
used to investigate the role of ROS involved in the photosensitization reaction 
(Rywkin et al., 1992) and radical mediated damage. In order to investigate the 
type of ROS involved in inactivation and degradation of HMGBC sodium 
azide, potassium iodide, thiourea, mannitol, catalase (only for H202), ascorbic 
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acid and uric acid were used. It was found that mannitol and thiourea, known to 
eliminate hydroxyl radicals have preventive effect on photo-inactivation as 
well as H202 induced damage of HMGBC. Potassium iodide, which is a triplet 
flavin state quencher, also shows protection against photoactivated riboflavin 
damage of HMGBC showing the involvement of flavin triplet state in the 
damage. Catalase also protects 69% of inhibitory- activity of HMGBC caused 
by H202 damage. Retention of inhibitory activity in treated HMGBC was also 
found in the presence of ascorbic acid, which is a known biological antioxidant 
(Arad et al., 1980). Uric acid, also a biological antioxidant was found to have 
no defensive effect against this damage. This may be because uric acid 
generates radicals with certain oxidizing species, which are capable of 
biological damage (Parshad et al., 1978) e.g., by inactivating certain enzymes. 
These findings indicate that HMGBC inactivation and degradation proceeds via 
hydroxyl pathway. Thus from data obtained for riboflavin and hydrogen 
peroxide induced damage on HMGBC, it can be concluded that hydroxyl 
radicals leads to extensive structural and functional modification of HMGBC. 
NO is a pleitropic molecule that is needed for physiological functions, 
especially in the brain .It induces vasodilatation ,inhibits apoptosis and plays a 
significant role in memory processes ,making it a putatively valuable 
therapeutic agent in ageing associated diseases. However, NO can be harmful 
under oxidative stress conditions, due to the oxidation of functional proteins. 
Thus, when NO is produced in excessive amounts in the brain, it changes from 
a physiological neuromodulator to a neurotoxic factor. 
The present study is of great significance showing that HMGBC could 
be damaged by reactive oxygen species which are generated during various 
neural diseases. As cystatins play significant role in controlling the unwanted 
proteolysis in mammalian system, thus because of their important functions 
they are involved in various pathophysiological conditions including 
Alzheimer's disease (Bernstein at al., 1996, cerebral amyloid angiopathy 
(Jensson, 1990) and other neurodegenerative diseases (Shannon, 2002), their 
inactivation needs to be prevented. 
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The results showed that nitric oxide free radical leads to functional and 
structural damage of HMGBC. It was found that NO leads to the degradation of 
HMGBC (Fig. 5.6) resulting in its functional inactivation (Table 1.7) .This 
functional inactivation may also be because of oxidation of tryptophan 
residues as shown by the intrinsic fluorescence results (Table 1.8). Present 
study, further investigated the protective role of curcumin against this damage. 
Results showed that curcumin prevents this damage to a very significant level. 
It was found that at 100 micromolar concentration it exhibits remarkable 
protection of HMGBC against the functional (Table 1.7) and structural damage 
(Table 1.8, Fig. 5.7) by NO. Oxidative stress plays a major role in the 
pathogenesis of various diseases including cerebral ischemia-reperfusion 
injury, hemorrahage and shock, neuronal cell injury, hypoxia and cancer 
(Valko, 2007). It was reported that curcumin exhibits strong anti-oxidant 
properties, comparable to vitamin E and C (Toda et al., 1985).Dietary 
supplementation of curcumin was also found to be beneficial in 
neurodegenerative diseases such as Alzheimer's disease (Calabrese, 2003; 
Yang, 2005). 
Thus in the light of this work and the previously reported results 
(Sreejayan et al., 1996), it can be concluded that curcumin exhibits very 
beneficial effects against the damage caused by nitrogen free radicals 
.Curcumin appears to have a significant potential role in the treatment of 
multiple diseases due to oxidative stress. The protective effects of curcumin 
may be attributed mainly to its antioxidant properties. The study of the effects 
of curcumin on inflammatory and other oxidative stress related conditions may 
help to develop novel drugs. 
Chapter -3 
VnfoCding studies in the -presence 
of chemicaC denaturants-
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4.3 RESULTS 
4.3.1 Effect of denaturants on HMGBC and LMGBC 
Inactivation of HMGBC and LMGBC by urea 
Results of the loss in the inhibitory activity of HMGBC and LMGBC 
after incubation for 2 hours in urea solution of different concentration are shown 
in Fig. 6.0A. HMGBC was found to be stable (89% activity is retained) upto 2.0 
M urea while 85% activity was retained at same concentration of urea for 
LMGBC. The activity was lost with increasing concentration of urea reaching 
50% loss at around 3.0 M for both the cystatins. Only 25% of inhibitory activity 
of HMGBC was left at 4.0 M urea however 46% was obtained for LMGBC at 
the same concentration. Both the cystatins were left with very negligible activity 
(less than 5%) at 7.0M urea concentration. 
89% inhibitory activity of HMGBC and 94% inhibitory activity for 
LMGBC were retained upon renaturation with 50 fold dilution of the 
preincubation mixtures at urea concentration of 8M (Fig. 6.1 A). 
Effect of guanidium hydrochloride (GdnHCl) on HMGBC and 
LMGBC inactivation 
Both HMGBC and LMGBC completely lost their activities at 6.0 M 
GdnHCl concentration as shown in Fig.6.0B. Both cystatins retained around 
89% activity upto 1.5 M GdnHCl concentrations. At 3.0 M concentration only 
33.3% of inhibitory activity was retained by HMGBC while only 25 % of 
LMGBC activity was left. 
in case of 6M GdnHCl 92% inhibitory activity of HMGBC and 96 % 
inhibitory activity of LMGBC was recovered back upon renaturation at 40 fold 
dilution of the preincubation mixtures (Fig. 6. IB). 
148 
Fig 6.0 A Urea inactivation of HMGBC (•) and LMGBC (A) 
Native cystatins (lyM) were incubated with increasing concentration of 
urea (0-8M) for 2 h at room temperature. The cystatin activity was assayed for 
loss of antiproteinase activity by caseinolytic assay of Kunitz (1947). Values 
are mean of four independent determinations. 
6.0B Guanidine hydrochloride inactivation of HMGBC (•) and 
LMGBC (A) 
Native cystatins (luM) were incubated with increasing concentration of 
GdnHCl (0-6M) for 2 h at room temperature. The cystatin activity was assayed 
for loss of antiproteinase activity by caseinolytic assay of Kunitz (1947). 
Values are meaii of four independent determinations. 
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Fig. 6.1A Renaiuration of Urea induced inactivated HMGBC (•) and 
LMGBC (o) uUn dilution 
Native cy$tatins (luM) were incubated with 8M urea (0-8M) for 12 h at 
room temperature in the presence of different fold dilutions of the same buffer 
as used under naftive conditions. The cystatin activity was assayed for regain of 
antiproteinase activity by caseinolytic assay of Kunitz (1947). Values are mean 
of four independent determinations. 
Results are expressed as % regain of inhibitory activity upon dilution as 
compared to native. Inhibitory activity at 8M urea concentration is considered 
as 0% while in h^e absence of denaturant the inhibitory activity was considered 
as 100%. 
Fig. 6.1B Ren^turation of GdnHCl induced inactivated HMGBC (•) 
and LMGBC (o) upon dilution 
Native cVstatins (luM) were incubated with 6M GdnHCl (0-6M) for 12 
h at room temperature in the presence of different fold dilutions of the same 
buffer as used under native conditions. The cystatin activity was assayed for 
regain of antipifoteinase activity by caseinolytic assay of Kunitz (1947). Values 
are mean of four independent determinations. 
Results are expressed as % regain of inhibitory activity upon dilution as 
compared to native. Inhibitory activity at 6M GdnHCl concentration is 
considered as 0% while in the absence of denaturant the inhibitory activity was 
considered as 100%. 
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4.3.2 Intrinsic fluorescence studies of HMGBC and LMGBC in the 
presence of denaturants 
Effect of urea on intrinsic fluorescence of HMGBC and LMGBC 
Intrinsic fluorescence is an excellent spectroscopic probe to 
investigate conformational changes in the structure of any protein. Results in 
Fig. 6.2A and 6.2B indicate the maxima for HMGBC native state to be at 335 
nm. Upon denaturation by 8M urea, the maxima was shifted to 337nm showing a 
red shift of 2nm (Fig. 6.2A). From 0.5M to 1.0M change in urea concentration 
an increase in the intrinsic fluorescence intensity was observed. At urea 
concentration higher than 1M there is a decrease in emission intensity with a red 
shift of 2nm, leading to the lowest at 2.0 M. Further increasing the denaturant 
concentration from 3.0 M, there is gradual increase in the fluorescence intensity 
upto 8M. 
In case of LMGBC, the maxima was obtained at 336nm for native (Fig. 
6.2B). With the increasing concentration of urea from 0.5M to 8M, there is 
prominent increase in the fluorescence intensity reaching its maximum at 8M 
with a red shift of 1 nm. 
Effect of GdnHCl on intrinsic fluorescence of HMGBC and LMGBC 
Both the cystatins showed different behaviour in presence of 
guanidine hydrochloride. HMGBC showed a gradual increase in the intrinsic 
fluorescence with increasing concentration of GdnHCl indicating an unfolding of 
the cystatin molecule. The inhibitor showed maximum emission intensity at 6M 
GdnHCl with 1 nm red shift only (Fig. 6.3A). 
LMGBC showed an intermediate state while unfolding in the 
presence of GdnHCl (Fig.6.3B). At 0.5 M urea concentration the intensity was 
increased. However increasing the concentration from 0.5 to 1.5 M the intensity 
decreased showing the presence of some intermediate state. While increasing the 
GdnHCl concentration from 2.0M to 6.0 M there is steady increase in 
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Fig 6.2A Intrinsic 
with various 
The concentration 
room temperature 
indicated concentrations 
excitation wave 
width of 5nm. 
concentrations 
8M are shown i 
fluorescence analysis of HMGBC on interaction 
concentrations of urea. 
of HMGBC was 5uM. It was pre incubated for 2hrs at 
in 50mM sodium phosphate buffer, (pH 7.5) containing the 
of urea (0.5-8M). Fluorescence was measured at an 
ength of 280nm in the emission range of 300-400nm with a slit 
Fluorescence spectra of HMGBC was measured in different 
urea (1-8M). Spectra of native, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 and 
the Fig.6.2A. in 
of 
Fig 6.2B Intrihsic fluorescence analysis of LMGBC on interaction 
with various concentrations of urea. 
The concentration of LMGBC was 5uM. It was pre incubated for 2hrs at 
room temperature in 50mM sodium phosphate buffer, (pH 7.5) containing the 
indicated concentrations of urea (0.5-8M). Fluorescence was measured at an 
excitation wavelength of 280nm in the emission range of 300-400nm with a slit 
width of 5nm. Fluorescence spectra of LMGBC was measured in different 
concentrations of urea (1-8M). Spectra of native, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 and 
8M are shown in the Fig.6.2B. 
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Fig 6.3A Intrinsic fluorescence analysis of HMGBC on interaction 
with various concentrations of GdnHCl 
The concentration of HMGBC was 5uM. It was pre incubated for 2hrs at room 
temperature in 50mM sodium phosphate buffer, (pH 7.5) containing the 
indicated concentrations of GdnHCl (0.5-6M). Fluorescence was measured at 
an excitation wavelength of 280nm in the emission range of 300-400nm with a 
slit width of 5nm. Fluorescence spectra of HMGBC was measured in different 
concentrations of GdnHCl (1-6M). spectra of native, 0.5, 1, 1.5, 2, 3, 4, 5, and 
6M are shown in the Fig.6.3A . 
Fig 6.3B Intrinsic fluorescence analysis of LMGBC on interaction 
with various concentrations of GdnHCl 
The concentration of LMGBC was 3uM. It was pre incubated for 2hrs at 
i 
room temperature in 50mM sodium phosphate buffer, (pH 7.5) containing the 
indicated concentrations of GdnHCl (0.5-6M).Fluorescence was >asured at an 
excitation wavelength of 280nm in the emission range of 300-400nm with a slit 
width of 5nm. Fluorescence spectra of LMGBC was measured in different 
concentration GdnHCl (1-6M). spectra of native, 0.5, 1, 1.5, 2, 3, 4, 5, and 6M 
are shown in the Fig. 6.3B. 
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fluorescence intensity of the cystatin showing complete unfolding at 6.0M 
GdnHCl. No marked shift of wavelength was observed. 
4.3.3 Changes in extrinsic fluorescence of HMGBC and LMGBC in 
the presence of denaturants 
Effect of urea 
The fluorescence emission of l-anilinonapthalene-8-sulphonic acid 
(ANS) is known to increase when the dye binds to the hydrophobic regions of 
the protein (Stryer, 1965). Fig. 6.4 and 6.5 shows the ANS fluorescence emission 
spectra of cystatins. 
For HMGBC, the maxima was observed at 480nm (Fig. 6.4A). At 
0.5 M to 1.0 M ,there is an increase in the ANS fluorescence while from 1.0 to 
4.0 M urea concentration there is a decrease in the extrinsic fluorescence with 
least at 2M urea indicating the formation of intermediates, may be the protein 
gets aggregated. The ANS fluorescence was found to be maximum at 5M urea 
concentration, showing the exposure of hydrophobic patches. Increasing the 
concentration of urea from 5M - 8M there is significant decrease in extrinsic 
fluorescence owing to the disruption of hydrophobic patches. 
In the presence of urea, extrinsic fluorescence of LMGBC was 
first gradually increased because of the exposure of hydrophobic patches till 
4.0M urea concentration. At higher concentration, the ANS fluorescence was 
decreased as the ANS bound patches were disrupted (Fig. 6.4B). 
Effect of guanidium hydrochloride 
GdnHCl induced HMGBC denaturation leads to continuous increase of 
ANS binding to the cystatin molecules till 3M GdnHCl. At 3M concentration, 
the fluorescence intensity was found to be maximum as highest numbers of 
hydrophobic patches are exposed. At 4.0 M and higher GdnHCl concentration 
fluorescence intensity was found to be decreased (Fig. 6.5A). 
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Fig 6.4A Extrinsic fluorescence analysis of HMGBC in the presence 
of urea 
The concentration of HMGBC was 5uM. It was pre incubated for 2hrs at room 
temperature in/ 50mM sodium phosphate buffer, (pH 7.5) containing the 
indicated concentrations of urea (0.5-8M). Fluorescence was measured at an 
excitation wavdength of 380nm in the emission range of 400-600nm with a slit 
width of 5nm. The protein: ANS concentration was taken as 1:60. Fluorescence 
spectra of HMGBC was measured in different concentrations of urea (1-8M). 
Spectra of natjve, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 and 8M are shown in the Fig.6.5A. 
Fig 6.4B Extrinsic fluorescence analysis of LMGBC in the presence 
of urea 
The concentration of LMGBC was 3uM. It was pre incubated for 2hrs at room 
temperature in 50mM sodium phosphate buffer, (pH 7.5) containing the 
indicated concentrations of urea (0.5-8M). Fluorescence was measured at an 
excitation Wavelength of 380nm in the emission range of 400-600nm with a slit 
width of 5hm. The protein: ANS concentration was taken as 1:60. Fluorescence 
spectra of LMGBC was measured in different concentrations of urea (1-8M). 
Spectra of native, 0.5, 1, 1.5, 2, 3,4, 5, 6, 7 and 8M are shown in the Fig.6.5B. 
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Fig 6.5 A Extrinsic fluorescence analysis of HMGBC in the presence 
ofGdnHCl 
The concentration of HMGBC was 5JLIM. It was pre incubated for 2hrs at room 
temperature in 50mM sodium phosphate buffer, (pH 7.5) containing the 
indicated concentrations of GdnHCl (0.5-6M). Fluorescence was measured at 
an excitation wavelength of 380nm in the emission range of 400-600nm with a 
slit width of 5nm. The protein: ANS concentration was taken as 1:60. 
Fluorescence spectra of HMGBC was measured in different concentrations of 
GdnHCl (1-6M). Spectra of native, 0.5, 1, 1.5, 2, 3, 4, 5 and 6M are shown in 
the Fig.6.6A 
Fig 6.5 B Extrinsic fluorescence analysis of LMGBC in the presence 
ofGdnHCl 
The concentration of LMGBC was 3uM. It was pre incubated for 2hrs at room 
temperature in 50mM sodium phosphate buffer, (pH 7.5) containing the 
indicated concentrations of GdnHCl (0.5-6M). Fluorescence was measured at 
an excitation wavelength of 380nm in the emission range of 400-600nm with a 
slit width of 5nm. The protein: ANS concentration was taken as 1:60. 
Fluorescence spectra of LMGBC was measured in different concentrations of 
GdnHCl (1-6M). Spectra of native, 0.5, 1, 1.5, 2, 3, 4, 5 and 6M are shown in 
the Fig.6.6B. 
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For LMGBC, the extrinsic fluorescence was found to increase at 0.5 M 
GdnHCl, it then decreased till 2M concentration with a maximum at 1.5M. 
From 2 M onwards it increased till 4M and then again it decreased at 5M and 
6M concentration because of disruption of hydrophobic patches (Fig. 6.5B). 
4.3.4 CD measurements 
CD studies of urea induced denaturation of HMGBC and LMGBC 
Far UV-CD spectroscopy was used to monitor the changes in the 
secondary structure content of cystatins upon urea and guanidium 
hydrochloride induced denaturation. 
The native spectra of FIMGBC and LMGBC showed the presence of 
significant secondary structure content (Fig. 6.6A, 6.6B). Both FIMGBC and 
LMGBC showed the loss of secondary structure as the concentration of urea 
was increased. At 8M urea concentration the secondary structure of both the 
cystatins was completely lost. 
CD studies of guanidium hydrochloride induced denaturation of 
HMGBC and LMGBC 
In presence of GdnHCl, the secondary structure of HMGBC 
was lost as the concentration of the denaturant was increased. At 6M GdnHCl 
concentration the secondary structure was completely lost (Fig. 6.7A). 
The GdnHCl induced LMGBC denaturation occurred in two 
steps. Fig.6.7B shows that at 0.5 M concentration the secondary structure 
component was less than that of native. But as the concentration is further 
increased from 0.5 to 2.0 the secondary structure content was increased 
showing that at this concentration the LMGBC was more compact as compared 
to the native (Fig.6.7B). As the concentration was further increased there is loss 
of the secondary structure content with complete loss at 6M concentration. 
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5.3 DISCUSSION 
The unfolding of proteins in denaturing compounds has been 
widely investigated. GdnHCl and urea are the most common denaturants used 
for the conformational, stability and unfolding studies of proteins. In the 
present study, denaturation and renaturation of two very important mammalian 
(goat) brain proteins namely HMGBC and LMGBC in presence of urea and 
GdnHCl have been reported. For several proteins difference in the behaviour 
has been reported from classical behaviour towards denaturants. Both the 
cystatins used in the study showed different behaviour while denaturing in the 
presence of urea and GdnHCl. High molecular mass goat brain cystatin 
(HMGBC) showed completely different way of unfolding with urea and 
GdnHCl. The denaturation of HMGBC in presence of urea takes place via 
intermediate stage. Firstly at lower concentrations the activity was retained till 
2.0M concentration, however a decrease in extrinsic fluorescence and intrinsic 
fluorescence intensity was observed maximally at 2.0 M urea and further 
increase in urea concentrations showed the formation of some intermediate 
state between native and completely denatured forms. At 2M urea 
concentration, the non native state or intermediate state is of the aggregated 
species formed during the urea induced unfolding. These aggregated species 
were found to have lesser activity, decreased intrinsic and extrinsic 
fluorescence as compared to the native state because of the burial of aromatic 
amino acids and hydrophobic patches of HMGBC at that urea concentration. 
As the concentration of urea was further increased till 8M there is complete 
unfolding of HMGBC. The secondary structure was found to be maximum for 
native HMGBC and its continuous decrease was found at higher concentrations 
leading to the complete loss at 7M and 8M urea concentration. Aggregation of 
protein molecules at lower urea concentration have been reported earlier also 
(Jaenicke, 1987). 
Although there is retention of 89% of activity during this aggregation, 
there is marked and very prominent conformational change in HMGBC as 
shown by the results obtained from intrinsic fluorescence, extrinsic 
fluorescence and far UV CD measurements. 
The mode of unfolding of LMGBC in the presence of urea was found 
to be highly cooperative process, as no significant intermediates are present 
during the transition of LMGBC from native to denatured states. Such type of 
two state model behaviour was generally found in small globular proteins and 
is previously reported for other proteins (Aune and Tanford, 1969). 
In the presence of GdnHCl, HMGBC was observed to follow simple two 
state models for unfolding where no intermediates were found between native 
and denatured state. Although the inactivation of HMGBC was found to be 
stronger at lower concentration of GdnHCl i.e., at 3M concentration as 
compared to 3M urea where 56% activity was retained while with GdnHCl 
only 33% activity was found. The changes obtained with the guanidine 
hydrochloride induced denaturation of HMGBC indicated the equilibrium 
unfolding where only native and denatured states are significantly populated. 
This type of denaturation has been reported in literature (Tanford, 1968; 
Ternstom et al., 2005). 
In contrast to HMGBC, LMGBC showed the existence of intermediate 
state while unfolding in the presence of GdnHCl. During the transition of 
LMGBC from native to denatured state there is an intermediate or non native 
state which was found to have decreased inhibitory activity, intrinsic, extrinsic 
fluorescence and more pronounced secondary structure as compared to the 
native form. This formation of intermediates can have several explanations. 
These can be due to micro environmental changes in the aromatic region of the 
protein, small local rearrangements of the native state (Ferreon and Bolen, 
2004) or the stabilizing effects of GdnHCl at low concentrations (Mayr and 
Schmid, 1993; Smith and Scholtz, 1996). There are several reports of GdnHCl 
and urea showing different denaturation behaviour for different proteins (Pace, 
1975; Yao and Bolen, 1995; Park et al., 2003; Deshpande et a l , 2003; Wang et 
al., 2000; Inui et al., 2003; Inouye et al., 2000). 
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Refolding was also observed both in HMGBC and LMGBC with urea 
and GdnHCl upon dilution. Almost 92% of HMGBC and 96% of LMGBC 
inhibitory activity was retained with 6M GdnHCl upon 40fold dilution with the 
buffer. In case of urea 50 fold dilutions with the buffer results in the retention 
of 89% of HMGBC and 94% of LMGBC inhibitory activity (Fig. 6.1 A and 
6.IB).Although urea and GdnHCl have similar modes of action, the different 
behaviour of proteins towards these denaturants may be because urea has only 
chaotropic effects whereas GdnHCl is a monovalent salt having both ionic and 
chaotropic effect. 
The unfolding behaviour of HMGBC and LMGBC with urea and GdnHCl 
indicate that these proteins follow different pathways and mechanisms for 
unfolding. The results obtained for these two cystatins in the presence of the 
denaturants are presented in the following proposed scheme A and B. 
0.5M-2.0M urea 
HMGBC ^ Non-native intermediate state 
(N) /Aggregates (I) 
0.5M-6M 
GdnHCl 
2M-8M urea 
Denatured /unfolded state 
(D) 
Scheme A: Schematic representation of the changes involved during 
HMGBC denaturation denaturation in presence of denaturants. 
1.0M-2.0M GdnHCl 
LMGBC 
(N) 
-> Non-native intermediate state 
(I) 
2M-6M GdnHCl 
0.5M-8M 
Urea 
Denatured /unfolded state 
(D) 
Scheme B: Schematic representation of the changes involved during 
LMGBC denaturation in presence of denaturants. 
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As the process of protein unfolding is very complex understand ding the 
conformational changes that result in a protein by various treatments would 
provide a powerful tool for drug and comprehension of cellular organization at 
the molecular level. Although tremendous work has been carried out in this 
field, our study is of great significance as it deals with the denaturation 
mechanism of two different proteins (cystatins) of the same superfamily, from 
the same tissue which is of utmost importance, brain. As cystatins play 
important roles in mammalian body specifically in brain owing to their cysteine 
proteinase inhibitory activity it is of extreme consequence that their 
conformation should be stable for maximum functional activity. The above 
observations have shed some light on the structural alterations and loss of 
function of cystatins which result due to exposure of these proteins towards 
denaturants leading to effect the normal functioning of the protein. 
Chapter -4 
Jfigh p!ff induced unfolding of 
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4.4 RESULTS 
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(A) High pH induced modifications of HMGBC and LMGBC 
Changes in the functional properties of HMGBC and LMGBC at high pH 
High pH induced changes in the functional properties of both the 
cystatins were studied by loss of their ability to inhibit papain (Fig. 6.8). In 
case of HMGBC, the inhibitory activity was found to be quite stable from pH 
7.0 to pH 9.0 with a maximum at pH 8.0. However, It was found to decrease 
sharply from pH 10 onwards reaching the complete loss of cystatin activity at 
pH 14.0, while only 10% of the activity was retained at pH 13.0.based on the 
enzyme activity results obtained, the pH of half transition was observed at pH 
11.0(Fig.6.8). 
For LMGBC, 80% inhibitory activity was retained upto pH 10. After 
pH 10.0, there is sharp decrease in the inhibitory activity of the cystatin which 
was completely lost at pH 14.0,retaining 15% activity at pH 13.0.the pH of 
half transition of inhibitory activity was observed at pH 11.5 (Fig. 6.8). 
Changes in the structural properties of HMGBC and LMGBC at 
high pH 
The pH dependent structural modifications of HMGBC and LMGBC 
were studied by investigating the changes in intrinsic and extrinsic or ANS 
fluorescence and CD spectra measurements. For LMGBC, the intrinsic 
fluorescence intensity, extrinsic fluorescence intensity and CD spectra results 
showed a different pattern of unfolding as compared to HMGBC (Fig. 6.9, 7.0 
and 7.1). 
For HMGBC, the intrinsic fluorescence at the tanax, 335nm was 
considered as 100% at pH 8.0 as its native state. Comparative to pH 8.0, the 
intensity was increased as the pH increased to pH 12.0. At pH 12.0 a 2nm red 
shift was observed with a sharp increase in the intrinsic fluorescence intensity. 
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Fig 6.8 Changes in the functional properties of HMGBC (—•—) and 
LMGBC (—A—) on high pH induced unfolding 
The values reported are relative to that observed at pH 8 for HMGBC 
and pH 7 for LMGBC. lum of HMGBC and LMGBC was dissolved in 50mM 
sodium phosphate buffer, pH 7.5. The pH of the solution was then adjusted to 
the desired pH using 1M sodium hydroxide and the samples were then 
incubated for 3 hrs at room temperature. After this the inhibitory activity of the 
cystatins was measured by their ability to inhibit caseinolytic activity of papain 
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Fig 6.9 Intrinsic fluorescence intensity of HMGBC and LMGBC at 
different pH values 
Changes in the intrinsic fluorescence at 335nm of HMGBC (—••—) and 
LMGBC (—A—) on alkaline induced unfolding are measured. The values 
reported are relative to that observed at pH 8 for HMGBC and pH 7 for 
LMGBC. lum of HMGBC and LMGBC was dissolved in 50mM sodium 
phosphate buffer, pH 7.5. The pH of the solution was then adjusted to the 
desired pH using 1M sodium hydroxide and the samples were then incubated 
for 3 hrs at room temperature and then subjected for the measurement of 
fluorescence. 
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From pH 12 onwards at pH 13.0 and 14.0, no further significant increase in 
intrinsic fluorescence intensity was observed (Fig.6.9). In case of LMGBC, 
The intrinsic fluorescence intensity of LMGBC at tanax at 335nm was found to 
increase from pH 7.0 to 10.0. At pH 11.0, the intensity decreased with least at 
pH 12.0 showing the formation of some compact structure. At pH 13.0 the 
intensity was further increased reaching the maximum intensity at pH 14.0 
(Fig. 6.9). 
Fig. 7.0 shows that the ANS fluorescence intensity at 480nm first it 
increases sharply from pH 8.0 to pH 12.0 in case of HMGBC. This was 
observed because as the pH increases, the hydrophobic patch or residues of the 
protein were exposed resulting in the increase of ANS binding. But at pH 13.0 
and 14.0, the intensity was again lowered resulting due to the disruption of the 
hydrophobic patches exposed at pH 12.0. However, the extrinsic fluorescence 
intensity of LMGBC at 480nm showed increase in the extrinsic fluorescence 
from pH 7.0 to 11.0 because of the exposure of hydrophobic residues. The 
intensity of ANS binding decreased at pH 12.0 with least intensity at pH 14.0 
(Fig. 7.0). 
CD spectral results showed that the maximum secondary structure 
content was found at pH 8.0 as indicated by the 0 value at 222nm and loss of 
peak at 0222- It was also observed that there is continuous loss of secondary 
structure as the pH increases from pH 8.0 to 13.0. The Q222 value at pH 14.0 did 
not show any further significant increase compared to the value at pH 13 (Fig 
7.1).The CD results of LMGBC indicate the formation of compact intermediate 
structure with significant secondary structure at pH 12.0. The secondary 
structure was found to be most ordered at pH 7 showing a proper peak at 0222. 
As the pH increases from pH 7.0 to 11.0 there is loss of secondary structure as 
shown by the 6222 value. At pH 12.0 the 0 value at 222nm indicated the 
formation of compact intermediate state (Fig. 7.1). 
These above results indicate that prominent or significant structural and 
functional changes occur with alkaline unfolding of HMGBC and LMGBC. 
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Fig 7.0 Extrinsic fluorescence intensity of HMGBC and LMGBC at 
different pH values 
Changes in the extrinsic or ANS fluorescence are measured 480nm for 
HMGBC ( - • - ) and LMGBC ( - A - ) on alkaline induced unfolding. The 
values reported are relative to that observed at pH 8 for HMGBC and pH 7 for 
LMGBC. lum of HMGBC and LMGBC was dissolved in 50mM sodium 
phosphate buffer, pH 7.5. The pH of the solution was then adjusted to the 
desired pH using 1M sodium hydroxide and the samples were then incubated 
for 3 hrs at room temperature and then subjected for the measurements. The 
protein: ANS concentration was taken as 1:60. 
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Fig 7.1 CD measurements at 222nm of HMGBC and LMGBC at 
different pH values 
Changes in the CD measurements are measured at 222nm for HMGBC 
(—•—) and LMGBC (—A—) on alkaline induced unfolding. The values 
reported are relative to that observed at pH 8 for HMGBC and pH 7 for 
LMGBC. 200ug/ml of HMGBC and LMGBC were dissolved in 50mM sodium 
phosphate buffer, pH 7.5. The pH of the solution was adjusted to the desired 
pH using 1M sodium hydroxide and the samples were then incubated for 3 hrs 
at room temperature and then subjected for the measurements. 
i 

Although HMGBC showed the transition of native to denatured state, LMGBC 
indicated the formation of some intermediate compact state at pH 12.0. 
(B) Salt induced refolding of high pH unfolded HMGBC and 
LMGBC 
Effect of salts KC1 and Na 2S0 4on the functional properties of high 
pH denatured HMGBC and LMGBC 
In the absence of salts high pH denatured HMGBC at pH 12.0 showed 
only 20% recovery on bringing back the pH to 7.5 by dialysis while LMGBC 
showed a maximum recovery of 28% (Fig. 7.2). In the presence of salts upon 
dialysis the inhibitory activity recovery was found to be prominently enhanced 
upto 84% for both HMGBC and 86% for LMGBC in the presence of 1M 
Na2S04 while in the presence of 3M KCl the HMGBC activity was recovered 
upto 75% and for LMGBC inhibitory activity was recovered 79% at the same 
concentration of KCl (Fig.7.2). 
Effect of salts KCl and Na 2 S0 4 on the structural properties of high 
pH denatured HMGBC and LMGBC 
The intrinsic fluorescence intensity measurements at 335nm for both the 
cystatins, HMGBC and LMGBC showed that the fluorescence intensity in the 
presence of varying concentrations of salts KCl and Na2S04 was recovered as 
compared to the unfolded state at pH 12.0. 
The intrinsic intensity spectral measurements of HMGBC (Fig 7.7) 
indicate that at pH 12.0, the intensity was much increased as compared to the 
native state which was decreased in the presence of salts. The 3M KCl and 1M 
Na2S04 at pH 12.0 showed the spectra much closer to the native state as 
compared to the unfolded form at pH 12.0 (Fig. 7.3 and 7.5). 
The spectral analysis of LMGBC showed that the intensity at pH 12.0 
was decreased compared to the native because of the formation of compact 
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Fig 7.2 Effect of increasing concentrations of saits on the recovery of 
inhibitory activity of high pH denatured HMGBC and LMGBC 
The HMGBC and LMGBC solution at pH 12, with the addition of KC1 
and Na2S04 was prepared as described in Fig. 6.8. The samples were then 
dialyzed against 50 volumes of 50mM sodium phosphate buffer, pH 7.5 at 25 
±1°C and then it was monitored for recovery of the enzyme activity by 
caseinolytic method. Appropriate controls were used. Upon dialysis in the 
absence of salts HMGBC recovered only 20% of the inhibitory activity while 
LMGBC recovered 28%of its inhibitory activity as compared to the native. In 
this figure 
( - • - ) represents HMGBC with Na2S04, 
(—o—) represents LMGBC with Na2S04. 
( - A - ) represents HMGBC with KC1 
(..-A—) represents LMGBC with KC1. 
1 1.5 2 
Cone, of salts [M] 
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Fig 7.3 Effect of increasing concentrations of salts on the intrinsic 
fluorescence intensity of high pH denatured HMGBC and LMGBC 
The HMGBC and LMGBC solution at pH 12, with the addition of KC1 
and Na2S04 was prepared as described in Fig. 6.8. the intrinsic fluorescence 
intensity at 335nm was measured. In the absence of salts at pH 12 recovery 
was considered as 0%. In the figure, 
( - • - ) represents HMGBC with Na2S04, 
(_..o—) represents LMGBC with Na2S04, 
( - A - ) represents HMGBC with KC1 
(—A—) represents LMGBC with KC1. 
100 -i 
0.5 1 1.5 2 2.5 
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Fig 7.4 Effect of increasing concentrations of salts on the extrinsic 
fluorescence intensity of high pH denatured HMGBC and LMGBC 
The HMGBC and LMGBC solution at pH 12, with the addition of KC1 
and Na2S04 was prepared as described in Fig. 6.8. the extrinsic fluorescence 
intensity was measured at 480nm . the protein :ANS concentration was taken 
as 1:60. In the absence of salts at pH 12 recovery of extrinsic fluorescence 
intensity was considered as 0%. In this figure, 
( - • - ) represents HMGBC with Na2S04, 
(...o—) represents LMGBC with Na2S04, 
( - A - ) represents HMGBC with KC1 
(—A—) represents LMGBC with KC1. 
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Fig 7.5 Effect of salts on the intrinsic fluorescence of HMGBC 
Intrinsic fluorescence of HMGBC was measured after addition of salts 
Na2S04 and KCl in the HMGBC mixture incubated at pH 12. The samples 
were prepared as described in Fig. 4.4.1 and incubated for 3 hrs at room 
temperature before taking the measurements. In the figure, 
a represents HMGBC at pH 8.0 
b represents HMGBC at pH 12.0 with 1M Na2S04 
c represents HMGBC at pH 12.0 with 3M KCl 
d represents HMGBC at pH 12.0 
e represents HMGBC in the presence of 6M GdnHCl. 
300 310 320 330 340 350 360 370 380 390 400 
Wavelength (nm) 
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Fig 7.6 Effect of salts on the intrinsic fluorescence of LMGBC 
Effect of addition of salts Na2S04 and KCI on the intrinsic fluorescence 
of LMGBC is shown in the figure. The samples were prepared as described in 
Fig. 6.8 and incubated for 3 hrs at room temperature before taking the 
measurements. In the figure, 
a represents LMGBC at pH 7.0, 
b represents LMGBC at pH 12.0, 
c represents LMGBC at pH 12.0 with 3M KCI, 
d represents LMGBC at pH 12.0 with 1M Na2S04 
e represents LMGBC in the presence of 6M GdnHCl 
-i 1 1 1 1 1 1 1 r 
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Fig 7.7 Effect of salts on the extrinsic fluorescence of HMGBC 
Effect of addition of salts Na2S04 and KCl on the extrinsic or ANS 
fluorescence of HMGBC is shown. The samples were prepared as described in 
Fig. 6.8 and incubated for 3 hrs at room temperature before taking the 
measurements. The protein: ANS concentration was taken as 1:60. In the 
figure, 
a represents HMGBC at pH 8.0, 
b represents HMGBC at pH 12.0, 
c represents HMGBC at pH 12.0 with 3M KCl, 
d represents HMGBC at pH 12.0 with 1M Na2S04 
e represents HMGBC in the presence of 6M GdnHCl 
1 1 1 1 1 1 1 1 1 1 
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Fig 7.8 Effect of salts on the extrinsic fluorescence of LMGBC 
In the figure the effect of salts of the extrinsic fluorescence of LMGBC 
has been shown. The samples were prepared as described in Fig. 6.8 and 
incubated for 3 hrs at room temperature before taking the measurements. In the 
figure, 
a represents LMGBC at pH 7.0, 
b represents LMGBC at pH 12.0, 
c represents LMGBC at pH 12.0 with 3M KC1, 
d represents LMGBC at pH 12.0 with 1M Na2S04 
e represents LMGBC in the presence of 6M GdnHCl 
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intermediate state. In presence of 1M Na2S04 and 3M KC1, the spectra 
obtained were much closer to the native intrinsic fluorescence spectra at pH 
7.0, indicating the refolding of LMGBC in presence of salts (Fig. 7.3 and 7.6) 
The extrinsic fluorescence intensity at 480nm, of HMGBC and LMGBC 
at pH 12.0 was found to be salvaged in the presence of varying concentrations 
of KC1 and Na2S04. The maximum recovery was observed in the presence of 
1M Na2S04 and 3M KCl at pH 12.0 comparable to the unfolded form at pH 
12.0 (Fig. 7.4). The ANS fluorescence was regained back very near to the 
native state in the presence of 3M KCl and 1M Na2S04 (Fig. 7.7). 
The extrinsic fluorescence intensity at 480nm, for LMGBC at pH 12.0 
was found to be recovered maximum in the presence of 1M Na2S04 and 3M 
KCl compared to the fluorescence at pH 12.0 (Fig. 7.4). The extrinsic 
fluorescence of HMGBC was prominently increased at pH 12.0 because of the 
unfolding of the cystatin leading to the exposure of hydrophobic patches. The 
extrinsic fluorescence intensity of LMGBC at pH 12.0 was found to be less 
than the native state at pH 7.0.This may be due to the formation of the compact 
intermediate state resulting in the burial of hydrophobic patches. The 
fluorescence intensity was found to be greatly recovered in presence of 3M 
KCl and 1M Na2S04 (Fig. 7.8). 
From the CD results obtained for HMGBC, it was observed that there is 
a retention of secondary structure at pH 12.0 in the presence of salts, 3M KCl 
and 1M Na2S04 as compared to the HMGBC denatured at pH 12.0 without 
salts ( Fig. 7.9). The CD spectra at pH 12.0 for LMGBC indicate that the 
secondary structure was more compared to the native. In presence of 3M KCl 
and 1M Na2S04 the secondary structure was observed to be closer to the native 
showing that the secondary structure of the LMGBC at pH 12.0 was reversed 
back near to native in the presence of salts (Fig. 8.0). 
The figures for intrinsic fluorescence, extrinsic fluorescence and CD 
results of salt induced refolding of HMGBC and LMGBC, also include curve 
for 6M GdnHCl unfolding to show a comparison with pH induced unfolding. 
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Fig 7.9 Effect of addition of salts Na2S04 and KCI on the far UV CD 
spectra of HMGBC 
The samples were prepared as described in Fig. 6.8 and incubated for 3 
hrs at room temperature before taking the measurements. 200jug/ml of 
HMGBC was used for all far UV CD measurements. In this figure. 
a represents HMGBC at pH 8.0, 
b represents HMGBC at pH 12.0, 
c represents HMGBC at pH 12.0 with 3M KCI, 
d represents HMGBC at pH 12.0 with 1M Na2S04 
e represents HMGBC in the presence of 6M GdnHCl 
Wavelength (nm) 
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Fig 8.0 Effect of addition of salts Na2S04 and KCI on the far UV CD 
spectra of LMGBC 
The samples were prepared as described in Fig. 6.8 and incubated for 3 
hrs at room temperature before taking the measurements. 200ug/ml of 
HMGBC was used for all far UV CD measurements. In the figure, 
a represents LMGBC at pH 7.0, 
b represents LMGBC at pH 12.0, 
c represents LMGBC at pH 12.0 with 3M KCI, 
d represents LMGBC at pH 12.0 with 1M Na2S04 
e represents LMGBC in the presence of 6M GdnHCl 
220 230 240 
Wavelength (nm) 
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5.4 Discussion 
It is a well known fact that the activity of proteins is strongly dependent 
on its conformational integrity. Folded proteins are usually stable in the 
thermodynamic sense at ambient temperature and at neutral pH. Although a lot 
of work has been carried out on alkaline unfolding of multimeric enzymes 
(Wang et al., 1995; He et al., 1995; Le et al., 1996) but high pH unfolding of 
monomeric enzymes specifically from mammalian brain has not been explored 
yet. In the present study the alkaline denaturation of HMGBC and LMGBC 
was studied to obtain the information about the behaviour of these proteins at 
high pH. The spectral parameters such as fluorescence intensity are dependent 
on the dynamic and electronic properties of the chromophore environment, 
hence fluorescence measurements have been extensively used to obtain 
information on the structural and dynamic properties of the proteins (Ghisla et 
al., 1974). The far UV-CD spectra of a protein in the far-UV region gives 
information about the conformation of polypeptide backbone and the 
hydrophobic dye ANS which binds to exposed hydrophobic regions of partially 
folded proteins is used in protein conformational studies to monitor the 
exposed hydrophobic patches (Johnson and Fersht, 1995, Stryer, 1965). 
To see the behaviour of both the cystatins at high pH under alkaline 
conditions, the cystatins were incubated with buffers at desired pH and then 
analyzed for their functional and structural modifications. It was observed that 
the cystatins are functionally stable under a wide range of pH from 7 to 10. But 
as the pH is further increased there is inactivation of the inhibitors (Fig. 6.8). 
For HMGBC, the intrinsic and extrinsic fluorescence and CD results 
obtained showed that there is no intermediate formation during alkaline 
unfolding. The intrinsic fluorescence was observed to be maximum at pH 14, 
indicating the exposure of tryptophan residues because of the unfolding of the 
inhibitor. As the pH was increased from pH 7 to 12 there is increase in the 
extrinsic fluorescence of HMGBC while at pH 13 and 14 there is decrease in 
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the ANS fluorescence, this is because from pH 7 to 12 the hydrophobic 
residues were exposed leading to the maximum binding of ANS to these 
patches but as the pH was increased further there is disruption of the 
hydrophobic patches leading to the decrease of ANS binding. The CD spectra 
of HMGBC showed that there is steady loss of secondary structural content as 
the pH increased from 8 to 14. Thus all these results for HMGBC suggest the 
native state —• unfolded state transition upon alkaline unfolding. 
LMGBC showed the formation of an intermediate state at pH 12.0, the 
results obtained from intrinsic and extrinsic fluorescence as well as CD spectra 
(Fig. 6.9, 7.0 and 7.1) showed that upon high pH unfolding firstly there is 
unfolding of the protein from pH 7 to 10. But at pH 11 and 12, there is 
decrease in the intrinsic and extrinsic fluorescence intensities indicating the 
formation of a compact intermediate state. The intrinsic fluorescence was again 
increased after pH 12. CD results also showed the formation of some compact 
intermediate state of LMGBC at pH 12 upon high pH induced unfolding. Thus 
the unfolding of LMGBC can be represented as Native —>• intermediate —>• 
unfolded state. Formation of compact intermediates upon alkaline denaturation 
has also been reported earlier (Bai et al., 1998). 
In the present study, two salts KC1 and Na2S04 were considered for the 
refolding and protein stability effects.. The results of the activity 
measurements, intrinsic fluorescence, extrinsic fluorescence and CD spectra 
indicated that the addition of salts (KC1 and Na2S04) to the protein solution at 
high pH aids in the refolding of the alkaline unfolded HMGBC and LMGBC. It 
was observed that the proteins regain their inhibitory activity upon addition of 
salts. For refolding of the inhibitors by dialysis in the buffer of pH 7.5, in the 
absence of salts only 20% of HMGBC and 28% of LMGBC inhibitory activity 
was recovered however in the presence of 3M KC1 and 1M Na2S04 the 
recovery was significantly increased as a result of the renaturation of both 
HMGBC and LMGBC in the presence of the salts, KC1 and Na2S04. It also 
showed that KC1 is required at higher concentration (3M) as compared to the 
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Na2S04 (1M) for refolding of these proteins, suggesting that the latter is more 
effective in refolding. 
The main forces unfolding the protein under extreme conditions of pH are 
the repulsive forces between charged groups on the protein molecule (Kim and 
Baldwin, 1990). The folding of protein in the presence of salts occurs by the 
formation of counter ions as well as the specific effects of the salts. The 
stabilizing or destabilizing effects of salts on proteins arise either by effects on 
water structure, hydrophobic interactions or by specific interactions with the 
charged group. According to the Hoffmeister series (Von Hippie and Wong, 
1965), Na2S04 is much more effective than KCl in stabilizing the major 
hydrophobic interactions needed for protein folding and thus stability of 
proteins as the results obtained in the study also indicate that Na2S04 is more 
effective even at lower concentration in protein folding as compared to KCl. 
Salt dependent conformational changes at alkaline and acidic pH are the 
general property of proteins. However, the concentration of salt required and 
the extent of folding depends upon the particular protein and specified 
conditions. 
The present study performed to understand the alkaline unfolding of 
cystatins from goat brain and their refolding by salts will add to the existing 
knowledge of unfolding and refolding process of proteins. 
SliMiejgxapfijy, 
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4.3.2 Intrinsic fluorescence studies of HMGBC and LMGBC in the 
presence of denaturants 
Effect of urea on intrinsic fluorescence of HMGBC and LMGBC 
Intrinsic fluorescence is an excellent spectroscopic probe to 
investigate conformational changes in the structure of any protein. Results in 
Fig. 6.2A and 6.2B indicate the maxima for HMGBC native state to be at 335 
nm. Upon denaturation by 8M urea, the maxima was shifted to 337nm showing a 
red shift of 2nm (Fig. 6.2A). From 0.5M to 1.0M change in urea concentration 
an increase in the intrinsic fluorescence intensity was observed. At urea 
concentration higher than 1M there is a decrease in emission intensity with a red 
shift of 2nm, leading to the lowest at 2.0 M. Further increasing the denaturant 
concentration from 3.0 M, there is gradual increase in the fluorescence intensity 
upto 8M. 
In case of LMGBC, the maxima was obtained at 336nm for native (Fig. 
6.2B). With the increasing concentration of urea from 0.5M to 8M, there is 
prominent increase in the fluorescence intensity reaching its maximum at 8M 
with a red shift of 1 nm. 
Effect of GdnHCl on intrinsic fluorescence of HMGBC and LMGBC 
Both the cystatins showed different behaviour in presence of 
guanidine hydrochloride. HMGBC showed a gradual increase in the intrinsic 
fluorescence with increasing concentration of GdnHCl indicating an unfolding of 
the cystatin molecule. The inhibitor showed maximum emission intensity at 6M 
GdnHCl with 1 nm red shift only (Fig. 6.3A). 
LMGBC showed an intermediate state while unfolding in the 
presence of GdnHCl (Fig.6.3B). At 0.5 M urea concentration the intensity was 
increased. However increasing the concentration from 0.5 to 1.5 M the intensity 
decreased showing the presence of some intermediate state. While increasing the 
GdnHCl concentration from 2.0M to 6.0 M there is steady increase in 
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Oxidative Stress Induced Functional and Structural Modifications of High 
Molecular Mass Goat Brain Cystatin 
Sadia Sumbul and Bilqees Bano* 
Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh -202002, India 
Abstract: Cystatins are thiol proteinase inhibitors ubiquitously present in mammalian body. In brain, they prevent un-
wanted proteolysis and are involved in several neurodegenerative diseases. In the present study, it has been demonstrated 
that photoactivated riboflavin and H202 induced modifications of high molecular mass goat brain cystatin (HM-GBC) 
leads to its inactivation and degradation. It was found that the damage with both the oxidants occurred mainly because of 
the hydroxy 1 radicals. It has been also proposed that susceptibility of HM-GBC to oxidation by reactive oxygen species 
generated in vivo arise from oxidative modifications may lead to damage of this significant protein as it is so well pro-
nounced, in vitro. 
Keywords: Mammalian cystatin, High molecular mass goat brain cystatin, riboflavin, H202, and oxidative stress. 
INTRODUCTION 
Oxidants are constantly generated by a variety of differ-
ent processes in the mammalian body. They may be gener-
ated accidentally or deliberately to serve important biological 
functions. At high concentrations however, free radicals and 
reactive oxygen species [ROS] react with non-radical species 
and can initiate adverse chain reactions causing damage to 
various biological macromolecules including lipids, DNA 
and proteins [1]. This oxidative modification of macromole-
cules by ROS plays a role in wide range of common diseases 
and age related degenerative conditions [2, 3, 4, 5]. These 
include cardiovascular diseases [6] and neurodegenerative 
diseases such as Alzheimer [7] and cancer [2, 3, 4]. 
Proteins are major targets for ROS as a result of their 
abundance in biological systems. Oxidants react rapidly with 
protein backbone and side chain sites causing various delete-
rious consequences including protein damage and degrada-
tion [8], modification of amino acids [9] and changes in sec-
ondary and tertiary structures of proteins [10]. 
Riboflavin and H202 are two common reactive oxidants 
present in mammalian body under various conditions. 
Flavins are known to photooxidize amino acids and also ef-
fect the conformation of proteins [11, 12, 13]. They are 
known to generate singlet oxygen, hydroxyl radicals and 
flavin triplet state on photoillumination. Riboflavin is an 
important constituent of our daily diet .It is present in free 
and conjugated form in almost all biological tissues and flu-
ids [14, 15] H : 0 2 is another important oxidant generated as 
diffusible cofactors in inflammation .The steady state con-
centration of H202 in the cell is 10 9 to 10"8 M [16]. Its con-
centration may markedly increase when tissues are exposed 
to ionizing radiations during metabolism of carcinogens and 
at inflammatory sites [17,18]. Generated H202 may modify 
•Address correspondence to this author at the Department of Biochemistry, 
Faculty of Lite Sciences, Aligarh Muslim University, Aligarh -202002. 
India: Tel: +91-571-2700857: Fax: +91-571-2702758. ' 
E-mail: bilqees2007(a:ginail com 
amino acids [18], degrade heme in red blood cells [19] and 
inactivate enzymes [20] and antiproteinase [21,22]. 
We investigated the role of these two major physiological 
oxidants - riboflavin and H202 in deteriorating the antiprote-
olytic activity of high molecular mass cystatin [HM-GBC] 
isolated from goat brain [23]. Cystatins are thiol proteinase 
inhibitors ubiquitously present in the mammalian body to 
regulate the activity of endogenous proteinases which other-
wise may cause uncontrolled proteolysis and damage [24]. 
Cystatins are present in the brain to protect it against exces-
sive unwanted proteolysis. They are also involved in various 
neurodegenerative diseases including Alzheimer and cerebral 
amyloid angiopathy [25, 26] .In the present study, it was 
found that both riboflavin and H202 cause fragmentation and 
degradation of the cystatin leading to the loss of its native 
structure and its antiproteolytic activity. Hydroxyl radicals 
and flavin triplet state were found to be involved in these 
modifications of the inhibitor with photoactivated riboflavin 
as showed by the use of various scavengers and quenchers. 
However in case of H202 mainly hydroxyl radicals leads to 
this damage. Jhe comprehensive structural and functional 
modifications of HM-GBC with these two oxidants in this 
work are characterized by polyacrylamide gel electrophore-
sis and several spectroscopic techniques. 
MATERIALS 
Papain, riboflavin, H202 and Sephadex G-100 matrix 
were purchased from Sigma chemicals, St. Louis, USA. 
DEAE-cellulose was purchased from SRL, India .All other 
chemicals were of highest purity commercially available. 
EXPERIMENTAL PROCEDURES 
Purification of HM-GBC 
HM-GBC was purified from goat brain by the method of 
Sadia et al. [23] .Fresh goat brain, collected from slaughter 
(150grams) was homogenized in 50mM sodium phosphate 
buffer (300ml), pH 7.5 containing 0.15 M NaCl, 3 mM 
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